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ABSTRACT
Members of the genus Bacteroides are obligately anaerobic Gram-negative rods
which constitute a substantial part of the normal colonic microbial flora, and as such
play an important part in gut homeostasis and function. When they escape from the
gut, they frequently become pathogenic, and B. fragilis, the type species, is the
principal cause of anaerobic infections in man. Despite this, there are certain diseases
where Bacteroides species could be very important, but to date have been overlooked
or dismissed as insignificant. Sepsis is an example of such a disease; it is widely
thought that enterobacteria and their products are exclusively responsible for the
development of sepsis, despite the fact that they are greatly outnumbered in the gut by
Bacteroides species. The aim of this thesis was to examine the interaction between
Bacteroides species, in particular their cell surface antigens, and selected aspects of
the immune system, both in health and disease.
Complement-mediated killing of Bacteroides species was examined. It was found
that growth environment could have a profound effect on serum sensitivity of certain
strains. When grown in proteose peptone-yeast extract medium, all 12 strains tested
were sensitive to complement. However, when grown in Van Tassell and Wilkins'
medium, six of the strains became markedly more complement-resistant, and when
grown in heat-inactivated sheep serum, five of these six strains became totally
resistant. Two B. fragilis strains were selected which demonstrated these differences,
and expression of their surface antigens in the three media was examined to try to
discover the biochemical basis for the observed changes in complement resistance.
Differences in degree of encapsulation, outer membrane protein expression and
lipopolysaccharide (LPS) expression in the three media were seen, and in one of the
strains, it appeared that complement resistance was due, at least in part, to the
expression of smooth LPS.
X
Immunoglobulin G (IgG) levels to bacteroides LPS, and to a cocktail of rough LPS
from three enterobacteria and P. aeruginosa were examined in enzyme-linked
immunosorbent assay (ELISA), firstly in healthy individuals (641 blood donors). All
donors screened had anti-bacteroides and anti-enterobacterial LPS IgG present in
their serum, with levels highly variable between different individuals. The degree of
cross-reactivity of the serum IgG was examined by inhibition ELISA. This showed
some cross-reactivity between the different anti-bacteroides LPS IgG, but very little
between the anti-bacteroides LPS IgG and the anti-enterobacterial LPS IgG. Serum
IgG was then measured daily over five to nine day periods in 12 sepsis patients (six
survivors, six non-survivors) and in a healthy individual. In all patients IgG levels
fluctuated to a greater extent than in a healthy subject. Variations all followed similar
trends, and indicated that exposure to bacteroides LPS had occurred In five of the
six survivors, IgG levels increased at the end of the period, whilst in four of the non-
survivors levels decreased, with an exception showing increasing levels to B. fragilis
LPS. In five of the non-survivors, IgG levels against B. fragilis LPS were
substantially higher than those against the other LPSs. In summary, this study
demonstrated that there were some trends in antibody kinetics recognised which
suggest that bacteroides LPS may be significant in sepsis.
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The relationships which exist between micro-organisms and their hosts can be
broadly placed into three categories:
• Commensalism: the micro-organism derives benefit from the host without
causing the host any damage.
• Mutualism / Symbiosis: both the micro-organism and the host benefit from the
relationship.
• Parasitism: the micro-organism benefits from the relationship to the detriment of
the host.
These descriptions suggest clear-cut categories into which all micro-organisms can be
conveniently placed. However, in reality the relationship between micro-organism
and host is often much less simplistic; a commensal or symbiotic micro-organism
may under certain circumstances become parasitic, or a commensal organism may be
to an extent parasitic without causing significant damage to the host.
The human body has an extensive and varied microbial flora which is in a state of
dynamic equilibrium. In health, the relationship between micro-organisms and man
is either one of commensalism - for example skin-associated bacteria, or mutualistic -
for example intestinal bacteria which are provided with both the environment and
nutrients necessary for their survival, and in return aid in food degradation and
produce vitamins. In disease, the relationship is parasitic, and the greater the capacity
a micro-organism has to cause disease, the more pathogenic it is said to be.
Opportunistic pathogens will only cause disease in immunocompromised hosts. At
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the other extreme, strict pathogens are always associated with disease. Between
these two extremes, facultative pathogens (the majority of organisms) will cause
disease in a healthy or relatively healthy host if they get out of their usual niche, or if
the normal balance ofmicrobial flora is disrupted.
Man has evolved a sophisticated recognition system for potential pathogens, along
with highly efficient inflammatory and immune responses to prevent their growth and
spread, and to eradicate them from the body. In turn, pathogenic micro-organisms
have evolved ways of bypassing these host defences. The ability to adapt, evolve and
exploit weaknesses in host defences is one shared by most successful pathogens.
This thesis will examine the interaction between Bacteroides spp. (Gram-negative
facultative pathogens) and selected aspects of the immune system both in health and
disease. First it is necessary to review the general structure of Gram-negative bacteria
and the host / pathogen interaction.
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1.1 THE GRAM-NEGATIVE CELL ENVELOPE
The cell envelope of a Gram-negative bacterium is a complex structure which gives
the cell shape and rigidity, acts as a protective barrier and also as a functional
interface through which the bacterium senses and responds to the environment
(Poxton 1993). The major structures which constitute the cell envelope are the inner
or cytoplasmic membrane, the periplasm and the outer membrane (Figure 1). In
addition, many Gram-negative bacteria also possess fimbriae, flagella and a
polysaccharide capsule or slime layer.
The areas of the envelope which are in direct contact with the environment outside
the cell (including the host immune system in the case of potential pathogens) are the
outer membrane and the structures beyond. These are discussed in detail below.
1.1.1 THE OUTER MEMBRANE
The outer membrane is composed of three major components: protein,
lipopolysaccharide (LPS) and phospholipid. It acts as a selective permeability
barrier, normally only allowing the passage of small hydrophilic molecules through to
the periplasm. This barrier function is controlled by proteins and LPS.
1.1.1a Outer Membrane Proteins
There are three types of outer membrane proteins (OMPs): major OMPs or porins,
minor OMPs and lipoproteins (Benz 1988). Porins form relatively non-specific
diffusion channels or pores in the outer membrane through which small hydrophilic
nutrients can pass. Minor OMPs act as specific transport channels for molecules
which are at low concentrations in the environment (e.g. iron and vitamins) or are too
large to pass through porins. Lipoproteins have no pore function, but help to
maintain the structure and rigidity of the outer membrane. The degree of expression








Figure 1. The cell surface of a Gram-negative bacterium.
LP = lipoprotein; P = protein; PL = phospholipid. From Hancock & Poxton (1988).
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1.1.1b Lipopolvsaccharide
LPS is unique to Gram-negative bacteria. It is found in the outer leaflet of the outer
membrane where it replaces phospholipids (Stanier 1986). It is made up of three
major components: lipid A, core oligosaccharide and O-polysaccharide or O-antigen.
• Lipid A: this region is composed of long-chain saturated fatty acids, and anchors
the LPS to the outer membrane. The structure of lipid A results in very close packing
of LPS molecules into the membrane, creating an extremely rigid barrier which
prevents the passage of hydrophobic molecules into or out of the cell (Poxton 1993).
It is the region of LPS responsible for the pathophysiological or "endotoxic" effects
of LPS (endotoxin is synonymous with LPS in an infected host: Rietschel & Brade
1992). Lipid A is generally highly conserved between different Gram-negative
bacteria (Mutharia et al 1984), but substitution patterns of fatty acids and phosphates,
and chain lengths of fatty acids are variable which can result in large differences in
biological activities (degree of endotoxicity) of different LPSs (Poxton 1993).
• Core oligosaccharide: the core oligosaccharide is composed of inner and outer
regions; the inner core is fairly conserved between different bacterial species
(Jansson et al 1981) and contains two unusual sugars - heptose and 3-deoxy-D-manno-
2-octulosonate (KDO) which links the core to lipid A via an acid-labile bond (Wicken
& Knox 1980).
• O-antigen: the O-antigen is composed of a long chain of repeating oligosaccharide
units which is highly variable between different bacterial species and strains, and is
often an important determinant of pathogenicity (see Section 1.2.2). Not all Gram-
negative bacteria possess an O-antigen; those which do are referred to as having
smooth (S-) LPS and those which lack it are referred to as having rough (R-) LPS.
This can be visualised on polyacrylamide gels, where smooth strains demonstrate a
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characteristic "ladder pattern" in the high molecular weight region, with each "rung"
of the ladder representing the addition of one repeating oligosaccharide unit.
In order for a Gram-negative bacterium to be viable, it must possess lipid A and
KDO; mutants defective in synthesis of these regions have never been isolated
(Davis 1990).
1.1.2 CAPSULAR POLYSACCHARIDE AND SLIME LAYERS
Many Gram-negative bacteria are covered by either a discrete polysaccharide capsule
or a loosely attached slime layer. These form a hydrophilic matrix around the
bacterium which is used for adhesion, aggregation and biofilm formation (Poxton
1993) and is often involved in evasion of the immune system by pathogenic bacteria
(see Section 1.2.2).
1.1.3 FIMBRIAE AND FLAGELLA
Most Gram-negative bacteria have short, rigid, filamentous appendages made of
protein, called fimbriae (formerly called pili). There are usually several hundred per
cell, and they are fairly evenly distributed around the cell. Their function is one of
adhesion, and they therefore often play an important role in pathogenesis.
Flagella are present on many rod-shaped and curved bacteria, and confer motility on
the cell. They are longer and less rigid than fimbriae, are also made of protein and
may be polar (present at one or both poles of a cell) or peritrichous (all around the
cell). Flagella are important in pathogenesis when the bacterium is growing in liquid
- for example urine (Davis 1990).
1.1.4 ENVIRONMENTAL REGULATION OF THE CELL ENVELOPE
The ability of a bacterium to survive and grow anywhere is entirely dependent on its
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ability to adapt to the surrounding environment. In the case of a potential pathogen
trying to survive in a host, this will necessitate rapidly finding a place to establish
itself and grow, scavenging for nutrients and evading host defence mechanisms. All
of these adaptive processes are mediated by the cell envelope, and so the more
quickly a bacterium can adapt by appropriately changing its cell surface, the better its
chances of survival (Smith 1990). There have been numerous reports of variation in
expression of cell surface molecules with environment. Moreover, it has been
observed that expression of surface molecules by pathogenic bacteria grown in vivo
or in vitro in physiological media such as serum is markedly different from
expression in rich laboratory media (Brown & Williams 1985, Miller et al 1989b,
Smith 1990, Nelson et al 1991, Camprubi et al 1992), which is obviously an
important consideration when studying the mechanisms of pathogenesis of any given
bacterium.
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1.2 THE INTERACTION BETWEEN THE HOST AND THE PATHOGEN
Any infectious agent whether a bacterium, fungus, virus or parasite contains a huge
variety of proteins and polysaccharides which the host recognises as foreign. These
substances, collectively known as antigens (Ags) are responsible for the induction of
the host immune response.
This section will focus on the relationship between man and potentially pathogenic
bacteria.
1.2.1 HOST DEFENCES
Man has two different defence mechanisms with which to fight off potential invaders.
These act in tandem to give maximum protection (Janeway & Travers 1994).
• Innate immunity. Responsible for the early phases of the host response to
infection. A variety of innate resistance mechanisms recognise and respond to the
presence of a pathogen. These are present in all individuals at all times, are non¬
specific and do not increase with repeated exposure to any given pathogen (i.e. do not
develop immunological memory).
• Acquired immunity. Directed against specific micro-organisms, and mediated by
antigen-specific lymphocytes. This response also includes the development of an
immunological memory, which gives long-term protection from the pathogen against
which it is directed and gives a quicker and more intense response on a second
encounter with the pathogen.
1.2,1a Innate Immunity
Innate immunity can be divided into two categories - external and internal defence
mechanisms. This division is not clear-cut as many of the defence mechanisms
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usually regarded as being internal also play a role in external defence against
infection.
External Defences
The external barriers which help to protect man from potential pathogens are
summarised in Figure 2.
Internal Defences - Cellular
Phagocytic cells play a vital role in innate immunity by ingesting and destroying
invading organisms. Phagocytic cells in man are comprised of neutrophils,
monocytes and macrophages (Janeway & Travers 1994). All of these cell types
originate in the bone marrow. Neutrophils and monocytes are found in blood;
monocytes differentiate in tissues to become macrophages. All types of phagocyte
are attracted to, and engulf antigenic material much more efficiently if the Ag is
opsonised (made more attractive to the phagocyte) with antibody (Ab) and
complement (see Section 1.2.1b).
Internal Defences - Humoral
Many enzymes and proteins contribute to man's innate immune system. They are
found in tissues and body fluids such as blood, lymph, saliva, mucus and tears. One
of the most important of these is complement.
Complement
The complement system is a cascade of over 20 heat-labile proteins in serum which
lyses Gram-negative bacteria and infected cells by forming holes in their membranes.
The cascade proceeds by two distinct pathways, which are initiated in different ways.


























Figure 2. Summary of the external defence mechanisms of the human body.
Adapted from Murray et al (1994).
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to be initiated is by Ab / Ag complexes (Muller-Eberhard 1975). Only certain classes
of Ab are capable of initiating the classical pathway when complexed to Ag (Eisen &
Gefter 1990). Other substances have also been found to initiate this pathway, and
these include the lipid A region of LPS in certain bacteria (e.g. some E. coli spp:
Zohair et al 1989), porins form Gram-negative bacteria (Sim & Reid 1991), myelin
basic protein (Cyong et al 1982) and urate crystal surfaces (Giclas et al 1979). The
first component in this pathway, named CI, binds to Ab / Ag complexes or other
initiating substances, becomes activated and then splits proteins C4 and C2 to C4a
and C4b, and C2a and C2b respectively (Figure 3). C4b and C2a complex together
on the bacterial cell surface to form C3 convertase, which splits protein C3 into C3a
and C3b. C3b then complexes with C3 convertase on the membrane to form C5
convertase, which in turn splits C5 into C5a and C5b. C5b binds to the membrane,
followed by the sequential addition of proteins C6, C7, C8 and C9. These proteins
assemble to form the membrane attack complex which forms a pore in the bacterial
cell membrane, which results in lysis of the cell (Kolb et al 1972, Poddack &
Tschopp 1982).
• Alternative pathway. This pathway is initiated by various substances which
include the polysaccharide region of LPS (Morrison & Kline 1977), zymosan,
teichoic acids, bacteria, some parasites and Ab / Ag complexes where the Ab is not of
a class which initiates the classical pathway (Muller-Eberhard 1975). It is
constitutively activated at low levels in the blood, thereby providing a constant
defence against invading bacteria (Taylor 1983, Abbas et al 1991). In the alternative
pathway, Factor B binds to C3b, and then with Factor D (Figure 3). This splits the
Factor B in the complex to Ba and Bb. Bb remains complexed with the C3b to form
C3 convertase. The pathway then proceeds in an analogous fashion to the classical
pathway. The classical and alternative pathways merge at the membrane attack
complex formation stage, and thereafter are identical.
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Complement has other important functions besides cell lysis. Some C3b produced
binds directly to the cell membrane rather than forming C5 convertase, and in doing
so enhances chemotaxis of phagocytes, which have receptors for C3b. C3a and C5a
have powerful anaphylatoxic activity (Frank & Fries 1991). C5a also stimulates
phagocytes to release hydrolytic enzymes and to stimulate platelet aggregation, the
result of which is thrombosis, swelling and tissue injury (Sims & Wiedner 1991).
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Figure 3. The classical and alternative pathways of complement activation. Adapted
from Murray et al (1994).
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1.2.1b Acquired Immunity
There are two main mechanisms by which the host mounts an acquired immune
response against infection - a humoral (antibody) response and a cell-mediated
response.
Antibody Response
Antibodies or immunoglobulins (Ig) are proteins in blood and secretions which are
produced in response to infection. They are specifically directed against antigens
present on the pathogen, and they are the primary agents that protect the body against
extracellular bacteria (Sleigh & Timbury 1990). Their basic structure is shown in
Figure 4.




Figure 4. General structure of a monomeric immunoglobulin. The structure consists
of an Fc fragment (the stem of the Y) and an Fab fragment (the arms of the Y). The
Fab fragment contains binding sites for specific antigens. All immunoglobulins have
both heavy and light protein chains, held together by disulphide bridges. The type of




Immunoglobulins are produced by B- (bone marrow-derived) lymphocytes. When an
Ag encounters B-cells in the spleen or lymph nodes, the B-cells are activated and
change into Ig-secreting plasma cells. There are five different classes of Ig: IgM,
IgG, IgA, IgE and IgD, which have 11, y, a, e and 8 heavy chains respectively. In
addition, IgG and IgA are further divided into subclasses, based on differences in
heavy chain structure in the Fc fragments. B-cells produce different classes of Ig at
different stages of an infection: initially IgM is produced, and then gene
rearrangement occurs within the B-cell and a class switch occurs to one of the other
classes.
IgM is produced approximately 5-7 days following infection, and exists in a
pentameric form, with the five IgM monomers linked together at the foot of the Fc
regions by a J chain (a protein of approximately 15 kDa). The pentamer is very
effective at activating the classical complement pathway (Taylor 1983).
IgG is the most abundant Ig in serum and appears approximately 14 days post¬
infection. There are four subclasses of IgG: IgGl, IgG2 and IgG3 activate the
classical complement pathway, and IgG4 activates the alternative pathway. IgG is the
only class of Ig to cross the placenta. Memory cells are produced from B-cells as part
of the IgG response, and these cells can persist in the blood for decades. On
subsequent exposure to the same Ag, these cells will differentiate to form IgG
secreting plasma cells within 1-2 days.
IgA is divided into two subclasses - IgAl and IgA2. Both activate the alternative
complement pathway. IgA can exist in monomeric, dimeric or polymeric forms. The
IgA dimer has a single J chain (like the IgM pentamer), and also has another chain
termed secretory piece, which is necessary for its transport across epithelial cells into
external secretions. IgA normally accounts for less than 10% of the total Ig in human
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serum, but is the principal Ig in external secretions such as respiratory and intestinal
mucin, and as such plays an important role in protecting mucosal surfaces from
infection. In human serum, about 80% of the IgA is monomeric, whereas in
secretions about 90% is polymeric (mainly dimeric). Memory cells are produced as
part of the IgA response.
IgE is mainly found attached to mast cells. These are large cells, occurring
principally in submucosal tissues of the gastro-intestinal and respiratory tracts, and in
connective tissue along blood vessels, which contain granules of histamine. When Ag
binds to the cell-bound IgE, the mast cell releases the histamine granules which
induce a localised inflammatory response to clear the infection (discussed below).
IgE activates the alternative complement pathway. The function of IgD is unknown
(Eisen & Gefter 1990, Janeway & Travers 1994).
The antimicrobial properties of immunoglobulins are as follows (Murray et al 1994):
• Opsonisation - promote chemotaxis and ingestion by phagocytic cells in
conjunction with complement.
• Block attachment to host cells (IgA)
• Neutralise toxins
• Agglutinate bacteria
• Render motile organisms non-motile
• Ab + Ag activates complement. This results in bacteriolysis and induces an
inflammatory response, which brings fresh Ab and phagocytes to the site.
Cell-Mediated Response
T- (thymus-derived) lymphocytes comprise 75% of the circulating lymphocytes in
man, and are functionally more diverse than B-cells. Although the binding of Ags to
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B-cells is sufficient to initiate Ab production, an optimal B-cell response, and Ig class
switching by B-cells, requires additional signals from T-cells which are stimulated by
the same Ag. However, not all Ags stimulate T-cells; Those which do not (often
bacterial polysaccharides and other high Mr Ags) are referred to as T-cell
independent. This type of response only results in IgM production, as T-cells are
necessary for class switching. Ags which do stimulate T-cells (often proteins) are
referred to as T-cell dependent (Eisen & Gefter 1990).
There are different subsets of T-cells: T helper cells respond to specific antigenic
stimulation by releasing lymphokines (discussed below). Cytotoxic T-cells destroy
infected cells. T suppressor cells are thought to block the activity of B-cells and other
T-cells, and are possibly involved in regulation of the immune response.
1.2.1c Cytokines
Cytokines are proteins which are not antigen-specific but which play an important
role in modifying the immune response. There are two types of cytokines:
• Monokines: produced by cells of the innate immune system (monocytes and
macrophages). Include a-interferon, interleukin-1, tumour necrosis factor (TNF) a
and colony stimulating factors.
• Lymphokines: produced by cells of the acquired immune system (T-lymphocytes).
Include y-interferon, interleukin-2 and TNF p.
The role of cytokines is to modulate the immune response. Some cytokines (e.g.
TNF a, interleukin-1, interleukin-6) are proinflammatory, and produce an acute
inflammatory response, in order to contain an infection and prevent its spread from
the initial focus by stimulating the innate and acquired immune system to respond
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more efficiently to Ags. They have the following activities, which together with
activation of complement and clotting factors form the definition of an acute
inflammatory response (Murray et al 1994):
• Inhibition of macrophage migration (localises macrophages to the infection site).
• Chemotactic attraction of lymphocytes, macrophages and neutrophils to the
infected site.
• Dilatation of capillaries to increase blood flow to the infected site.
• Increase in capillary permeability to allow cellular and humoral components of
the immune system increased access to the infected site.
• Mitogenic activity or stimulation of unsensitised lymphocytes to divide, and Ig
class switching.
Other cytokines (e.g. prostaglandin E2, interleukin-10) are contra-inflammatory, and
act to control the level of, and down-regulate the inflammatory response. These are
extremely important, as an uncontrolled or prolonged inflammatory response can
have serious, even fatal consequences.
1.2.1 d The Normal Flora and the Host Immune Response
Before the subject of host defences is closed, it is important to consider the
relationship of the host with the normal microbial flora. The host must be able to
distinguish between normal flora and pathogenic bacteria, and only evoke an immune
response to invading pathogens or to normal flora when they escape from their usual
niche. An area of the body where this is particularly important is the gut. The
immune system in the gut mucosa (sometimes referred to as gut-associated lymphoid
tissue) must be able to recognise and respond to pathogens in a background of
constant stimulation from normal flora- and dietary-derived Ags. The mechanism by
which it does this is unknown. It is possible that defects in the gut immune system
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may predispose to certain diseases; for example, an under-active mucosal immunity
may increase the risk of development of systemic inflammatory response syndrome or
sepsis, whilst an over-active mucosal immunity may increase the risk of developing
inflammatory bowel disease (Ferguson et al 1994). Both of these diseases are
discussed in detail in Section 1.5.
1.2.2 THE PATHOGEN FIGHTS BACK
1.2.2a Microbial Virulence
Given the arsenal of host defences, it may appear unlikely that any invading micro¬
organism would be able to cause disease. However, this is obviously not the case.
Bacteria have evolved mechanisms to overcome the host's immune system by
adaptation, avoidance or exploitation.
In order to cause disease, a bacterium must be able to colonise host tissues, grow,
overcome the immune system and cause damage to the host (Smith 1984). The more
able a bacterium is to cause disease, the more pathogenic or virulent it is said to be.
Virulence depends on the presence of virulence factors produced by the bacterium.
These are either molecules on the surface, or excreted out of the bacterial cell which
are able to interact with the host's immune system in various ways to prevent killing
(Poxton & Arbuthnott 1990).
The ability of a bacterium to cause disease is dependent on both host and bacterial
factors. These are both discussed below.
1.2,2b Host Factors Which May Increase Risk of Disease (Sleigh & Timbury 1990)
• Malnutrition - e.g. vitamin or protein deficiency, which will impair the immune
system.
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• Age - the very young (especially pre-term neonates) and the elderly have less
efficient immune systems than other people.
• Impairment of the immune system by immunosuppressive drugs (e.g. steroids,
cytotoxic drugs), or by disease (e.g. leukaemia, AIDS).
• Change in host's microbial flora - e.g. after broad spectrum antibiotic treatment
harmless bacteria may be depleted, allowing establishment of pathogens.
1.2.2c Bacterial Colonisation
Most bacterial infections are initiated by bacterial attachment to host cells, followed
by replication which establishes colonisation (Murray et al 1994). Adherence may be
mediated by non-specific means, such as polysaccharide capsules, or may require the
interaction of structures on the bacterial surface such as lipoteichoic acids, outer
membrane proteins, haemagglutinin, flagella or fimbriae with specific glycoprotein or
glycolipid receptors on host cells (Beachey 1981). Some examples of bacterial
adherence mechanisms are listed below:
• Enterotoxigenic Escherichia coli have adhesin molecules on their fimbrial tips
which adhere to specific receptors on epithelial cells in the small intestine (Smyth et
al 1991).
• Most E. coli strains that cause pyelonephritis have fimbrial adhesins termed P
fimbriae. These binds to specific receptors on urinary tract epithelial cells (Kallenius
et al 1981).
• Streptococcus pyogenes causes throat infections and adheres to fibronectin on
buccal epithelial cells, using lipoteichoic acid (Patterson 1991).
1.2.2d Bacterial Growth
Nearly all bacteria that have been appropriately investigated need iron to grow
(Guerinot 1994). In the human body, virtually all iron is sequestered in haem-binding
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proteins, transferrin and lactoferrin. An important virulence attribute is therefore the
ability to obtain iron in this environment. Certain bacteria, such as E. coli, secrete
siderophores (iron-chelating compounds) into the surrounding environment, and
simultaneously increase expression of OMPs which act as receptors for the
siderophore / iron complex (Guerinot 1994), Some bacteria, for example Klebsiella
and Salmonella spp. are able to sequester siderophores produced by other bacteria or
fungi which they are unable to synthesise themselves (Griffiths 1993). Other bacteria
(e.g. Vibrio cholerae) produce haemolysins, lyse erythrocytes and obtain the iron
within them (Stoebner & Payne 1988). Neisseria meningitidis, N. gonorrhoeae and
Haemophilus influenzae utilise iron bound to lactoferrin or transferrin (Guerinot
1994).
1.2 2e Bacterial Resistance to the Immune System
To sustain an infection following initial colonisation and growth, a pathogen must be
able to overcome host immunological defence mechanisms. This has been achieved
by bacteria in a multitude of ways, the most well-known and important of which are
described below.
Capsules and Slime
Capsular polysaccharide and slime impair phagocytosis by their hydrophilic nature
(Murray 1994, Poxton & Arbuthnott 1990). They can also prevent phagocytosis by
size alone; mucoid Pseudomonas aeruginosa grows in microcolonies surrounded by
slime (alginate) in the cystic fibrosis lung which are too big to be engulfed (Govan &
Glass 1990). Slime can also "mop up" host opsonins such as Ab and complement,
thus preventing deposition of the opsonins on the bacterial cells (Murray et al 1994).
Some bacteria produce capsules which mimic host tissue, with the result that the
host's immune system fails to recognise the encapsulated bacterium as foreign (Jann
& Jann 1987); for example, Group A streptococci have hyaluronic acid capsules,
21
which is also present in host connective tissue (Whitnack et al 1981). Finally,
capsules can mask surface components such as LPS or teichoic acids which would
otherwise activate the alternative complement pathway (Marques et al 1992).
Antigenic Variation
Certain bacteria can rapidly vary antigenic expression. Neisseria gonorrhoeae
produces at least 12 different types of fimbriae (Swanson & Berrera 1983, Heckels
1984) with the result that the host is unable to produce sufficient Ab to clear the
infection, and vaccines against fimbriae are totally ineffective.
Anti-Immunoglobulin Proteases
Antibodies can be destroyed by specific proteases - e.g. N. gonorrhoeae produces an
IgA-specific protease (Smith 1984). Some of the effects of Abs are destroyed by
interference with complement activation (discussed below).
Prevention ofPhagocytic Killing
Certain bacteria can avoid phagocytic killing, either by encapsulation (described
above), production of enzymes which lyse phagocytes (e.g. Clostridium perfringens a
toxin; Poxton & Arbuthnott 1990) or avoidance of intracellular killing (e.g.
Salmonella typhimurium, Miller et al 1989a).
Inhibition of the Action ofComplement
The ability to destroy or avoid complement is a major virulence factor in that it will
circumvent bacteriolysis and phagocytosis. Some examples of complement resistance
are given below.
• Wild-type Salmonella minnesota (with smooth LPS) is resistant to complement,
whereas rough mutants are sensitive. The membrane attack complex assembles in
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smooth strains on the part of the O antigen most distal to the outer membrane and is
therefore unable to lyse the cell (Frank et al 1987).
• Moraxella catarrhalis is a commensal of the upper respiratory tract in children, but
some strains can become pathogenic. The clinical isolates are resistant to
complement due to a specific OMP which has anti-complement activity; complement-
sensitive strains lack this protein, and treatment of complement-resistant strains with
trypsin renders them sensitive (Verduin et al 1993).
• Group B type III streptococci have sialyated capsules. These mimic host tissue and
also mask the teichoic acids on the cell surface which would otherwise initiate the
alternative pathway (Marques et al 1992).
• Some strains of Serratia marcescens secrete a non-specific protease which cleaves
amongst other things complement components (Molla et al 1989).
• Mycobacterium leprae has receptors for complement on its surface, which it uses to
facilitate its own phagocytosis, as it is an obligate intracellular pathogen (Schlesinger
& Horwitz 1991).
1 2 2f Damage to the Host
The final requirement for pathogenicity - damage to the host - is mediated by
extracellular enzymes or other toxic substances produced by the bacterium, or
bacterial Ags which either cause damage directly or induce immunopathological
reactions:
Extracellular Enzymes
These aid the growth and spread of bacteria by breaking down host tissue and
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enabling the bacteria to withstand host defences. For example, Staphylococcus
aureus produces hyaluronidase which breaks down host tissue, and coagulase which
initiates blood clotting, thereby forming a barrier between the bacterium and the
immune system components (Iandolo 1989).
Exotoxins
These are proteins exported out of intact bacterial cells which are specific in their
actions. They may act only at the infected site or may spread via the blood stream or
the nervous system to act systemically. Examples of exotoxins include tetanus toxin,
produced by Clostridium tetani, which is a neurotoxin, and various enterotoxins
produced by E. coli which cause watery diarrhoea and may cause haemorrhagic
colitis (Poxton & Arbuthnott 1990).
Endotoxin tLipopolvsaccharidel
The toxic part of LPS is in the lipid A region. This part alone can cause all the toxic
effects of endotoxin. However, the core and the O-antigen affect the fate of
endotoxin in the host; S-LPS is more stable in the host but causes less severe damage
than R-LPS. In man, the main biological effects of LPS are pyrexia, complement
activation, activation of clotting factors, B-cell mitogenicity and cytokine induction
(Poxton & Arbuthnott 1990). If small amounts of LPS are present in the host, the
biological effects will be localised and the LPS will be neutralised and cleared.
However, if large amounts are present, a systemic inflammatory response can occur
which frequently results in death (Bone 1993; discussed in detail in Section 1.5).
Immunopathological Mechanisms
There are four types of immunopathological mechanisms by which bacteria can
damage the host besides the effects of endotoxin (Smith 1984). These effects can in
some cases be severe or even fatal.
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• Type I - immediate hypersensitivity (anaphylaxis). IgE bound to mast cells
reacts with antigens which would be innocuous in most people. The mast cells
release histamines which induce an acute inflammatory response. This is the typical
"allergic reaction" seen in hay fever, sensitivity of skin to chemicals etc. In severe
cases a systemic reaction can occur, leading to anaphylactic shock and death if not
immediately treated.
• Type II - cytotoxic reaction. This occurs when bacterial Ags are similar to
molecules in host cells; the Ags evoke Abs, which then also react with the host cells -
an autoimmune effect. This happens in rheumatic heart fever following streptococcal
infection.
• Type III - Arthus type reactions. Ab / Ag complexes are deposited on tissue,
which are then attacked by phagocytes causing tissue damage. This happens in the
kidneys following infection by Proteus mirabilis.
• Type TV - delayed hypersensitivity. Normally an infected area becomes acutely
inflamed, and the infection is cleared. However, if the infection persists for any
length of time, host tissue as well as the pathogen will be damaged by phagocytic
enzymes. This occurs in tuberculosis (Smith 1994) and cystic fibrosis (Govan &
Glass 1990).
1.2.3 SUMMARY
Pathogenicty is multi-factorial and dependent on host and parasite factors. The host-
parasite relationship is complex and delicately balanced, host defences must protect
against uncontrolled replication of the normal flora and against invasion, but at the
same time allow a symbiosis with the normal flora. When the internal balance of the
normal flora is disrupted, or when organisms invade from outside, disease results.
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1.3 BACTEROIDES IN HEALTH AND DISEASE
Members of the genus Bacteroides are Gram-negative obligate anaerobes which make
up a major part of the harmless human microbial flora of the gastro-intestinal tract but
can become pathogenic under certain circumstances. This section will discuss the
taxonomy and classification of Bacteroides spp., where they are found in health, the
circumstances in which they become pathogenic and the various diseases that they
cause.
1.3.1 THE GENUS BACTEROIDES-. TAXONOMY AND CLASSIFICATION
Until recently, the genus Bacteroides consisted of over 50 species, some of which
were only very distantly related. This was a result of poor taxonomic classification,
which allowed species that only shared marginal biochemical similarities and with a
huge range of DNA base composition (guanine + cytosine 28-61 mol %) to be
deposited into the genus Bacteroides (Shah & Gharbia 1991). Therefore a major
reclassification was proposed by Shah & Collins in 1989 to restrict the genus to those
species which were closely related chemically and biochemically to the type species
Bacteroides fragilis. This reduced the number of species in the genus to the
following ten, which were formerly known as the "true Bacteroides" or the "B.
fragilis group": B. fragilis, B. caccae, B. distasonis, B. eggerthii, B. merdae, B.
ovatus, B. stercoris, B. thetaiotaomicron, B. uniformis and B. vulgatus.
Members of the genus Bacteroides as it now stands have the following properties
(Shah & Collins 1989, Shah & Gharbia 1991):
• Gram-negative, obligately anaerobic, non-sporing bacilli or cocco-bacilli
• Non-motile
• Bile tolerant - grow in, and often stimulated by the presence of 20% bile
• DNA base composition within the range guanine + cytosine 40-48 mol %
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• Saccharolytic - produce acetic and succinic acids as the major end products of
glucose metabolism
• Possess malate, glutamate, glucose-6-phosphate and 6-phosphogluconate
dehydrogenases
• Possess sphingolipids
• Possess predominantly methyl branched long chain fatty acids
• Possess menaquinones as sole respiratory quinones
• Peptidoglycan contains /weso-diaminopimelic acid
In addition to the ten species currently classified as Bacteroides, it has been recently
proposed that an eleventh species, B. variabilis, be added to the genus as it also
possesses the above criteria (R. Brown, personal communication; paper submitted).
For the purposes of this thesis, B. variabilis is included as a member of the genus
Bacteroides.
1.3.2 BACTEROIDES IN HEALTH
Members of the genus Bacteroides form part of the normal human microbial flora in
the large intestine. Human faeces contains approximately 10i0-10u bacteria per
gram, with strict anaerobes outnumbering facultative bacteria (such as E. coli) by
between 100-1000 to 1 (Hentges 1993). Bacteroides is the predominant genus in
faeces, accounting for approximately 20-30% of all faecal anaerobes isolated
(Namavar et al 1989). However, the proportion of these organisms relative to other
faecal organisms varies greatly with diet; people taking a typical "Western diet" high
in saturated fat and low in fibre have a higher proportion of Bacteroides spp. than
people eating a vegetarian diet. This is thought to be because bile production is
stimulated by food with a high fat content, allowing increased growth of Bacteroides
spp. which are resistant to, or stimulated by the presence of bile (Drasar & Duerden
1991, Thompson et al 1992). It has also been suggested previously that emotional
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stress may alter the composition of faecal flora (Holdeman et al 1976).
1.3.3 RELATIVE FREQUENCIES OF DIFFERENT BACTEROIDES SPP. IN
THE LARGE INTESTINE
Extensive studies carried out on faecal samples showed B. vulgatus, B.
thetaiotaomicron and B. distasonis to be the most common Bacteroides spp. present.
B. fragilis was the least common, accounting for only 0.3-0.6% of all Bacteroides
spp. isolated (Moore & Holdeman 1974, Holdeman 1976). These and many other
similar studies carried out on faecal samples assumed that faecal flora was
representative of the flora in the entire colon. A more recent study compared the
frequency of Bacteroides spp. in faeces, colon lavage fluid and colonic mucosa
(Namavar et al 1989). This study found B. vulgatus, B. uniformis and B.
thetaiotaomicron to be the most common Bacteroides spp. in faeces, accounting for
approximately 45, 22 and 15% of isolates respectively, and B. fragilis to be one of the
least common, representing approximately 4% of isolates. However, the frequency of
B. fragilis increased considerably in colon lavage fluid, coming second only to B.
vulgatus, and in colonic mucosa B. fragilis was the most frequently isolated spp.,
accounting for approximately 43% of all Bacteroides isolates, with B. vulgatus
accounting for about 25%. B. fragilis was the only sp. with a lower prevalence in
faeces than colonic mucosa, which suggests that it has a closer association with the
gut mucosa than other Bacteroides spp., and presumably means that it has a greater
capacity to adhere to gut epithelial cells. Moreover, these results suggest that the
occurrence ofB. fragilis in the intestinal flora has previously been underestimated.
1.3.4 NORMAL MICROBIAL FLORA: ADVANTAGES AND
DISADVANTAGES
The normal microbial flora can be both advantageous and disadvantageous to the
host. One of the principal advantages is that it prevents colonisation by potential
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pathogens; gut bacteria release a number of factors with bactericidal activity (e.g.
bacteriocins, colicins, metabolic waste products), which together with lack of
available oxygen prevent establishment of other species. The sheer number of
bacteria present in the normal intestinal flora means that almost all of the available
ecological niches are occupied, preventing growth of invading species. In addition,
gut bacteria release organic acids, B vitamins and vitamin K which can then be
utilised by the host. They are also thought to play an important part in normal
development of the immune system; germ-free animals are very vulnerable to, and
very poor at coping with infection (Mims et al 1993).
The normal flora become disadvantageous when they get out of their usual niche and
spread to previously sterile parts of the body, where they can become pathogenic.
This usually occurs with gut bacteria following intestinal perforation. Bacteroides
spp. in the gut are generally thought of as harmless, but when they escape from the
gut into other areas of the body they frequently become pathogenic, and are one of
the major causes of anaerobic infections in man (Finegold 1995).
1.3.5 ANAEROBIC INFECTIONS: GENERAL OVERVIEW
Anaerobic infections are common, can occur anywhere in the body, are often serious
and sometimes fatal. The incidence of anaerobic infections is probably generally
underestimated due to difficulties in specimen collection, transportation and
processing. Moreover, treatment of these infections often proves difficult, as many
anaerobes are inherently resistant to a large range of antibiotics, and failure to treat
for anaerobes in mixed infections (which occurs if the anaerobe is not detected) often
leads to little or no response (Finegold 1995).
Many anaerobic infections in man are caused by the normal microbial flora,
originating mainly from mucosal surfaces and (much less frequently) the skin. Some
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of the factors which may predispose a person to anaerobic infection are as follows
(Drasar & Duerden 1991):
• Impaired blood supply
• Disruption of epithelial barriers
• Tissue injury (reduces redox potential)
• Compromised host defences
• Presence of aerobic and facultative bacteria (reduces redox potential)
• Bacterial virulence factors
1.3.6 BACTEROIDES IN DISEASE
Bacteroides spp. are involved in a variety of infections including intra-abdominal,
pelvic, brain and lung abscesses, and (less frequently) diabetic foot ulcers, wound
infections, bacteraemia and endocarditis (Patrick 1993, Finegold 1995). B. fragilis is
the most commonly isolated anaerobe in clinical specimens, and the most common
cause of anaerobic bacteraemia (Lindberg et al 1979). Its greater pathogenicity
compared to the other Bacteroides spp. is thought to be due at least in part to its
closer association with the gut mucosa (Namavar et al 1989). Other Bacteroides spp.
are also isolated from infections, but less frequently than B. fragilis. In a study by
Brook (1989), clinical isolates from abdominal and pelvic wound infections,
abscesses and bacteraemia were collected over a 12 year period. B. fragilis was the
most commonly isolated of the Bacteroides spp., accounting for 78% of all isolates,
followed by B. thetaiotaomicron (14%), B. ovatus and B. vulgatus (both 3%).
Interestingly, although B. fragilis is by far the most common clinical isolate, it has
been reported that mortality rates are higher from infections involving B.
thetaiotaomicron, B. vulgatus and B. distasonis (Chow & Guze 1984, Brook 1989).
However, this should be viewed with caution due to the small numbers of patients
involved in these studies and the lack of information on patient histories.
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By far the most common site from which clinical Bacteroides isolates are recovered is
intra-abdominal abscesses. These are discussed below.
1.3.7 INTRA-ABDOMINAL ABSCESSES
1,3 ,7a Aetiology and Pathology
An abscess consists of a collection of leukocytes (live and dead), bacteria and cell
debris surrounded by a thick wall of damaged and inflamed tissue which the host
makes to try to contain the infection. It can have serious consequences for the host as
it can spread to nearby sites with resultant necrosis of adjacent tissue, acts as a
reservoir of bacteria which can then enter the blood stream, and the resulting
bacteraemia can cause shock or produce metastatic infections at distant sites (Tally
1993). Intra-abdominal abscesses usually occur as a result of perforation of the gut
wall, causing spillage of intestinal contents into the peritoneal cavity. Gut perforation
may occur following direct trauma, appendix or diverticular rupture, and is also one
of the most frequent post-operative complications following abdominal surgery
(Brook 1993).
The infectious process leading to abscess formation is biphasic; it starts with acute
inflammation, which will be followed by abscess formation if host defences are
unable to eradicate the infection. Both the acute inflammation and the abscess stages
of infection are polymicrobial in nature, consisting of a mixture of facultative
anaerobes and anaerobic bacteria. At the moment when the colonic contents are
spilled, the peritoneal cavity is well-oxygenated. Therefore in the inflammation
(peritonitis) stage, facultative anaerobes (mainly E. coli) are numerically predominant
in the infection. However, strict anaerobes that are able to resist the toxic effects of
oxygen remain viable, and when the area becomes more anaerobic (due to facultative
bacteria depleting available oxygen and a decrease in blood supply to the site) the
anaerobes will grow, and become numerically predominant in the abscess stage
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(Finlay-Jones et al 1991, Tally 1993).
It is usual in an abscess to have several anaerobic species present. The most
frequently isolated anaerobe is B. fragilis, followed by B. thetaiotaomicron, then
other Bacteroides spp. (Finegold 1995). Members of the genus Bacteroides are
generally oxygen-resistant (especially B. fragilis), which together with their high
numbers in the colon probably explains why they feature so strongly in intra¬
abdominal abscesses. Bacteroides are often numerically predominant, but there may
also be other species present such as peptostreptococci, fusobacteria and Clostridia
(Brook 1993).
1.3 7b Microbial Synergy
For a long time it was thought that the contribution of anaerobes to the virulence of
mixed infections was insignificant (Rotstein 1993). However, it was subsequently
observed that in experimental models of intra-abdominal infection, abscess formation
and lethality were greater when a mixture of a facultative anaerobe and an anaerobe
was injected, as opposed to just one or the other (Onderdonk et al 1976, Rotstein et al
1989). Moreover, it was observed that patients with abscesses who were treated with
antibiotics effective against both facultative anaerobes and anaerobes made
significantly better recoveries than patients treated with antibiotics effective against
facultative anaerobes only (Berne et al 1982). It was also shown that killing of
facultative anaerobes by phagocytes in vitro was inhibited by the presence of B.
fragilis (Ingham et al 1977, Ingham et al 1981), and both the capsule (Reid & Patrick
1984) and the LPS (Jones & Gemmell 1986) of B. fragilis were implicated in this
process. The exact mechanism by which B. fragilis impairs phagocytic killing is
unclear, but it has become evident that anaerobes and facultative anaerobes exist in a
synergistic relationship in a mixed infection. Anaerobes appear to be able to impair
killing of both themselves and the facultative bacteria, whilst the facultative bacteria
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keep the redox potential low, allowing survival and growth of the anaerobes.
1.3.8 TREATMENT OF INTRA-ABDOMINAL ABSCESSES
Successful treatment of intra-abdominal abscesses often proves difficult. A combined
medical and surgical approach is usually required; the surgical side involves repair of
the perforation which is allowing spillage of intestinal contents into the peritoneal
cavity, and drainage of the abscess. However, even after drainage abscesses can often
recur. The medical treatment involves antibiotic administration. As mentioned
earlier, this is only usually successful if antibiotics are given which will be effective
against all of the bacteria in the abscess. Unfortunately there are two major problems
with this - firstly a lot of anaerobes are resistant to many antibiotics. Bacteroides spp.
all contain (3 lactamases and are therefore resistant to penicillin-based drugs unless the
drug also contains a p lactamase inhibitor. They are also resistant to many
cephalosporins, and some recent surveys from the USA have reported isolation of
clinical Bacteroides strains resistant to all antibiotics except the chloramphenicols
(Finegold 1995). The second major problem with antibiotic treatment of abscesses is
that the nature of the abscess itself reduces the efficacy of many antibiotics; the poor
blood supply, low pH, low oxygen content and high bacterial inoculum all impair
antibiotic action (Drasar & Duerden 1991). Despite all this, it is usually possible to
successfully treat an abscess if a proper diagnosis is made, followed by surgical
intervention and administration of an appropriate and large enough course of
antibiotics.
33
1.4 BACTEROIDES VIRULENCE FACTORS
To date, the vast majority of work to determine the virulence mechanisms of
Bacteroides spp. has been carried out on B. fragilis, as it is the most common
anaerobic pathogen. This chapter will therefore mainly deal with B. fragilis, but
other Bacteroides spp. will be mentioned where information is available.
Possible virulence determinants of B. fragilis include surface polysaccharides
(capsular polysaccharide [CP] and LPS), resistance to complement and phagocytosis,
nutrient uptake in vivo, release of extracellular degradative enzymes, fimbriae and
enterotoxin production (Namavar et al 1991, Patrick 1993). These are discussed in
turn below.
1.4.1 SURFACE POLYSACCHARIDES
There has been a lot of research carried out on the surface polysaccharides of B.
fragilis, but unfortunately many of the results obtained to date are confusing,
controversial and remain open to debate. One of the main reasons for this is that the
surface polysaccharides of B. fragilis (and probably other Bacteroides spp.) are very
closely linked and therefore very difficult to purify. This has led to numerous
situations in the past of researchers working with material which they have claimed to
be "purified" CP or LPS, whereas in fact the material was not pure, and what it
actually contained was dependent on the extraction procedure employed to obtain it.
Bearing this in mind, there follows a summary of what is known about the CP and
LPS of Bacteroides spp.
1.4, la Bacteroides Capsular Polysaccharide
The CP of B. fragilis has been considered for many years to be a major determinant
of pathogenicity. It was originally reported that B. fragilis was the only member of
the genus Bacteroides to possess a capsule, and that this was the reason why it was
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more pathogenic than the other spp. (Kasper 1976, Kasper et al 1977, Onderdonk et
al 1977a). However subsequent studies using light and electron microscopy showed
other strains (B. vulgatus, B. thetaiotaomicron and B. ovatus) to have capsules also
(Babb & Cummings 1978, Bjornson et al 1983). The main areas of research carried
out on Bacteroides CP are in antigenic variation, virulence of encapsulated spp. and
CP structure.
Antigenic Variation of Capsular Polysaccharide
Babb & Cummins (1978) noted varying degrees of encapsulation of different cells
within any given strain. Following on from this observation, Patrick and colleagues
found that altering the growth medium from nutrient-rich to the minimal medium of
Van Tassell & Wilkins resulted in greatly enlarged capsules in B. fragilis, facilitating
classification and quantification of different cell types (Patrick 1993). The different
cell types were separated using Percoll discontinuous density centrifugation; a step
gradient of Percoll was produced by layering equal volumes of 80, 60, 40 and 20%
Percoll into a test tube. A sample of the test bacterial culture was layered on top of
the gradient, and following centrifugation, three distinct sub-populations of cells
resulted, which were visualised by light microscopy and India ink staining. Cells at
the 0-20% Percoll interface had large capsules (LC), those at the 20-40% interface
had small capsules (SC), those at the 40-60% interface were a mixture of SC and non-
capsulate (NC) cells and those at the 60-80% interface were NC (Patrick & Reid
1983). Subsequent studies using electron microscopy revealed large and small
fibrous networks in the LC and SC populations respectively, and a narrow electron
dense layer (EDL) outside the outer membrane in NC cells (Patrick et al 1986).
Monoclonal antibodies (MAbs) were produced against the different cell populations,
and studies using these gave several surprising revelations. First, the SC was
antigenically distinct from the LC, and not simply a smaller amount of LC; second,
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the EDL was antigenically distinct from the SC and not simply a smaller amount of
fibrous material (Reid et al 1987); third, some MAbs reacted with both the LC and
EDL cell populations - in the LC population the MAbs reacted with both cell-
associated material and also cell-free material, whereas in the EDL population they
reacted with cell-free material only (Lutton et al 1991).
This antigenic variation of cell surface structures could be extremely important in the
pathogenisis of B. fragilis - for example in evasion of the acquired immune system.
Unfortunately it has not been taken into consideration by many researchers, with the
consequence that many experiments have been carried out using heterogeneous cell
populations which have given conflicting and confusing results.
Virulence ofEncapsulated Bacteroides species
Onderdonk et al (1977a) compared the ability of encapsulated and non-encapsulated
B. fragilis strains to produce abscesses in rats. They found that live encapsulated
strains produced abscesses in nearly all cases, whereas live non-encapsulated strains
rarely did. In addition, they found that heat-killed encapsulated strains and purified
CP produced sterile abscesses in most cases. It was subsequently shown that abscess
induction by B. fragilis CP could be prevented by prior immunisation with this
polysaccharide and that the immune response which protected against abscess
formation was T-cell dependent (Onderdonk et al 1982, Shapiro et al 1982).
Whether it was CP that was solely responsible for abscess formation is a matter of
debate, as the "purified" CP was probably contaminated with protein and LPS. CP
subsequently obtained using improved purification methods (Pantosti et al 1991) is
still reported to induce abscesses in experimental animals (Tzianabos et al 1993), but
whether the material is totally pure remains debatable. However it does appear that
CP plays a major, if not necessarily exclusive role in abscess formation.
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Encapsulated B. fragilis strains were reported to adhere to rat epithelial cells better
than other Bacteroides spp. (which at the time were thought to be non-capsulate:
Onderdonk et al 1977b). Unfortunately the ability of non-encapsulated B. fragilis
strains to adhere was not investigated, but despite this, these results are in agreement
with the later study by Namavar et al (1989) which showed B. fragilis to be in closer
association with the gut mucosa than other Bacteroides spp. The greater capacity of
B. fragilis to adhere to host cells compared to other Bacteroides spp. is likely to be
one of the reasons for its greater pathogenicity.
The ability of encapsulated and non-encapsulated B. fragilis cells to resist
phagocytosis has been investigated (Reid & Patrick 1984). It was found that
encapsulated organisms were significantly more resistant to engulfment and killing by
phagocytes than their non-capsulate counterparts. This might suggest that in mixed
infections capsulate Bacteroides spp. prevent phagocytosis of both themselves and
facultative anaerobes, possibly by mopping up host opsonins. A study by Brook et al
(1992), which found 78% of Bacteroides spp. isolated from human abscesses to be
capsulate, appears to support this theory. However, studies carried out on
experimental animals found that Bacteroides spp. present in abscesses or implanted
chambers were often non-capsulate (Patrick et al 1986, Jotwani et al 1992). The CP
in at least one of these studies (Patrick et al 1986) was present as cell-free slime,
which would still inhibit phagocytosis. Differences such as these between animal
models and human studies highlight the fact that in vivo models are often not an
accurate representation ofwhat happens in "real life".
Structure ofBacteroides fragilis Capsular Polysaccharide
Recent studies have reported that the CP of the type strain B. fragilis NCTC 9343
consists of two distinct high molecular weight polysaccharides, termed PSA and PSB
(Pantosti et al 1991). Each polysaccharide is composed of repeating oligosaccharide
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units which both contain positive (amino) and negative (phosphate and / or carboxyl)
groups (Baumann et al 1992). The overall charge of PSA is neutral, whereas the
overall charge of PSB is negative, and the two polysaccharides form a complex
structure which is held together by ionic interactions (Tzianabos et al 1992).
The structures of hundreds of bacterial polysaccharides are now known, and the
presence of oppositely charged groups on the constituent oligosaccharides is highly
unusual. Tzianabos et al (1992) noted that only polysaccharides with these unusual
structures were capable of inducing abscesses in experimental animals. To try to
discover which part of the structure was important in abscess formation, chemical
modifications were introduced into B. fragilis NCTC 9343 CP, and the ability of the
modified CP structures to induce abscesses was assessed (Tzianabos et al 1994). It
was found that the positively and negatively charged groups were required together
for abscess induction, and although no specific type of negatively charged group was
necessary, the presence of a non-acetylated free amino group was required.
A potential major flaw in this work is that the authors have not considered that they
have probably extracted and analysed CP from a heterogeneous cell population.
MAbs raised against PSA and PSB only partially cross-reacted with CP extracted
from other B. fragilis strains (Pantosti et al 1992, Pantosti et al 1993), which suggests
antigenic variation. Moreover, in these studies it was quoted that PSA and PSB
exhibit variable expression on the cell surface of B. fragilis NCTC 9343, and that this
explains the antigenic differences between LC, SC and EDL populations as observed
by Patrick & colleagues. However, it is equally possible that the CP of some cells




Bacteroides fragilis Lipopolvsaccharide: Rough or Smooth?
Controversy surrounding bacteroides surface polysaccharides does not stop with CP;
there has been an ongoing debate for years as to whether the LPS of B. fragilis is
rough or smooth. The confusion in this case has largely arisen due to different
extraction techniques employed to obtain the LPS. B. fragilis LPS was originally
reported to be rough (Kasper et al 1983, Weintraub et al 1985), but it was obtained
using the phenol / chloroform / petroleum ether (PCP) extraction method of Galanos
et al (1969) which is selective for rough LPS. Moreover, Kasper et al (1983)
assumed that the surface polysaccharides of B. fragilis were composed simply of CP
and LPS, which could be easily separated as, for example, those of E. coli can.
However, Cousland & Poxton (1984) demonstrated by crossed
immunoelectrophoresis that the surface polysaccharides of B. fragilis were
structurally and antigenically very complex. Subsequently, ladder patterns
characteristic of smooth LPS were observed by polyacrylamide gel electrophoresis
(PAGE) and immunoblotting of some B. fragilis strains (Poxton & Brown 1986).
This was achieved by using aqueous phenol, which selectively extracts smooth LPS
(Westphal & Luderitz 1954). In addition, a common antigen band was observed in
all strains, migrating behind the lipid A and core regions which had not been
observed in PCP extracts. Further reports of smooth LPS in B. fragilis have since
been published; ladder patterns have been observed in LPS from the NC cell
population ofB. fragilis NCTC 9343 using MAbs (Lutton et al 1991), and in some B.
fragilis strains by silver staining (Maskell 1994).
Bacteroidesfragilis Lipid A Structure: Relation to Biological Activity
The structure ofB. fragilis lipid A has been elucidated. It is markedly different from
E. coli lipid A (Figure 5), and has a lower biological activity than that ofE. coli. The
differences in biological activity are thought to be a direct result of differences in
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Figure 5. Differences in lipid A structure of E. coli (A) and B. fragilis (B): O the
fatty acids of B. fragilis lipid A have chain lengths of 15-17 carbon atoms, whereas
those of£. coli have 12-14 , © there are 4-5 fatty acids per diglucosamine residue in
B. fragilis lipid A, c.f. 6 in E. coli, © there is one ^-hydroxy fatty acid substituted
with a non-hydroxylated fatty acid in B. fragilis c.f. two in E. coli, © B. fragilis lipid
A has one phosphate residue c.f. two in E. coli and © (not illustrated) the KDO of B.
fragilis is phosphorylated whereas that of E. coli is not. From Magnuson et al (1989).
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structure. The degree of difference is yet another matter of controversy; Lindberg et
al (1990) found the biological activity of PCP-extracted LPS to be 100- to 1000-fold
less than that of E. coli in various in vivo and in vitro assays. In contrast, a recent
study in our laboratory found B. fragilis LPS to be more biologically active than
previously thought, and degree of biological activity was highly dependent on
extraction technique (Delahooke et al 1995a). LPS was extracted from bacteria using
three different techniques: Triton-Mg2+ (Uchida et al 1987: mild, non-selective
extraction), PCP and aqueous phenol. The Triton-Mg2+ and PCP methods both gave
low biological activities in various assays, comparable to previously published
reports. However the aqueous phenol extracts showed much higher activity, with B.
fragilis being up to 30-fold more active than E. coli in the limulus amoebocyte lysate
chromogenic (LAL) assay, and 4-fold less active than E. coli in a TNF induction
assay.
Lipopolvsaccharide of Bacteroides species other than Bacteroidesfragilis
There has not been a vast amount of work carried out on the LPS of Bacteroides spp.
other than B. fragilis. B. fragilis LPS has been reported to be more biologically
active in a range of assays than other Bacteroides spp., which is in keeping with its
greater pathogenicity (Delahooke et al 1995a). Resolution of bacteroides LPS by
PAGE often proves difficult due to problems in separating the surface components,
meaning that material staining on gels may not necessarily be LPS but could be
residual protein or CP. Electrophoretic analysis of bacteroides LPS has shown B.
vulgatus, and some strains of B. stercoris and B. eggerthii to produce ladder patterns
characteristic of smooth LPS. The LPS profiles of B. thetaoitaomicron, B. caccae
and B. ovatus have been shown to be very similar, and although some minor inter-
strain variations were seen, most species generally showed a species-specific profile
(Maskell 1991, Masked 1994). There have not been any reports published of
variation in bacteroides LPS expression in different growth environments.
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1.4.2 RESISTANCE TO COMPLEMENT
Previous studies have shown that Bacteroides strains isolated from infections are
generally more resistant to complement than those isolated from faeces (Casciato et al
1975, Casciato et al 1979), suggesting that complement resistance is an important
virulence factor for Bacteroides spp. In addition, clinical isolates of B. fragilis were
found to be more resistant to complement than clinical isolates of other Bacteroides
spp. (Casciato et al 1979, Rotimi & Eke 1984), which represents another factor
contributing to the greater pathogenicity of B. fragilis. Another study found
complement resistant strains of B. fragilis to survive better than complement sensitive
strains in a subcutaneous model of infection (Namavar et al 1991). However, the
mechanism of complement resistance in Bacteroides spp. is unknown. Reid &
Patrick (1984) compared the ability of capsulate and non-capsulate B. fragilis strains
to resist complement. It was found that possession of a capsule did not confer
complement resistance, and in one strain tested, the non-capsulate cells were
significantly more resistant than capsulate cells. This could be because the non-
capsulate cells excrete CP as cell-free slime (Lutton et al 1991) which could
theoretically mop up complement components at a distance from the bacterial cells,
thereby preventing their deposition on the cell surface. It has been shown that
complement resistance in B. fragilis and B. vulgatus is not due to lack of C3
deposition on the cell surface (Vel et al 1986), and in B. fragilis and B.
thetaiotaomicron it is not due to lack of activation of the alternative complement
pathway (Bjornson et al 1987). However, the roles of LPS, OMPs, other bacterial
factors and host factors such as classical complement pathway activation in
complement resistance of Bacteroides spp. have not been investigated. Moreover,
complement resistance of strains grown in different environments (which can
significantly alter cell surface antigen expression) have not been investigated.
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1.4.3 NUTRITION IN VIVO
Any bacterium which escapes from the gut will find that nutrients are much less
abundant elsewhere in the body. In order to survive, pathogenic Bacteroides spp.
must be able to obtain nutrients at the infected site. This is achieved in two ways
described below.
1.4 .3 a Release of Extracellular Enzymes
Bacteroides spp. have been found to release extracellular enzymes including
hyaluronidase, DNase, lipase, proteases and neuraminidase, all of which are capable
of breaking down host tissues and cells (Rudek & Haque 1976). The fact that
Bacteroides spp. in infected sites do not cause extensive, fast destruction of host
tissue suggests that the activity of these enzymes is localised (Patrick 1993). The
breakdown products are probably taken up into the cell and used as a nutrient supply.
1.4,3b Outer Membrane Protein Expression and Iron Uptake
In order to survive in a new environment, a bacterium must be able to change OMP
expression appropriately to obtain nutrients. It therefore might be expected that the
OMP profile of any given strain grown in vitro would be different to the profile in
vivo. However, a study which compared OMPs of B. fragilis grown either in broth
culture or in chambers in mouse peritoneal cavities did not reveal any major
differences in OMP expression (Patrick & Lutton 1990). It is possible in this case
that some subtle differences were not picked up as Coomassie blue was used to stain
the proteins, which is not particularly sensitive.
The OMP profiles of Bacteroides spp. have been shown to be much more complex
than those of E. coli (Diedrich & Martin 1981, Kotarski & Salyers 1984). Several
bacteroides OMPs have been identified. The first to be identified was a porin from B.
distasonis (Wexler et al 1992) and the second was a 44 kDa protein expressed by B.
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fragilis under iron limitation (Otto et al 1990b). Recently, three porins have been
identified in B. fragilis, all of which allow the diffusion of small (Mr < 340-400)
molecules through the membrane (Kanazawa et al 1995). There is no evidence to
date that Bacteroides spp. produce siderophores (Otto et al 1988), although they may
be able to utilise those produced by other bacteria, and there is no evidence that they
utilise iron bound to transferrin or lactoferrin. However it appears that the 44 kDa
iron-regulated OMP is involved in uptake of haem (Otto et al 1990a), and research to
date suggests that B. fragilis uses haem from haemoglobin as an iron source in vivo.
Further supporting evidence for this is that Abs against the 44 kDa OMP have been
found in patients with B. fragilis infections, demonstrating that the protein is
expressed in vivo (Otto et al 1992), and B. fragilis has been recently reported to
produce a haemolysin (Otto et al 1995).
1.4.4 FIMBRIAE
It has previously been reported that the ability of bacteria to agglutinate erythrocytes
is sometimes associated with the presence of fimbriae (Hofstad 1984). Fimbriae were
first recognised in B. fragilis when it was observed that some clinical unencapsulated
strains were able to agglutinate erythrocytes (Pruzzo et al 1984). Moreover, the
haemagglutinating strains were up to 20-fold more adhesive to epithelial cells, and
also up to 7-fold more sensitive to phagocytosis than non-haemagglutinating strains
(presumably due to increased adherence to phagocytic cells). All of these strains
were shown by electron microscopy to possess fimbrial-like structures. A later study
by Brook et al (1992) which looked at the percentage of B. fragilis strains with
fimbriae isolated from different sites showed 6% from blood, 75% from abscesses
and 69% from normal flora to possess fimbriae. These studies suggest that fimbriae,
possibly in addition to capsule, are involved in adherence of B. fragilis to host cells,
and are therefore important in attachment and colonisation of potentially pathogenic
species. Furthermore, localised agglutination of erythrocytes may erect a barrier
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between the bacterial cell and the host immune system, as does coagulase produced
by S. aureus. In abscesses and the gut, the majority of strains expressed fimbriae,
which would presumably localise them to the area and facilitate attachment to host
cells, whereas in blood only 6% of strains expressed fimbriae, so attachment would
be less efficient and systemic spread would be facilitated. Fimbriae have been looked
for in all Bacteroides spp. (Brook 1992) but have only been detected in B. fragilis,
which may partly explain why it is more closely associated with gut mucosa than
other spp., and may represent another facet of its greater pathogenicity.
Attempts have been made to characterise fimbriae from B. fragilis. Van Doom et al
(1987) reported that fimbriae from B. fragilis were approximately 4 nm in diameter
and were composed of subunits with molecular weights of 40 to 42 kDa. The
expression of fimbriae appeared to be environmentally regulated, being repressed
under iron limitation and at a growth temperature of 20°C. Subsequently Lutton et al
(1989) visualised fimbriae from different B. fragilis strains grown in vitro by electron
microscopy and immunoblotting. Electron microscopy showed fimbrial structures
which are thought to be dehydrated capsular material on LC and SC, but not EDL cell
populations. Immunoblotting with serum against purified fimbrial antigens detected
fimbriae predominantly in SC cell populations, but in some strains fimbriae were
also detected in LC and EDL populations. In addition, four B. fragilis strains were
grown in chambers in mouse peritoneal cavities, and fimbrial antigen was detected in
all strains by immunoblotting. Expression of fimbriae in this in vivo model is in
agreement with results from the human study which showed a high percentage of
strains from abscesses to express fimbriae (Brook et al 1992).
Studies on fimbriae of Bacteroides spp. are far from complete. Progress in this area
has proved difficult due to problems in visualising fimbriae on cells, and a general
lack of knowledge of growth conditions which favour the expression of fimbriae
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(Patrick 1993). Moreover, although it is thought that B. fragilis fimbriae enhance
attachment to host cells, the mechanism by which they do so is unknown, and
whether they mediate attachment via specific host cell receptors as some other
bacterial fimbriae do remains to be seen. Lastly, as was the case with capsule, it may
transpire that species of Bacteroides other than B. fragilis also produce fimbriae.
1.4.5 ENTEROTOXIN
Enterotoxigenic B. fragilis strains were initially isolated from the faeces of lambs,
calves, pigs and foals with diarrhoea. In 1987, Myers et al isolated enterotoxigenic
strains from 8 of 44 humans with diarrhoea. Symptoms lasted from 1-4 weeks, and
included watery diarrhoea, intestinal cramps, and infants additionally had pyrexia,
vomiting and bloody diarrhoea. Subsequent studies revealed that enterotoxigenic B.
fragilis appear to be carried in approximately 5-10% of the general population (Shoop
et al 1990).
An enterotoxin from B. fragilis has been purified (Van Tassell et al 1992), which was
found to produce both enterotoxic and cytotoxic effects. It has recently been shown
to be a metalloprotease (Moncrief et al 1995). Clinical and faecal isolates of B.
vulgatas, B. thetaiotaomicron and B. distasonis have also been examined for
enterotoxin, but none were found to produce it (Van Tassell et al 1992).
Diarrhoea kills around 10 million people per year worldwide, and in many cases the
cause is never discovered. It is possible that enterotoxigenic B. fragilis may be
responsible for at least some of these deaths. Moreover, it is possible that some of the
localised tissue damage seen in B. fragilis infections is due to enterotoxin. It would
be interesting to find out how many B. fragilis strains isolated from abscesses and
other infections were enterotoxigenic.
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1.4.6 SUMMARY
Bacteroides spp., particularly B. fragilis, possess a lot of potential virulence
determinants, but despite extensive research many unanswered questions remain.
Confusion has mainly arisen due to the complexity of the surface antigens. Different
virulence determinants are probably involved in pathogenesis at different stages of the
infectious process, and it is likely that strains which are best able to co-ordinate
virulence factor expression are the ones which will survive outwith the gut and cause
infection.
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1.5 POTENTIAL ROLE OF RACTEROIDES SPECIES IN SYSTEMIC
INFLAMMATORY RESPONSE SYNDROME AND INFLAMMATORY
BOWEL DISEASE
Bacteroides spp., especially B. fragilis, have been shown to be important pathogens
which are frequently isolated from anaerobic infections. Despite this, there are some
disease processes in which bacteroides could play a major role, but to date have been
largely overlooked or dismissed as insignificant. Two examples of these are systemic
inflammatory response syndrome (SIRS) and inflammatory bowel disease (IBD). A
summary of current knowledge of SIRS and IBD is given below, and the possible role
of bacteroides in these diseases is discussed.
1.5.1 SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
1.51a Definition of Systemic Inflammatory Response Syndrome
SIRS is the latest in a long list of terms which have been used to describe a severe
generalised illness which is the leading cause of death in intensive care patients (Bone
1993, Darville et al 1993). Other terms which have been used include sepsis, severe
sepsis, septic shock and sepsis syndrome.
SIRS is diagnosed by the presence of two or more of the following manifestations
(Bone et al 1992):
• Temperature > 38°C or < 36°C
• Heart rate > 90 beats per minute
• Respiratory rate > 20 breaths per minute or pC02 <32 mm Hg
• Leukocyte count > 12 x 109 cells per litre or < 4 x 109 cells per litre, or the presence
of > 10% immature neutrophils
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1.5.1b Aetiology and Pathology
SIRS occurs as a result of bacterial products (usually endotoxin [LPS]) entering the
circulation and binding to host cells via specific receptors (CD14, plus possibly other
receptors, in the case of LPS: Rietschel & Brade 1992). This binding stimulates
certain host cells (macrophages, neutrophils, T-cells and endothelium) to produce
inflammatory mediators such as cytokines, oxygen free radicals and lipids (including
clotting factors). Complement is also activated. The concentration of mediators
produced is dependent on both the amount and the biological activity of the
endotoxin; a low concentration of endotoxin will result in a low-level, controlled
inflammatory response which will neutralise the endotoxin and kill any bacteria
present. On the other hand, a high concentration of endotoxin will initiate production
of an uncontrolled cascade of inflammatory mediators, resulting in a systemic
inflammatory response (i.e. SIRS) which frequently leads on to shock, multiple organ
failure (MOF) and death (Figure 6).
It is worth mentioning at this point that some researchers use the term "SIRS" to
define the above illness when there is no obvious Gram-negative infection detectable,
but use the term "sepsis" to define the same illness when Gram-negative infection is
present (Mercier 1993, Bone 1995). Other authors use the two terms synonymously
(Evans & Cohen 1993, Lynn & Cohen 1995), with the result that some of the
literature on this subject is confusing to read (Gibb 1993).
1.51c Incidence of Systemic Inflammatory Response Syndrome
The number of deaths attributable to SIRS may be underestimated, as it is not a
reportable disease (Bone 1993). Nevertheless, the mortality rates are extremely high;
SIRS is reported to be the thirteenth leading cause of death in the USA (Darville et al
1993), with the number of deaths estimated at between 300,000 to 400,000 per year
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Figure 6. Sequence of events following host cell stimulation by endotoxin. High
levels of proinflammatory mediators lead to the development of sepsis or SIRS.
Abbreviations: IL = interleukin; PAF = platelet activating factor. Adapted from
Rietschel & Brade (1992) and Lynn & Cohen (1995).
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mortality rates due to SIRS, probably because of differences in definitions of the
disease, because it is not a reportable disease and because the original diagnosis may
be recorded as the cause of death rather than SIRS. Mortality rate estimates range
from 20 to 60% (Bone 1993, Corriveau et al 1993, Evans & Cohen 1993), with
mortality after the onset of shock greater than 40% (Darville et al 1993) and with
shock plus MOF as high as 90% (Bone 1993).
1.5.Id Translocation
It would be a reasonable assumption to make that the endotoxin responsible for SIRS
must be derived from an infection. However, previous studies have shown Gram-
negative bacteraemia in only 12% (Willats et al 1994) to 37% (Gibb 1993) of SIRS
patients, and in many SIRS patients an infectious focus is never found, even at post¬
mortem (Marshall et al 1988). It was first suggested over 30 years ago that in
patients where there is no obvious Gram-negative infection, the source of endotoxin
could be the intestinal flora (Fine et al 1959), and over the last several years this idea
has gained popularity (Marshall et al 1988, Runcie & Ramsay 1990). The gut wall
normally acts as a highly effective barrier, preventing the systemic spread of
intestinal bacteria and their products. However, if the gut wall becomes ischaemic
and starts to break down, its barrier function is reduced, theoretically allowing
bacteria and / or their products to enter the circulation via the mesenteric lymph nodes
and the portal vein - a process termed translocation (Wells et al 1988, Runcie &
Ramsay 1990).
Studies measuring antibody levels to the LPS of various intestinal bacteria suggest
that translocation may occur in healthy individuals. It has been found that healthy
individuals have endogenous Abs against LPS core from a range of
Enterobacteriaceae and closely related spp. (Barclay & Scott 1987, Barclay 1990).
The levels of Ab vary between different individuals but they appear to be present in
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everyone, suggesting that all individuals must have, or have had, enterobacterial LPS
in their circulation at some stage. The most likely source of this LPS is the gut.
However, to date, it has not been conclusively proved that bacteria and / or LPS
translocate across the human gut wall. One recent study detected bacteraemia in two
out of fifty patients following colonoscopy, but both had obstructing bowel cancer
which could have significantly altered mucosal barrier function (Schoeffel et al
1994). Despite the lack of sound evidence in humans, translocation of bacteria
(Mainous et al 1991, Wells et al 1992, Katouli et al 1994) and inert beads (Mora et al
1991) has been shown to occur in experimental animals. How relevant this is to the
human situation remains to be seen.
Some of the circumstances under which gut barrier function has been shown to be
reduced are as follows (Mainous et al 1991):
• Haemorrhagic shock
• Thermal injury
• Physical disruption of the gut mucosa
• Total parenteral nutrition
• Malignant disease of the gut
• Disruption of the ecological equilibrium of the intestinal flora resulting in bacterial
overgrowth
• Impaired host immune defences
In studying this list, and assuming that the theory of translocation is correct, it
becomes apparent why intensive care patients are so at risk from SIRS. Many
intensive care patients have been involved in major accidents, suffered extensive
burns and / or undergone major surgery. All of these would result in large fluid
losses. When blood volume is severely depleted, the body responds by directing the
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remaining blood to the "vital areas" - the heart and brain, and away from the "non-
vital areas" - the gut and peripheries (Guyton 1992). The lack of oxygen to the gut
causes the ischaemia and mucosal barrier breakdown. In addition, many intensive
care patients receive total parenteral nutrition, meaning that the gut is not being used
and so its blood supply is reduced, many are on antibiotic therapy which may change
the balance of intestinal flora, and many are immunocompromised.
1.5. le Treatment of Systemic Inflammatory Response Syndrome
Despite recent advances in technology and drug therapy which have resulted in great
improvements in management of critically ill patients, mortality attributable to SIRS
has changed little over the last 20 years (Lynn & Cohen 1995). A vast array of
treatment strategies have been, and are currently under investigation. Many have
given promising results in animal models, but unfortunately these have not been
repeated when applied to humans. Approaches for treatment of SIRS fall into three
broad categories: prevention of host cell activation, inhibition of host inflammatory
mediators and limitation of organ damage. These are discussed in turn below.
Prevention ofHost Cell Activation
Treatment strategies to prevent host cell activation have centred around the
interaction of host cells with endotoxin. As this is the primary event in the
pathogenesis of SIRS, these treatments are likely to be of most benefit when
administered either early in the disease process, or when given prophylactically to
high risk patients. Various methods have been suggested to identify high risk
patients. Obviously, any critically ill patient who has suffered significant fluid loss
and / or has a Gram-negative infection is high risk. Some patients diagnosed as
having SIRS by the standard criteria will have much milder disease than others, so a
severity-of-illness scoring system will help to identify those at greater risk. Previous
studies have suggested that individuals who have low endogenous levels of anti-
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enterobacterial LPS core Abs have a poorer survival rate from SIRS than those who
have high levels (McCabe et al 1972, Windsor et al 1993, Barclay 1994). It has
therefore been suggested that measurement of anti-LPS Abs may be a means of
identifying high risk patients. How useful this is in practice is debatable, as by the
time a patient arrives in intensive care, they are invariably very sick, and their Ab
levels at this stage may bear no resemblance to those in health. It has also been
suggested that people with poor mucosal immunity may be at high risk of developing
SIRS, as they would be less able to prevent translocation than people with normal
mucosal immunity (Ferguson et al 1994). This would, however, be very difficult to
measure and assess in practice.
The treatment strategy to prevent host cell activation which has received the most
attention is the administration of anti-LPS Abs. These should bind to and neutralise
excess LPS, thereby preventing it from activating host cells. Various antibodies, both
monoclonal and donor-derived, have been tested for their ability to treat SIRS. Many
of these have been specific for the lipid A and core regions, as these are the most
conserved regions of the molecule, and so Abs against these regions should give a
high degree of cross-protection. The most infamous of these was an ill-fated human
monoclonal IgM named HA-1A, which bound specifically to lipid A from a range of
enterobacteria and closely related spp. (Teng et al 1985). It was reported to reduce
mortality in mice with SIRS (Teng et al 1985, Young et al 1989), but these studies
should have been interpreted with more caution, as they were performed with ascites
or hybridoma fluids, and not with purified Abs. The promising data from these
studies resulted in the rapid progression of HA-1A to clinical trials. Initial trial
results reported that it reduced mortality in SIRS patients (Ziegler et al 1991, Wortel
et al 1992). However, subsequent re-analysis of these results suggested that the initial
conclusions drawn were "over-optimistic" (Wenzel 1992), and whilst HA-1A reduced
mortality in some categories of patients, it actually increased mortality in others
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(Gibb 1993, Baumgartner 1994). This resulted in the withdrawal of HA-1A from
trials and scared many drug companies which were developing other anti-LPS Abs
into discontinuing research. Poor scientific research into HA-1A, followed by poor
interpretation of data has caused major setbacks in this field, which is unfortunate, as
other anti-LPS Abs could well prove useful in the treatment of SIRS (Dunn et al
1986, Cross et al 1993, Di Padova et al 1993, Bhattacharjee et al 1994, Di Padova et
al 1994).
Other treatment strategies to prevent host cell activation include the use of MAbs to
block CD14 (and therefore prevent LPS binding), LPS neutralising proteins and lipid
A analogues which bind to CD14 but do not activate the host cells (Lynn & Cohen
1995).
One cautionary note with any anti-LPS treatments is that although it is assumed that
LPS plays the pivotal role in SIRS, this has not been proven to always be the case,
and if microbial products other than LPS were inducing SIRS in some patients, then
in these cases anti-LPS therapy would be totally inappropriate. In order to make an
accurate diagnosis to administer appropriate treatment, a rapid, reliable means of
detecting LPS in blood is required. This often proves very difficult; when LPS
enters the circulation it quickly becomes bound to host molecules, and is rendered
undetectable by the LAL assay (Majde 1992, Yentis 1995). Barclay et al (1989)
demonstrated that in some SIRS patients a sudden decrease in anti-enterobacterial
LPS core Abs was concurrent with an episode of endotoxaemia (confirmed by LAL
assays). In other cases there was consumption of Ab but no detectable endotoxin.
However, endotoxin could have been present in these cases but undetectable by LAL.
Measurement of anti-LPS Abs could therefore be a useful indirect method of
detecting endotoxaemia. Measurement of urinary nitrate (which will be elevated
during endotoxaemia due to nitric oxide released by activated host cells) has also
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been suggested as an indirect method of detecting endotoxaemia and / or bacteraemia
(Ingeborg et al 1994).
Inhibition of Inflammatory Mediators
Although SIRS can develop by many different mechanisms, cascades of
inflammatory mediators are always produced as part of its pathophysiology.
Therefore treatments aimed at neutralisation of proinflammatory mediators should be
beneficial to all SIRS patients. Many of these have been aimed at TNF, as this is the
first proinflammatory cytokine produced and is thought to play a pivotal role in
induction of the cytokine cascade (Manthey & Vogel 1992). Some strategies include
MAbs which bind to TNF or other proinflammatory mediators thereby neutralising
their effects, the administration of soluble TNF receptors, which would mop up
excess TNF and administration of antagonist molecules (e.g. interleukin-1-receptor
antagonist) which bind to receptors and therefore prevent binding of inflammatory
mediators (Lynn & Cohen 1995). The cautionary note in this case is that a low level
of mediators is essential for the host to be able to deal with an infection and any LPS
present. Therefore a balance must be maintained between effective inhibition of
excessive host responses and the abolition of essential defences, which makes dosage
decisions very difficult.
Limitation ofOrgan Damage
Much of the tissue injury that complicates SIRS results from the migration of
activated neutrophils into tissues, which then release destructive enzymes and other
destructive molecules. Strategies to limit this include inhibition of neutrophil
migration, prevention of neutrophil activation, administration of scavanger molecules
to mop up oxygen free radicals and protease inhibitors (Lynn & Cohen 1995).
In summary, treatment strategies for SIRS to date which have been successful in
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animal models have generally given disappointing results when applied to humans.
The main reason for this is probably that SIRS can be initiated in a multitude of ways,
and a single strategy to treat such a complex disorder in a range of patients with
complicated, totally different histories is unlikely to be successful. Reliance on
animal models of SIRS, which are usually much less complex than the human
situation, has led to incorrect conclusions being drawn about treatments. It is possible
that SIRS will only be effectively treated by employing several different therapies at
different stages of the disease process, which are tailor-made to suit the individual
patient's circumstances.
1.5.If Are Bacteroides Involved in the Pathogenesis of Systemic Inflammatory
Response Syndrome?
It has previously been reported that anaerobes translocate very poorly in animal
models (Wells et al 1988, Berg 1995), and that their presence in the gut actually
reduces translocation of facultative bacteria (Wells et al 1987). However, it is
possible that any translocated anaerobes had died by the time they were cultured from
blood and were therefore not detected in these studies, and in addition translocation of
LPS from anaerobic bacteria as opposed to whole, viable bacteria has not been looked
at.
As previously discussed, in SIRS patients with no obvious Gram-negative infection
the most likely source of endotoxin is the gut. It has previously been assumed that
the endotoxin from the gut responsible for SIRS is that of E. coli, with anaerobic gut
organisms not thought to be significant (Runcie & Ramsay 1990). However,
although E. coli LPS is up to 1000-fold more biologically active than that of
Bacteroides spp., there are up to 1000-fold more strict anaerobes in the gut than
facultative anaerobes. Given the differences in numbers between E. coli and
bacteroides in the gut, there is potentially as much if not more biological activity
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from bacteroides LPS as there is from that of E. coli.
1.5.2 INFLAMMATORY BOWEL DISEASE
IBD is the term used to describe collectively two distinct diseases - Crohn's disease
(CD) and ulcerative colitis (UC). These diseases are idiopathic in nature, and many
aspects of their pathogenesis are unclear. Both are progressive and go through acute
exacerbation and remission stages.
1.5 .2a Crohn's Disease
Description
CD is a non-specific inflammatory process affecting all layers of the intestinal wall
(i.e. the mucosa, submucosa, muscle and connective tissue layers). It most commonly
affects the ileum, but may occur in multiple segments and can affect any part of the
gastro-intestinal tract. There is inflammation and thickening of the submucosa, and
ulceration and hypertrophy of the muscle wall, which cause narrowing of the lumen
of the intestine. As the ulceration heals, scar tissue formation prevents absorption of
nutrients and also causes strictures.
Clinical Features and Complications
A person with CD has a history of general ill health, weight loss and anaemia.
Intermittent, often severe colicky pain associated with diarrhoea may occur three or
four times daily, and the stools often contain blood, mucus, pus and undigested food.
Malabsorption of nutrients causes a deterioration in general health. Oedema and
congestion can result in adhesions between loops of bowel or other abdominal organs,
and lead to the formation of fistulae or abscesses. Intestinal obstruction may occur
due to strictures (Chilman & Thomas 1981).
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Treatment
There is no cure for CD, so treatment is aimed at alleviation of symptoms. Steroids
are given during acute exacerbations to reduce inflammation. Antibiotics are given if
there are any signs of infection and abscess formation. Antispasmodic drugs help to
alleviate pain associated with diarrhoea. Severe exacerbations may require
intravenous blood and fluid replacement. Complications such as intestinal
obstruction, abscess or fistula formation will require surgery, and grossly affected
segments of disease can be excised (Podolsky 1991b).
1.5 .2b Ulcerative Colitis
Description
UC is an inflammatory disease involving the mucosa and submucosa of the large
intestine. Initially the mucosa of the sigmoid colon becomes swollen and congested,
and the disease may spread to other parts of the large intestine. The mucosa bleeds
easily and patchy ulceration occurs where the mucous membrane has been eroded.
Clinical Features and Complications
The initial symptoms of UC are often vague, and present as abdominal discomfort,
mild diarrhoea and blood in the stools. The symptoms then become more defined,
with loose stools and frequent, urgent discharge of blood and mucus, which can result
in severe blood and fluid loss. In acute exacerbations, the person suffers from weight
loss, anaemia, pain, fever and general debility. Over time, the continuous ulceration
and healing processes and formation of scar tissue cause loss of both elasticity and
absorptive capability of the colon. Infection may occur, which will result in muscle
tone loss, dilatation of the colon and risk of perforation. Malignant changes and




Distressing diarrhoea can be controlled by drugs which will slow down the
hyperactive colon. Blood and fluid losses during an acute exacerbation may require
intravenous replacement. The non-steroidal anti-inflammatory drug sulphasalazine is
given orally in periods of remission to prevent relapse, and in severe cases steroids
may be prescribed. Surgery will be indicated if medical treatment fails to control the
symptoms, and may involve subtotal or total colectomy (Podolsky 1991b).
1,5,2c Predisposing Factors to Inflammatory Bowel Disease
Epidemiological studies have implicated several factors which may predispose certain
individuals or groups of individuals to IBD. There has been a steady rise in the
incidence of CD in Western Europe and the USA over the last 50 years, which could
be related, at least in part, to the post-war high fat, low fibre "Western diet". On the
other hand, the incidence of UC has changed little over the same time period (Rose et
al 1988, Sonnenberg 1990). Smoking is known to exacerbate CD, but it actually
appears to alleviate the symptoms of UC (Boyko et al 1987, Calkins 1989). Genetic
factors also appear to predispose people to IBD; there is increased incidence of IBD
in certain races of people (e.g. Ashkenazi Jews: Podolsky 1991a), and also in first-
degree relatives of affected people (Bennet et al 1991). In addition, a study carried
out on twins has demonstrated that there is a much higher incidence of monozygotic
twins both having CD than dizygotic twins (Tysk et al 1988). It has been suggested
that IBD - UC in particular - is more likely to develop in people of a nervous, highly-
strung disposition (Chilman & Thomas 1981). This is probably a somewhat unfair
suggestion, as the nature of both of these diseases is likely to put a large amount of
stress on anyone suffering from them.
1.5 .2d Hypotheses for Aetiology and Pathology of Inflammatory Bowel Disease
In a healthy individual, when an Ag is encountered by the gut immune system, a dual
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response occurs. Initially, an active local immune response occurs against the Ag,
which includes Ab production (IgM then IgA), and a local inflammatory response
(mediated by cytokines, complement, lipids and oxygen free radicals) which is down-
regulated following clearance of the Ag. This down-regulation prevents immune-
mediated damage to the gut wall. Subsequently, there is an antigen-specific
suppression of the systemic immune system, including suppression of IgG, IgE and T
cell immunity. This phenomenon, known as oral tolerance, is critical in preventing
potentially damaging hypersensitivity and allergic reactions to frequently-encountered
Ags (Ferguson et al 1994). The Ags which elicit oral tolerance are usually non¬
invasive and harmless. In people with IBD, there is a lack of down-regulation of the
immune response, resulting in excessive proinflammatory mediator production
(Mahida et al 1989, Ligumsky et al 1990). This abnormal immune response could
happen in two fundamental ways (Podolsky 1991a):
• Antigenic material (e.g. dietary or bacterial Ags) could initiate an abnormal,
prolonged response, due to a defect in triggering of the gut immune system.
• A normal response to Ags could be initiated, but this response could then be
abnormally prolonged and / or severe due to a defect in regulation of the immune
response.
At present, it is not known if one or both of these defects occur in IBD, or if some
individuals have the first defect whilst others have the second. Whatever the cause is,
the outcome is damage to the mucosa by immunopathological mechanisms causing
inflammation, possible autoimmune effects and immune complex formation, and a




The fundamental cause of IBD is highly likely to be genetic. Mutated genes could
encode an abnormal immune regulatory product (Podolsky 1991a), or a product that
causes a structural alteration in the gastrointestinal tract (e.g. increased permeability:
Gibson et al 1988, Olaison et al 1988), which would render it more susceptible to
attack by infection, toxins or autoimmune action (Delpre et al 1989). Some factors
which could trigger the expression of abnormal gene products, thereby causing
exacerbations of disease, are as follows:
Inappropriate Response to Innocuous Antigens
As mentioned previously, oral tolerance normally develops to dietary and other
commonly-encountered Ags. In IBD, there could be an abnormal, over-active
response to these Ags, and tolerance would be reduced as a result. This would lead to
the production of excessive Ab, including IgE, resulting in damage to tissue through
immune complex formation and a hypersensitivity or allergic reaction in the gut. It
has been shown that mast cells are degranulated at sites of active IBD in the gut,
which supports this theory (Sommers 1966, Dvorak et al 1978, Fox et al 1993).
Also, abnormally high levels of certain IgG subclasses have been found in both the
serum and gut mucosa of people with IBD; CD is associated with high levels of
IgG2, whereas UC is associated with high levels of IgGl (MacDermott et al 1989).
Infection
It has been suspected that infectious agents may be responsible for CD and UC ever
since they were first recognised. Dalziel (1913) noted that IBD was similar in
pathology to a ruminant disease caused by infection with Mycobacterium
paratuberculosis, and subsequently Crohn et al (1935) noted many similarities
between CD and intestinal tuberculosis. Other infectious agents which have been
implicated in IBD include certain pathogenic strains of E. coli (Burke & Axon 1978),
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Yersinia enterocolitica (Ibbotson el al 1992), Clostridium difficile exotoxin (Trnka &
Lamont 1981), Chlamydia trachomatis (Orda et al 1990) and Saccharomyces
cerevisiae (Barnes et al 1990). However, efforts to find an infectious agent
consistently associated with CD and / or UC have been unsuccessful, as the infectious
agents above have also been isolated from some control volunteers who did not have
IBD (Podolsky 1991a). It is possible that people with IBD have an abnormal immune
response to certain infectious agents.
Normal Gut Flora
The mechanism by which the gut immune system distinguishes between normal flora
and pathogens is unknown. It has been suggested that normal flora may be poorly
immunogenic (Berg & Savage 1972), or oral tolerance is elicited in response to
normal flora. However, both of these theories must be doubtful as normal flora elicit
a large systemic immune response, and oral tolerance is usually only developed in
response to non-invasive, harmless Ags. It is possible that a normally non-pathogenic
microbe may become pathogenic in people with IBD, and elicit an abnormal immune
response.
Gut flora secrete or contain various products which are capable of inducing a large
inflammatory response - for example LPS, peptidoglycan and formyl peptides. It is
therefore possible that in IBD an abnormal response is initiated to one (or more) of
these products (Podolsky 1991a). Supporting evidence for this theory has come from
a study investigating IgA against S. minnesota Rc LPS, both in serum and in the gut.
It was found that both serum- and gut-associated IgA levels were significantly raised
in people with CD compared to those with UC and healthy controls (Ferguson et al
1994). Although S. minnesota is not part of the normal gut flora, Abs against the
rough core are highly likely to cross-react with E. coli LPS. In addition, Abs against
epitopes common to both enterobacterial Ags and Ags on host cells have been found
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in people with IBD (Roche et al 1985), which could cause autoimmune damage.
In summary, despite extensive investigations, an explanation for the cause of IBD
remains elusive. This suggests that its pathogenesis is more complex than a single
cause and effect relation, and is likely to be the result of genetic factors, certain
triggers and modifying factors, which may vary between different individuals
(Shanahan 1993). If the cause, and therefore a cure, for IBD is not found in the near
future, it is possible that novel treatments such as neutralisation of proinflammatory
mediators may prove useful; for example, an interleukin-1-receptor antagonist has
been found to reduce inflammation in a rabbit model of colitis (Cominelli et al 1990).
1.5.2e Are Bacteroides Involved in the Pathogenesis of Inflammatory Bowel
Disease?
To date, the vast majority of work carried out on bacterial involvement in IBD has
centred around either pathogenic bacteria or gut-derived E. coli. However, anaerobic
gut flora could be very significant in IBD. A study investigating the nature of the gut
flora in people with CD showed that some have increased numbers of strictly
anaerobic Gram-positive cocco-bacilli and Gram-negative bacilli compared to
controls (Van der Merwe et al 1988). This was noted in some of these cases before
the clinical onset of CD, suggesting that an altered gut flora is involved in the
aetiology and pathology of CD, rather than a response to the disease. If gut bacteria
or their products are responsible for IBD, then there is a vast pool of material from
Bacteroides spp. capable of inducing an inflammatory response. Some experimental
evidence implicating bacteroides in IBD is that germ-free guinea pigs fed B. vulgatus
were found to develop colonic ulceration with and without carragenan treatment
(Onderdonk et al 1981), and immunisation of normal guinea pigs with B. vulgatus
prior to carragenan treatment and ingestion of this organism resulted in a more rapid
development of ulceration (Onderdonk et al 1983). OMPs and LPS were
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subsequently implicated as causative agents for this phenomenon (Breeling et al
1988). B. fragilis did not produce this effect. Human studies are necessary to assess
the significance of these models in IBD.
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ATMS OF THIS THESIS
• To assess the influence of growth environment on cell surface Ag expression in
Bacteroides species.
• Where possible, to relate any observed changes in surface Ag expression to
pathogenicity.
• To investigate the complement and antibody response to bacteroides, both in health
and in selected diseases where bacteroides may be significant.
• To examine the cell surface polysaccharide complex of B. fragilis chemically and






2.1.1 BLOOD AND SERUM SAMPLES
Whole venous blood samples were obtained from healthy volunteers (work
colleagues), from SIRS patients in Edinburgh Royal Infirmary and from IBD patients
attending an outpatient clinic at the Western General Hospital, Edinburgh.
Serum samples were obtained from a random selection of blood donors attending the
Scottish National Blood Transfusion Service, Edinburgh (SNBTS), and from
abdominal SIRS patients who were blood culture negative (Scottish Sepsis
Intervention Group).
2.1.2 SAMPLE PROCESSING
Serum to be used as a source of complement was obtained from whole venous blood
by two different methods:
Method A: Freshly drawn blood was allowed to clot at 37°C for 30 min, then
centrifuged at 4000# for 10 min. Sera were removed, centrifuged as before and the
supernates were pooled (Herbert 1989).
Method B: Freshly drawn blood was left to clot overnight at 4°C. It was then placed
at room temparature for 30 min before removal of serum. Sera were centrifuged at
4000g- for 10 min before the supernates were pooled (Hudson & Hay 1989).
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In both methods, half of the pooled sera obtained were divided into 1 ml aliquots into
lml cryotubes (Nunc) and stored at -70°C until immediately before use, whilst the
remaining sera were heat-inactivated (56 °C / 30 min) prior to storage.
Sera to be used in antibody studies were obtained from whole venous blood by
Method A described above, or were supplied already fractionated. These was stored
at -20°C until use, either in 1 ml cryotubes (healthy volunteers, SIRS patients and
IBD patients), or in 96-well sealed microtitre plates (Greiner; random blood donors).
2.1.3 BACTERIAL STRAINS
Bacterial strains used in this thesis are listed in Table la (Bacteroides strains) and in
Table lb (other bacterial strains).
2.1.4 CHEMICALS
Unless otherwise stated all chemicals were AnalR grade (BDH) and were prepared in
distilled water (Milli-Q water purification system).
2.1.5 MEDIA
All media were prepared using pyrogen-free (PF) water (Milli-Q).
2.1.5a Bacteroides Strains: Complex Media
• Proteose peptone-yeast extract medium (PPY). This was prepared as previously
described (Holbrook et al, 1977). The proteose peptone and yeast extract were from
Oxoid.
• Heat-inactivated sheep serum (HISS). Filter-sterilised sheep serum was obtained
from the Moredun Animal Diseases Research Institute, Edinburgh. Prior to using it
for bacterial growth it was heat-inactivated (56°C / 30 min). In certain cases a
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mixture of 50% HISS and 50% Van Tassell and Wilkins' minimal medium (described
below) was used for bacterial growth.
• Columbia blood agar (CBA: Oxoid). Columbia agar base was supplemented with
5% horse blood.
2.1.5b Bacteroides Strains: Defined Medium
• Van Tassell and Wilkins' minimal medium (VT) was prepared as previously
described (Van Tassell & Wilkins, 1978). For some experiments (indicated in
relevant results sections) 300 fiM ethylenediaminetetra-acetic acid (EDTA), 450 |iM
ethylenediamine-N,N'-diacetic acid (EDDA) or 0.5 mM ethyleneglycol-bis ((3-
aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA) were added.
2.1.5c Other Bacterial Strains: Complex Media
• Nutrient broth (NB: Gibco) was prepared at the SNBTS Protein Fractionation
Centre, Edinburgh.
2.1.6 MISCELLANEOUS
Sheep erythrocytes and anti-sheep erythrocyte IgG for determination of the
haemolytic value of complement (CH50) were obtained from the Scottish Antibody
Production Unit (SAPU), Law Hospital, Lanarkshire.
Polyclonal antiserum to Bacteroides strains was originally prepared in New Zeland
rabbits, and was donated by Dr. I. R. Poxton (Dept. of Medical Microbiology,
Edinburgh University) and by Dr. S. Patrick (Dept. of Microbiology and
Immunology, Queen's University, Belfast). Murine MAbs (produced from
hybridoma cell lines) against B. fragilis NCTC 9343 cell surface Ags were donated
by Dr. S. Patrick, and are listed in Table 2.
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Table la. Bacteroides Strains
Species Strain No. Source
B. fragilis NCTC 9343 (T) Appendix abscess
B. fragilis MPRL 1504 Wound swab
B. fragilis MPRL 1652 Faeces
B. fragilis MPRL 1978 Blood
B. fragilis NCTC 9344 Wound swab
B. fragilis MPRL 1582 Unknown
B. fragilis MPRL 1583 Unknown
B. fragilis MPRL 1584 Rectal abscess
B. fragilis MPRL 1585 Rectal ulcer
B. fragilis MPRL 1586 Abscess
B. fragilis MPRL 1588 Wound swab
B. fragilis MPRL 1590 Vaginal swab
B. fragilis MPRL 1981 Blood
B. fragilis MPRL 1986 Blood
B. vulgatus NCTC 11154 (T) Unknown
B. vulgatus MPRL 1651 Faeces
B. vulgatus MPRL 1985 Blood
B. thetaiotaomicron NCTC 10582 (T) Faeces
B. thetaiotaomicron MPRL 1959 Blood
B. distasonis ATCC 8503 (T) Unknown
B. distasonis MPRL 1522 Faeces
B. ovatus ATCC 8483 (T) Unknown
B. ovatus MPRL 2370 Blood
B. uniformis ATCC 8492 (T) Unknown
B. uniformis MPRL 1542 Faeces
B. uniformis MPRL 1987 Blood
B. variabilis VPI 11368 (T) Unknown
B. variabilis MPRL 2244 Unknown
B. eggerthii NCTC 11155 (T) Faeces
B. eggerthii MPRL 1523 Faeces
B. eggerthii MPRL 1216 Appendectomy
B. caccae ATCC 43815 (T) Faeces
B. caccae MPRL 1555 Wound
B. merdae ATCC 43 814 (T) Faeces
B. stercoris ATCC 43813 (T) Faeces
NCTC = National Collection of Type Cultures, UK; ATCC = American Type
Culture Collection; VPI = Virginia Polytechnic Institute, USA, MPRL =
Departmental stock culture; (T) = Type Strain.
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Table lb. Other Bacterial Strains
Species Strain No. Source





MPRL 0947 Prof. I.W. Sutherland,











MPRL 1091 Prof. Pauline Meadows,
UCL, London.
Abbreviations as in Table 1.
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Table 2. Murine monoclonal antibodies against B. fragilis NCTC 9343 cell surface
Ags.
MAb name Class Epitope
3C8 IgG2b O-Ag
3D7 IgGl LC / EDL
4C5 IgGl LC / EDL / slime
1A4 I«G1 99% ofB. fragilis isolates
6G3 IgG2b ? Common Ag







NC = not classified
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2.2 METHODS
2.2.1 MAINTENANCE AND GROWTH OF BACTERIA
Bacterial strains were obtained initially from freeze-dried stocks, and thereafter were
maintained at -70°C in 10% w / v skimmed milk (Oxoid).
All bacteria were grown at 37°C. Lyophilised bacteria were resuspended in
approximately 0.5 ml of PPY (Bacteroides strains) or NB (other strains) and were
streaked onto CBA. Following growth, bacterial suspensions were prepared by
emulsifying several single colonies in 0.8 ml of skimmed milk in 1 ml cryotubes.
Bacteria were streaked onto CBA from the -70°C stocks and were sub-cultured onto
fresh plates within seven days. A maximum of three sub-cultures were performed
after which fresh plates were prepared from frozen stocks.
Bacteria were inoculated into 10 ml of liquid medium from plates, which could then
if required be used as a starter culture to inoculate into larger volumes.
2 2,1a Bacteroides Strains
Bacteroides strains were incubated either in an anaerobic cabinet (Forma) in an
atmosphere of H2 10%, C02 10% and N2 80%, or in anaerobic jars in an atmosphere
of H2 90% and C02 10%. All liquid media used for growth of Bacteroides strains
was pre-reduced for 24-48 h prior to inoculation.
2.21b Other Strains
All other strains were incubated aerobically. Liquid cultures were incubated in an
orbital incubator (Gallenkamp) at 100-120 rpm.
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2.2.2 PURITY CHECKS
Purity checks were carried out for all bacterial cultures at each new inoculation stage
and at the end of all experimental procedures. Cultures were examined by Gram's
staining, and by aerobic and anaerobic incubation on CBA.
2.2.3 MEASUREMENT OF BACTERIAL CONCENTRATION
2.2.3a Viable Counts
Serial ten-fold dilutions of Bacteroides strains were prepared in phosphate-buffered
saline (PBS: Oxoid), and 100 pi volumes were spread onto CBA plates. Plates were
incubated for 48 h and colonies were counted.
2 .2 .3b Measurement ofOptical Density
Optical density measurements were made at 600 nm in a spectrophotometer (Pye
Unicam SP6-550 UV / VIS). The suspending medium was used as a diluent and as a
blank for optical density (OD) readings. Standard curves of log10 bacterial numbers
(determined by viable counts) against OD600 was drawn. An OD600 of 0.15 is
equivalent to a concentration of approximately 108 colony forming units (cfu) of
Bacteroides strains per ml.
2.2.4 PREPARATION OF LIPOPOLYSACCHARIDE USING PROTEINASE
K DIGESTION OFWHOLE BACTERIA
LPS was prepared for visualisation by PAGE and silver staining by digestion of
whole bacteria with Proteinase K (Protese Type XI, Sigma). Overnight cultures (10
ml) of Bacteroides strains were subjected to Proteinase K treatment using the method
of Hitchcock & Brown (1983) as described by Hancock & Poxton (1988). This
method is non-selective, and can be used to prepare both S- and R-LPS.
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2.2.5 PREPARATION OF LIPOPOLYSACCHARIDE USING A MIXTURE
OF AQUEOUS PHENOL / CHLOROFORM / PETROLEUM ETHER
Two litre batch cultures of E. coli, S. typhimuriiim, K. pneumoniae and P. aeruginosa
were harvested by centrifugation (lOOOOg- / 20 min), washed twice in PBS and
lyophilised. Lyophilised cells were then used for the preparation of LPS by the PCP
method of Galanos et al (1969), as described by Hancock & Poxton (1988). The
resulting LPS obtained was lyophilised, and dry weights of both the cells and LPS
were noted. LPS was resuspended to 1 mg / ml in PF water and stored at -20°C until
just prior to use. The PCP method is selective for R-LPS.
2.2.6 PREPARATION OF LIPOPOLYSACCHARIDE USING AQUEOUS
PHENOL
The aqueous phenol method of Westphal & Luderitz (1954) as described by Hancock
& Poxton (1988) was used to extract LPS from 1 L batch cultures of selected
Bacteroides strains. In certain cases (indicated in the relevant results sections) the
final rotary evaporation and ultracentrifugation steps were omitted. Cells were
harvested, washed and lyophilised as described for the PCP extraction, and the final
LPS pellet was lyophilised. Dry weights of the cells and LPS were noted.
Lyophilised LPS was resuspended to either 1 mg / ml or 10 mg / ml in PF water and
stored at -20°C until just prior to use. The aqueous phenol method is reported to be
selective for S-LPS.
2.2.7 PREPARATION OF LIPOPOLYSACCHARIDE USING A RAPID
AQUEOUS PHENOL EXTRACTION METHOD
Overnight cultures (10 ml) of Bacteroides strains were used to prepare LPS for
examination by PAGE by the micromethod of Fomsgaard et al (1993). This method
is based on the aqueous phenol method ofWestphal & Luderitz (1954).
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2.2.8 PREPARATION OF OUTER MEMBRANE PROTEINS
OMPs were prepared from selected Bacteroides strains by a method based on that of
Filip et al (1973). Batch cultures of bacteria (400 ml) grown to stationary phase in
either PPY, VT or 50% VT / 50% HISS were harvested by centrifugation (lOOOOg /
20 min), washed twice in PBS and resuspended to a final volume of 5 ml in PF water
containing 0.1 mM phenylmethylsulphonyl fluoride. Cells were broken by sonication
on ice (MSE soniprep) at an amplitude of 10 p. for a total of 5-7 min. Lysis was
assessed by phase contrast microscopy. Unbroken cells were removed by
centrifugation (4000g / 5 min), and the supernate was mixed with 30% w / v N-
lauroyl sarcosinate (Sarkosyl) to give a final concentration of 0.7% w / v Sarkosyl.
OMPs were sedimented by centrifugation (75000g / 1 h), washed once in 5 ml of PF
water and re-centrifuged as before. The final pellet was resuspended in
approximately 0.5 ml ofPF water and stored at -20 °C.
2.2.9 FRACTIONATION OF THE SURFACE POLYSACCHARIDE
COMPLEX OF B. FRAGILIS NCTC 9343
An attempt was made to separate and purify the different components of the surface
polysaccharide complex (CP and LPS) of B. fragilis NCTC 9343 by a method based
on that of Pantosti et al (1991). All reagents used in this procedure were made up
with PF water. Cells were grown to stationary phase in 4 x 1 L batch cultures in PPY
and then harvested by centrifugation (10000g / 15 min). The cells were washed twice
in 0.15 M NaCl, the pellet was resuspended in 200 ml of PF water, and an equal
volume of 75% aqueous phenol was added. The mixture was stirred at 68°C for 30
min, allowed to cool and then centrifuged (5000# / 20 min) to separate the aqueous
and phenol phases. The phenol phase was then re-extracted as above. The two
resulting aqueous phases were pooled, extracted with an equal volume of ether, left at
20°C overnight to remove the ether, dialysed extensively against PF water until the
smell of phenol could no longer be detected, and lyophilised.
76
The lyophilised aqueous phase (2.45 g dry weight) was resuspended in 30 ml of 0.1
M sodium acetate buffer (pH 4.5) containing 10 mM CaCl2 and 10 mM MgCl2. It
was then treated with 0.5 mg DNase Type 1 (Sigma) and 2.5 mg RNase A (Sigma) at
37°C for 2 h. Toluene (100 (il) was added to the mixture to prevent bacterial growth.
This treatment was repeated overnight. The pH was then adjusted to 7.0 using 5 M
NaOH before 5 mg Pronase (BDH Biochemical Grade) was added twice, once for 2 h
at 37°C and again overnight. Toluene was added as before, and removed following
treatments by heating the mixture to 60°C. The material was brought to a
concentration of 80% v / v ethanol and left at 4°C overnight. The alcohol-insoluble
precipitate was recovered by centrifugation (10000g- / 20 min) and dissolved in buffer
(pH 9.8) containing 0.5% sodium deoxycholate, 50 mM glycine and 10 mM EDTA to
a final volume of 9 ml. Three millilitres of this material were loaded onto a
Sephacryl S-300 gel filtration column (1.5 x 60 cm: Pharmacia) which had been
equilibrated in the same buffer as the samples. The fractions collected (1.8 ml; 250
ml in total) were examined by PAGE (10% separating gel, non-SDS; see Section
2.2.17). The fractions that contained high, intermediate and low Mr material were
pooled separately, precipitated in 80% ethanol, dialysed against PF water and
lyophilised. Prior to lyophilisation, the UV absorbance was measured at 280 nm to
ensure that all traces of nucleic acids had been removed.
To achieve separation of the different components of the CP (PSA and PSB), 4.2 mg
of the high Mr material was treated with 10ml of 5% acetic acid for 1 h at 100°C.
The acetic acid was removed by rotary evaporation before the sample was lyophilised
and resuspended in 5 ml of 50 mM Tris (2-amino-2-(hydroxymethyl) propane-1,3-
diol)-HCl (pH 7.3) and loaded onto a DEAE-Sephacel (Pharmacia) ion-exchange
column (1.5 x 15 cm) equilibrated in the same buffer. Buffer (100 ml) was washed
through the column and 5 ml fractions were collected. The material bound to the
column was eluted with a linear gradient of 0 to 0.5 M NaCl and collected in 5 ml
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fractions (100 ml in total). Material obtained during the washing stage and at the low
end (up to 0.1 M NaCl) of the gradient was pooled (PSA), and that obtained from the
remainder of the gradient (>0.1 M NaCl) was pooled separately (PSB). Both pools
ofmaterial were lyophilised.
Following lyophilisation, samples were desalted by resuspending them in 5 ml PF
water and running them in 200 pi aliquots through disposable polystyrene
chromatography columns (80 x 8 mm: Pierce & Warriner). The columns were packed
with Sephadex G25 (Pharmacia) washed in PF water and calibrated with Blue
Dextran 2000 (Pharmacia) prior to use. The desalted fractions were lyophilised.
All lyophilised samples obtained from the entire fractionation procedure (high,
intermediate and low Mr material from the gel filtration column and PSA and PSB
from the ion exchange and desalting columns) were resuspended to 1 mg / ml in PF
water and stored at -20°C.
2.2.10 PERIODATE TREATMENT OF AQUEOUS PHENOL EXTRACTS OF
LIPOPOLYSACCHARIDE
Aqueous phenol extracts of LPS from selected B. fragilis strains were treated with
periodate to destroy carbohydrate. Aqueous phenol extracts (200 pi) resuspended in
PF water to 10 mg / ml were mixed with an equal volume of 0.1 M sodium periodate.
The mixture was left in the dark overnight at 20°C. Ethylene glycol (50 pi) was then
added to remove the periodate before an equal volume of double strength PAGE
sample buffer (see Section 2.2.14) was added. On addition of sample buffer the
bromophenol blue turned yellow due to the acidic pH. Tris was added a crystal at a
time until the solution turned blue. Samples were stored at -20 °C.
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2.2.11 PROTEINASE K TREATMENT OF AQUEOUS PHENOL EXTRACTS
OF LIPOPOLYSACCHARIDE
Contaminating protein present in aqueous phenol extracts of LPS from selected B.
fragilis strains was removed by Proteinase K treatment. Proteinase K (1.25 mg) was
dissolved in 0.5 ml buffer (0.0625 M Tris-HCl with 2% w/v sodium dodecyl sulphate
[SDS], pH 6.8). Aqueous phenol extracts (150 pi of a 10 mg / ml solution) were
mixed with 60 pi of the Proteinase K solution before heating to 60°C for 1 h. Double
strength PAGE sample buffer (90 pi) was added. Samples were stored at -20°C.
2.2.12 ESTIMATION OF PROTEIN CONCENTRATION
Protein concentration was estimated in selected LPS preparations, in surface
polysaccharide fractions and in all OMP preparations using the Lowry assay (Lowry
etal 1951).
2.2.13 ESTIMATION OF CARBOHYDRATE CONCENTRATION
Carbohydrate (i.e. neutral sugar) concentration was estimated in selected aqueous
phenol extracts and in surface polysaccharide fractions using the method of Dubois et
al (1956), as described by Hancock & Poxton (1988).
2.2.14 ESTIMATION OF ORGANIC PHOSPHORUS CONCENTRATION
Organic phosphorus was estimated in selected aqueous phenol extracts and in surface
polysaccharide fractions using the method of Chen et al (1956), as described by
Hancock & Poxton (1988).
2.2.15 ESTIMATION OF KDO CONCENTRATION
KDO was measured in selected aqueous phenol extracts and in surface polysaccharide
fractions using a thiobarbiturate assay based on the method of Kharkanis et al (1978),
as described by Hancock & Poxton (1988).
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2.2.16 PREPARATION OF SAMPLES FOR POLYACRYLAMIDE GEL
ELECTROPHORESIS
PAGE sample buffer (pH 6.8) contained 0.0625M Tris with 2% w / v SDS, 10% v / v
glycerol, 1% v / v 2-mercaptoethanol and 0.001% bromophenol blue. Double strength
sample buffer (pH 6.8) contained the same constituents at double the concentrations.
All samples and Mr markers were boiled for 3 min after mixing with sample buffer
just prior to adding to gels in order to re-dissolve precipitated SDS in the sample
buffer.
2 2.16a Outer Membrane Protein Samples
OMP samples were mixed with an equal volume of double
Samples were added to the gels at a concentration of 40
possible. If the protein concentration of the sample was too
highest concentration possible was added.
2.2.16b Lipopolvsaccharide Samples
• Proteinase K samples were mixed with an equal volume of sample buffer and added
to gels at 20 pi per track.
• Aqueous phenol, rapid phenol and PCP extracts were mixed with an equal volume
of double strength sample buffer and added to gels at 20 (_il or 40 pi per track (for 20-
well gels) or at 1 ml per track (for l-well gels).
• Periodate-treated LPS samples were added to gels at 40 pi or 80 pi per track.
• Proteinase K-treated aqueous phenol extracts of LPS were added to gels at 20 pi or
40 pi per track.
2.216c Surface Polysaccharide Fractions
Fractions obtained from the surface polysaccharide purification procedure (Section
strength sample buffer,
pg per track wherever
low to achieve this, the
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2.2.9) from both the gel filtration column (high, intermediate and low Mr material)
and from the ion-exchange column (PSA and PSB) were mixed with an equal volume
of double strength sample buffer and added to gels at 40 (il or 80 (il per track (for 20-
well gels) or at 1 ml per track (for 1-well gels).
2,2,16d Molecular Weight Standards
Mr standards (10 (il) were electrophoresed alongside antigen samples in selected
cases. Standards (BDH Electrophoresis Grade) were reconstituted in single strength
PAGE sample buffer following manufacturers' instructions and consisted of
ovotransferrin, 78 kDa; albumin, 63 kDa; ovalbumin, 42.7 kDa; carbonic
anhydrase, 30 kDa; myoglobin, 17.2 kDa; cytochrome c, 12.3 kDa.
2.2.17 POLYACRYLAMIDE GEL ELECTROPHORESIS
PAGE was performed on acrylamide slab gels using the discontinuous buffer system
of Laemmli (1970). The following solutions were used:
• Separating buffer (double strength, pH 8.8): 0.75 M Tris-HCl with 0.2% w / v
SDS.
• Stacking buffer (double strength, pH 6.8): 0.25 M Tris-HCl with 0.2% w / v SDS.
SDS was omitted from stacking and separating buffers used to electrophorese LPS
and CP samples.
• Acrylamide stock solution (40% w / v):
Grade) and 2.7 g methylene bis acrylamide
up to 250 ml in distilled water.
100 g acrylamide (BDH Electrophoresis
(BDH Electrophoresis Grade) were made
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• Electrode buffer (pH 8.3): 0.025 M Tris (BDH Biochemical grade) and 0.192 M
glycine (BDH Chromatographically Homogeneous) with 0.1% w / v SDS.
The separating gel was prepared as described in Table 3 and poured between glass
plates (160 mm x 125 mm x 1.5 mm) using a needle and syringe. The gel was
overlaid with water-saturated butan-2-ol and allowed to set. After removal of the
butan-2-ol, the stacking gel (see Table 3) was poured onto the separating gel and
either a 20-well or 1-well comb was inserted. The gel was then placed in an
electrophoresis tank, the comb was removed and the electrode buffer was added.
Samples were loaded into the well(s) in the stacking gel. Samples were run through
the stacking gel at 60 V and then through the separating gel at 150 V. Following
electrophoresis, samples were visualised by staining the gel directly or by
immunoblotting after transfer to nitrocellulose.
Table 3. Preparation of Polyacrylamide Gels
Reagent Volume (ml) to give final acrylamide concentration of:
Separating gel Stacking gel
8% 10% 14% 4%
Distilled water 8.7 6.95 3.45 3.5
Separating buffer 17.5 17.5 17.5 .
Stacking buffer 5.0
40% acrylamide 7.0 8.75 12.25 1.0
TEMED* 0.05 0.05 0.05 0.02
Ammonium
persulphate
(15 mg / ml)
1.75 1.75 1.75 0.5
* N N N' N'-tetramethyl-l,2-diaminoethane.
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2.2.18 SILVER STAINING OF POLYACRYLAMIDE GELS
Silver staining was used to visualise LPS, CP and some OMP samples by the method
described by Hancock & Poxton (1988). This method is a modification of previous
silver staining methods developed by Tsai & Frasch (1982), Oakley et al (1980) and
Hitchcock & Brown (1983).
2.2.19 COOMASSIE BLUE STAINING OF POLYACRYLAMIDE GELS
OMP samples were visualised on gels using the alternative Coomassie Blue staining
method described by Hancock & Poxton (1988).
2.2.20 IMMUNOBLOTTING
Separated Ags were transferred to nitrocellulose membranes (pore size 0.2 (im,
Schleicher & Schuell) and then visualised by the method of Towbin et al (1979), as
described by Hancock & Poxton (1988). Ags were probed with the following Abs for
3 h at room temperature:
• Human serum diluted 1 in 10
• Rabbit polyclonal hyperimmune serum diluted 1 in 100
• Murine MAbs - supernates from MAb-producing cell lines used undiluted
The immune complexes were detected with appropriate anti-IgG horseradish
peroxidase (HRP) conjugates and HRP colour development reagent (BioRad). The
following conjugates were used:
• Anti-human IgG (whole molecule) diluted 1 in 1000 (Sigma)
• Anti-rabbit IgG (whole molecule) diluted 1 in 1000 (Sigma)
• Anti-mouse IgG (whole molecule) diluted 1 in 500 (ICN)
83
2.2.21 DOT BLOTTING
Aqueous phenol extracts (10 mg / ml) and surface polysaccharide fractions (1 mg /
ml) of B. fragilis NCTC 9343 were probed with polyclonal rabbit serum and murine
MAbs by dot blotting on nitrocellulose, as described by Hancock & Poxton (1988).
A total of 5 x 1 |il samples were placed onto the nitrocellulose for each antigen,
allowing drying between each application. Immune complexes were visualised as for
immunoblotting.
2.2.22 PERCOLL DISCONTINUOUS DENSITY CENTRIFUGATION
To assess the degree of encapsulation of Bacteroides strains grown in different
environments Percoll (Pharmacia) discontinuous density centrifugation was used.
Percoll was diluted as previously described (Patrick & Reid, 1983), and a step
gradient was produced by layering 1 ml volumes of 80% (bottom), then 60%, 40%
and 20% (top) Percoll into 70 x 20 mm glass test tubes. A sample of an early
stationary phase culture of the test organism (1.25 ml) was applied to the top of the
20% layer and the gradient was centrifuged at 2600 g for 20 min.
2.2.23 INDIA INK STAINING
Cells were removed from the Percoll gradients following centrifugation and degree of
encapsulation was examined microscopically using wet India Ink staining, as
described by Cruickshank (1965).
2.2.24 COMPLEMENT SENSITIVITY ASSAY
Selected Bacteroides strains were grown to early stationary phase in 10 ml of PPY,
VT and HISS or 50% VT / 50% HISS, and then tested for their ability to survive in
human serum. Serum used for the assay was collected and stored as described
previously (Section 2.1.2).
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2 2 24a Determination of the Haemolvtic Complement Value tCH50t of Serum
The CH50 value of all sera used as a source of complement was determined as
previously described (Hudson & Hay 1980), except that PBS was used as a buffer
instead of barbitone-buffered saline.
2,2,24b Serum Sensitivity Assay
Bacteria washed once in complement fixation test buffer (CFTB: Oxoid) were
resuspended to a concentration of approximately 105 cfu / ml in either CFTB only
(control), CFTB + 10% serum or CFTB + 40% serum and incubated aerobically (2 ml
in 2.5 ml closed plastic tubes) at 37°C for 2 h with end-over-end rotation. Samples
(100 |il) were taken at 0, 1 and 2 h in all cases and in some cases also at 20 and 40
min, diluted 1 in 50 in CFTB, and 100 pi of the resulting suspension were spread
onto CBA in duplicate. After anaerobic incubation for 48 h, colonies were counted
and the percentage survival was calculated compared to the start of the experiment.
As a further control, all bacteria found to be sensitive to serum were resuspended to
105 cfu / ml in CFTB + 40% heat-inactivated human serum and treated as above. In a
preliminary experiment, dilutions of bacteria were carried out in reduced (i.e.
anaerobic) CFTB, and survival was compared with that in aerobic buffers. No
differences were seen in bacterial survival.
2.2.25 CLASSICAL PATHWAY VERSUS ALTERNATIVE PATHWAY
ACTIVATION OF COMPLEMENT
The roles of the classical and alternative pathways of complement activation were
investigated in selected Bacteroides strains by two methods:
2.2,25a Absorption ofAnti-bacteroides Antibodies from Serum
Serum was subjected to a series of absorptions with bacteroides whole cells to remove
specific antibody (and therefore inhibit the classical pathway). Bacteria grown to
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early stationary phase in PPY, VT or HISS were harvested and washed once in
CFTB, and then resuspended in CFTB to approximately 108 cfu / ml. Bacterial
suspension (1.0 ml) was added to a 1.5 ml Eppendorf tube and cells were harvested at
1365g in a microcentrifuge. After removal of supernatant, bacteria were resuspended
in 1 ml of serum (thawed from -70°C then immediately placed on ice), incubated for
15 min on ice, and recentrifuged. The supernatant was then added to another pellet of
cells and the process repeated. This step was repeated at least three times. Finally the
serum was filtered (0.2 |liM, Millipore) to remove any bacteria still in suspension
before using it in the complement sensitivity assay. As a control, a further 1 ml of
serum was treated identically except no bacteria were added.
2,2,25b Use ofEGTA to Inhibit the Classical Pathway
Serum was treated with EGTA to inactivate specifically the classical pathway by
chelating Ca2+ ions but not Mg2+ ions as described by Fine et al (1979). A 200 mM
stock solution of EGTA was made in normal (0.9%) saline and adjusted to pH 7.45 as
described by Fine et al (1979). The EGTA stock was added to serum to a final
concentration of 10 mM immediately prior to using it in the complement sensitivity
assay.
2.2.26 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) REAGENTS
Polystyrene microwell strips (Immunomodule polysorp F8 Nunc, Intermed) fixed in
frames to form 'plates' were used in ELISA experiments. Sterile, endotoxin-free glass
tubes were used to make dilutions. All reagents and dilutions made for ELISA were
done with PF water. The following diluents and buffers were used in the ELISA
procedures:
• Coating buffer (pH 9.6): 0.05 M carbonate / bicarbonate with 0.02% w / v sodium
azide.
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• Post-coat (pH 7.2): PBS containing 5% v / v bovine serum albumin (BSA: ICN)
and 0.02% w / v sodium azide.
• Wash buffer (pH 7.2): PBS containing 0.05% v / v Tween 20 (Sigma) and 0.05%
w / v sodium azide.
• Dilution buffer (pH 7.2): PBS containing 0.05% v / v Tween 20, 0.5% v / v BSA,
4.0% w / v polyethylene glycol Mr 6000 (Sigma) and 0.02% w / v sodium azide.
• Alkaline phosphatase substrate solvent (pH 9.8): 0.05 M carbonate / bicarbonate
buffer with 1 mM MgCl2. Immediately prior to use, alkaline phosphatase substrate (p-
nitrophenyl phosphate: Sigma) was added to a final concentration of 1 mg / ml.
• Urease substrate solution (pH 4.8). A stock solution of urease substrate (Sera-lab)
was diluted 1 in 20 in water before adding to wells.
2.2.27 COATING OF LIPOPOLYSACCHARIDE ONTO ELISA STRIPS
2,2,27a Bacteroides Strains
Aqueous phenol LPS extracts resuspended to 1 mg / ml in water were complexed
with an equal volume of a 1 mg / ml solution of polymyxin B sulphate (Sigma) after
the method of Scott & Barclay (1987). The mixture was sonicated for 30 sec at 10 p.,
stirred for 90 min at 20°C, then re-sonicated as above. Following dialysis for 18 h
(Spectra por membrane MWCO 2000) against PF water at 20°C, the mixture was
diluted 1 in 50 in coating buffer. The strips were coated at 100 pi / well and
incubated at 20°C overnight before being washed x 4 using an ELISA plate washer
(Ultrawash 1, Dynatech). They were then post coated at 100 pi / well and were
incubated as above. Finally the strips were washed x 4 and rinsed x 1 in water.
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2.2.27b Other Bacterial Strains
A mixture of equal weights of PCP-extracted E. coli, S. typhimurium, K. pneumoniae
and P. aeruginosa rough LPS resuspended in water to 1 mg / ml was complexed with
polymyxin B sulphate and coated onto ELISA strips as above.
2.2.28 COATING OF WHOLE BACTERIA ONTO ELISA STRIPS
Selected B. fragilis strains grown to early stationary phase in PPY, VT and 50% VT /
50% HISS were harvested by centrifugation (4000g / 10 min), washed once in PBS
and resuspended in coating buffer to a concentration of approximately 2.5 x 107
bacteria per ml. Bacterial suspension (100 pi) was added to ELISA strips, which
were then centrifuged (630g / 4 min) to promote coating. Following overnight
incubation at 20°C the procedure was as described for LPS-polymyxin coating.
In all cases coated ELISA strips were stored at -20°C for up to a maximum of three
months.
2.2.29 DETECTION OF ANTI-BACTEROIDES AND ANTI-
ENTEROBACTERIAL / PSEUDOMONAS LIPOPOLYSACCHARIDE
ANTIBODIES IN HUMAN AND SHEEP SERUM BY ELISA
A 1 in 200 dilution of the serum samples to be tested was made in dilution buffer.
The diluted serum (100 pi) was added to each well on the appropriate LPS-coated
ELISA strips and incubated for 90 min at 37°C before washing x 4. Either anti-
human IgG (whole molecule: Sigma), anti-human IgG (7-chain-specific: Bionetics) or
anti-sheep IgG (whole molecule: Sigma), all conjugated to alkaline phosphatase, were
diluted in ELISA dilution buffer 1 in 1000 and added at 100 pi / well. The strips
were incubated and washed as above. Alkaline phosphatase substrate was added at
100 pi / well, the strips were incubated at 20°C for 30-40 min, and the absorbance at
405 nm was measured using an ELISA plate reader (Anthos 2001, Labtec). A
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negative control was included where the serum was replaced by diluent, and the
absorbance of the negative control was subtracted from each of the test wells.
2.2.30 INHIBITION ELISA USING LIPOPOLYSACCHARIDE TO ASSESS
CROSS-REACTIVITY OF SERUM IcG TO DIFFERENT
LIPOPOLYSACCHARIDES
This was carried out as above, except that after the serum was diluted 1 in 200, LPS
was added to a final concentration of 1 mg / ml, and this was incubated at 37°C for 30
min prior to carrying out the ELISA. Control serum was treated identically except no
LPS was added. Serum used in this case was pooled from 10 random blood donors.
2.2.31 INHIBITION ELISA USING WHOLE CELLS TO ASSESS CROSS-
REACTIVITY OF SERUM IcG TO DIFFERENT LIPOPOLYSACCHARIDES
This was carried out as above, except that the serum was subjected to a series of
absorptions with whole cells after being diluted 1 in 200 as described previously
(Section 2.2.25a) prior to carrying out the ELISA. Serum used was pooled from 10
random blood donors.
2.2.32 DETERMINATION OF MEDIAN LEVELS OF ANTI-
LIPOPOLYSACCHARIDE IcGWITHIN BLOOD DONOR POPULATION
Initially a sample of 50 random blood donors was screened by ELISA for IgG levels
to B. fragilis NCTC 9343, B. vulgatus MPRL 1985, B.thetaiotaomicron NCTC
10582 and the enterobacterial / Pseudomonas LPS cocktail. To standardise OD
readings, a control serum sample was included on each plate which had previously
been shown (by Dr. R. Barclay) to have close to median levels of IgG against the
enterobacterial / Pseudomonas R-LPS cocktail. When the OD of this sample had
reached ~ 1, the plates were read. After this initial screen, serum containing close to
median levels of IgG to all of the antigens was selected as a standard. A further 641
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donors were then screened, and to standardise the OD readings, on each plate a
sample of the standard serum was also tested. The OD of this serum was given an
arbitrary value of 100% in each case, and the ODs of the 641 sera were converted to
percentages using the standard serum. The median levels of IgG to all of the antigens
within the 641 donors were calculated .
2.2.33 DETERMINATION OF ANTI-LIPOPOLYSACCHARIDE IgG LEVELS
IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROME PATIENTS
AND INFLAMMATORY BOWEL DISEASE PATIENTS
ELISAs were performed on serum samples from 12 SIRS patients and 28 IBD
patients. To standardise OD readings, another serum was selected as a standard from
the 641 screened expressing close to median levels of IgG to all of the antigens and
used as above. As a control for the SIRS patients' experiment only, serum taken from
a healthy individual on six consecutive days was also tested.
2.2.34 COMPARISON OF BINDING OF IgG IN ELISA TO
LIPOPOLYSACCHARIDE ALONE WITH LIPOPOLYSACCHARIDE
COMPLEXEDWITH POLYMYXIN B SULPHATE
LPS alone or polymyxin B sulphate alone were coated onto ELISA strips: LPS
samples, or polymyxin B sulphate (both 1 mg / ml) were added to an equal volume of
PF water, diluted 1 in 50 and coated onto strips at 100 |il / well as described above.
Serum IgG levels from one SIRS patient were then measured in ELISA as described
above, and compared to levels obtained with LPS complexed with polymyxin B
sulphate.
To assess whether polymyxin B sulphate was preferentially binding certain parts of
the LPS molecule, LPS was complexed with polymyxin B sulphate as described
above, and the mixture was ultracentrifuged (100,000g / 3 h). The pellet and the
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supernate were lyophilised, resuspended in PF water to 1 mg / ml and examined by
PAGE and silver staining. As controls, uncomplexed LPS and polymyxin B sulphate
alone (both resuspended in PF water to 1 mg / ml) were also examined by PAGE.
2.2.35 MEASUREMENT OF BINDING OF C3b TO WHOLE BACTEROIDES
FRAGILIS CELLS IN ELISA
2.2.35a Treatment of Serum with Yeast Cell Walls
Prior to carrying out the ELISA, late complement proteins were depleted using yeast
cell walls to activate the alternative complement pathway, so that remaining C3b
would bind to bacterial cells but the cells would not lyse. Yeast cell walls (0.3 ml
[0.5 mg / ml]; donated by Dr. J. Stewart) were washed once in Hanks' Balanced Salts
Solution (HBSS: Gibco), centrifuged (1365# / 3 min) and the pellet resuspended to a
total volume of 1.5 ml. This was mixed with 1.5 ml human serum (collected by
method A; Section 2.1.2) and incubated for 30 min at 37°C. Yeast cell walls and
associated proteins were removed by centrifugation (630 g I 10 min).
2.2.35b C3b Binding ELISA
The yeast-treated serum was diluted further in HBSS to give a final concentration of
1% serum before being added at 100 jlxI / well to ELISA strips coated with whole
bacteria. The strips were incubated at 37°C for 30 min and then washed x 4. An
anti-human C3b murine MAb in ascites fluid (SAPU) was diluted 1 in 100, added to
the strips at 100 pi / well and incubated at 37°C for 90 min. After washing x 4, a
urease-conjugated polyvalent anti-mouse Ab (Sera-lab) was diluted 1 in 400 and
added at 100 pi / well. After a further 90 min incubation, the strips were washed x 4,
rinsed x 4 in water and developed with urease substrate solution (100 pi / well) for
30-40 min before OD was measured at 590 nm. A negative control was included
where the serum was replaced by pure diluent, and the absorbance of the negative




3.1 GROWTH OF BACTEROIDES SPECIES AND EXPRESSION OF £ELL
SURFACE ANTIGENS IN DIFFERENT ENVIRONMENTS
Alterations in growth environment can markedly change cell surface Ag expression,
and these changes can be crucial in determining whether a potential pathogen will
survive. The purpose of these experiments was to look at changes in bacteroides cell
surface Ag expression in different growth environments. Three basic growth media
were used: PPY (nutrient-rich), VT (minimal) and HISS ("physiological" medium).
3.1.1 GROWTH CURVES OF BACTEROIDES SPECIES IN DIFFERENT
MEDIA
It was necessary to determine growth rates in the different media, so that bacteria
could all be grown to approximately the same stage of the growth curve when cell
surface Ags were examined.
Growth of the eleven Bacteroides type strains was measured over 24 h by OD and
viable count (Figure 7). The growth curves of the type strains were taken to be
representative of the growth of each respective species. In all cases, the most dense
growth occurred in PPY. Some species grew better in VT than in HISS (e.g. B.
thetaiotaomicron, B. stercoris), and the reverse was true for other species (e.g. B.
eggerthii, B. uniformis). B. vulgatus did not grow in VT alone, and so for this species
only, the VT was supplemented with 10% HISS. All other strains tested grew in VT,
but in three cases (B. caccae, B. eggerthii and B. distasonis) the growth was poor.
Although all of the strains tested grew in HISS, the only species to achieve dense
growth in this medium was B. fragilis.
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Although the density of cells obtained was dependent on growth medium, the
different phases of the growth curve were reached at approximately the same time in
all media. Logarithmic phase occurred between approximately 2 and 12 hours, and it
was decided to harvest all cells at 14 hours when studying cell surface Ags, as this
was considered to be early stationary phase.
3.1.2 CAPSULATION OF CELLS IN DIFFERENT MEDIA
A step gradient of Percoll was used to assess the degree of capsulation of 14
Bacteroides strains grown to early stationary phase in PPY, VT and HISS.
Additionally, selected strains were grown in VT with the addition of various ion
chelators, and in a mixture of 50% VT / 50% HISS (VT & S). The results of these
experiments are shown in Figures 8a-c: Figure 8a shows a photograph of the Percoll
gradients of B. fragilis MPRL 1504 following growth in PPY, VT and HISS, and the
positions of the LC, SC and NC cells in the gradient are indicated. Figure 8b shows
India ink smears of the three cell types of B. fragilis MPRL 1504 (LC, SC and NC)
which were extracted from the Percoll gradients. Figure 8c shows diagrams of the
Percoll gradients of all 14 strains.
Percoll gradients and India ink smears showed all Bacteroides strains (except B.
eggerthii which was non-capsulate) to have a characteristic ratio of cells with large :
small : no capsule, and in all cases, this ratio varied with growth medium. There was
no inter-species correlation between degree of encapsulation and growth medium; in
any given medium some strains were mainly capsulate, whilst others were mainly
non-capsulate. Degree of encapsulation in any given medium also varied between







Figure 8a. Four-step (20, 40, 60 and 80%) Percoll- density gradients after
centrifugation with cultures ofB.fragilisMPRL 1504 grown to early stationary phase
in three media. Cells with large capsules were found at the 0-20% interface, those
with small capsules at the 20-40 and 40-60% interfaces, and those with no capsule at
the 40-60%, and (mainly) at the 60-80% interface.
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A
Figure 8b. Photomicrographs of B. fragilis MPRL 1504 showing bacteria with: A,
large capsules (from VT); B, small capsules (from PPY); C, no capsules (from
HISS). Cells were removed from the most concentrated band in each of the Percoll
gradients and stained with India ink
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B. fragilis MPRL 1504
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Figure 8c. Diagrammatic representations of the Percoll gradients of 14 Bacteroides
strains grown in different media. VT & S = 50% VT medium, 50% HISS.
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3.1.3 LIPOPOLYSACCHARIDE PROFILES OF BACTEROIDES STRAINS
GROWN IN THREE MEDIA
The LPS profiles of 25 Bacteroides strains grown to early stationary phase in PPY,
VT and HISS were examined by PAGE and silver staining. Initially Proteinase K
was used to extract the LPS; however, in the majority of cases the resultant LPS
stained very weakly with silver, and it appeared that in some cases a large amount of
material was not entering the separating gel (results not shown). Therefore,
extractions were repeated using the rapid aqueous phenol method of Fomsgaard et al
(1993), which gave better resolution of the LPS. These gels are shown in Figure 9a-
e. Protein molecular weight markers were also electrophoresed with the samples;
however, as proteins do not always migrate as a function of their molecular weights,
and may not migrate in the same fashion as LPS (Lesse et al 1990), any molecular
weights of LPS samples quoted are approximate, but are adequate for comparison
purposes. Each Bacteroides spp. had a species-specific LPS profile, although some
inter-strain variations were present. Differences in LPS profiles were apparent in
some strains grown in the different media, whereas in other cases there was very little
difference observed.
B. vulgatus was the only species which demonstrated a ladder pattern characteristic of
smooth LPS. This was also the case following proteinase K extraction (not shown).
There was no obvious ladder pattern in the LPS of the four B. fragilis strains tested.
The low Mr material was similar in all four strains, and all of the strains had the
common Ag in all growth media. The largest differences in B. fragilis LPS, both
between strains and within any given strain grown in the three media, were in the
high Mr (> 66 kDa) region of the gel. This material may have been CP or slime
rather than LPS.
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The two B. thetaiotaomicron strains had two low Mr bands, but in B.
thetaiotaomicron NCTC 10582 the heavier (~ 16.5 kDa) band was much stronger. B.
ovatus, B. uniformis, B. variabilis and B. caccae also had two low Mr bands, the
heavier of which were approximately 16.5 kDa, 15.5 kDa, 12.5 kDa and 19 kDa
respectively. In addition, B. caccae ATCC 43185 had a third low Mr band (~ 15
kDa) when grown in VT and HISS. Overall, the LPS profiles of these five species
shared many similarities.
B. distasonis, B. merdae, B. stercoris and B. eggerthii all had one strongly stained
lowMr band only. B. eggerthii MPRL 1216 had a very feint second low Mr band (~
6 kDa) when grown in VT, and in PPY had poorly defined, dark stained material in
the medium and high Mr regions. B. merdae ATCC 43184 also had a second feint
lowMr band when grown in VT. B. stercoris had a larger amount of lowMr material
when grown in HISS compared to when grown in PPY or VT. Overall, the LPS
profiles of these four species were quite similar.
Although the samples examined in these experiments were pure aqueous phenol
extracts, it was suspected that they were not pure LPS; the bands present in the
smooth LPS region in some of the B. fragilis strains were not evenly spaced and did
not look like smooth LPS. Also, there was a lot of dark staining, diffuse material in
some tracks, particularly in the high Mr regions, and in many cases material was
staining in the stacking gel which had never entered the separating gel.
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Figure 9. Silver-stained (14% acrylamide) LPS profiles of rapid aqueous phenol
extracts of 25 Bacteroides strains following growth to early stationary phase in PPY,
VT and HISS.
9a. Tracks: 1, B. fragilis NCTC 9343 (PPY); 2, B. fragilis NCTC 9343 (VT); 3, B.
fragilis NCTC 9343 (HISS); 4, B. fragilis MPRL 1504 (PPY); 5, B. fragilis MPRL
1504 (VT); 6, B. fragilis MPRL 1504 (HISS); 7, B. fragilis MPRL 1652 (PPY); 8, B.
fragilis MPRL 1652 (VT); 9, B. fragilis MPRL 1652 (HISS); 10, B. fragilis MPRL
1978 (PPY); 11, B. fragilis MPRL 1978 (VT); 12, B. fragilis MPRL 1978 (HISS);
13, B. thetaiotaomicron MPRL 1959 (PPY); 14, B. thetaiotaomicron MPRL 1959
(VT); 15, B. thetaiotaomicron MPRL 1959 (HISS); 16, B. vulgatus MPRL 1651
(PPY); 17, B. vulgatus MPRL 1651 (VT); 18, B. vulgatus MPRL 1651 (HISS); 19,
Mr markers. Abbreviations: L = low Mr material (lipid A and core), C = B. fragilis
common Ag, S = smooth LPS region, H = high Mr material (possibly CP or slime).
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9b. Tracks: 1, B. thetaiotaomicron NCTC 10582 (PPY); 2, B. thetaiotaomicron
NCTC 10582 (VT); 3, B. thetaiotaomicron NCTC 10582 (HISS); 4, B. vulgatus
MPRL 1985 (PPY); 5, B. vulgatus MPRL 1985 (VT); 6, B. vulgatus MPRL 1985
(HISS); 7,B. vulgatus NCTC 11154 (PPY); 8, B. vulgatus NCTC 11154 (VT); 9, B.
vulgatus NCTC 11154 (HISS); 10, B. eggerthii NCTC 11155 (PPY); 11, B. eggerthii
NCTC 11155 (VT); 12, B. eggerthii NCTC 11155 (HISS); 13, B. eggerthii MPRL
1523 (PPY); 14, B. eggerthii MPRL 1523 (VT); 15, B. eggerthii MPRL 1523 (HISS);
16, B. eggerthii MPRL 1216 (PPY); 17, B. eggerthii MPRL 1216 (VT); 18, B.
eggerthii MPRL 1216 (HISS); 19,Mr markers.
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9c. Tracks: 1, B. distasonis MPRL 1522; 2, B. distasonis MPRL 1522 (VT); 3, B.
distasonis MPRL 1522 (HISS); 4, B. caccae MPRL 1555 (PPY); 5, B. caccae MPRL
1555 (VT); 6, B. caccae MPRL 1555 (HISS); 7, B. distasonis ATCC 8503 (PPY); 8,
B. distasonis ATCC 8503 (VT); 9, B. distasonis ATCC 8503 (HISS); 10, B. caccae
ATCC 43185 (PPY); 11, B. caccae ATCC 43185 (VT); 12, B. caccae ATCC 43185
(HISS); 13, B. merdae ATCC 43184 (PPY); 14, B. merdae ATCC 43184 (VT); 15, B.
merdae ATCC 43184 (HISS); 16, B. stercoris ATCC 43183 (PPY); 17, B. stercoris
ATCC 43183 (VT); 18, B. stercoris ATCC 43183 (HISS); 19,Mr markers.
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9d. Tracks: 1, Mr markers; 2, B. ovatus ATCC 8483 (PPY); 3, B. ovatus ATCC
8483 (VT); 4, B. ovatus ATCC 8483 (HISS); 5, B. ovatus MPRL 1987 (PPY); 6, B.
ovatus MPRL 1987; 7, B. ovatus MPRL 1987 (HISS); 8, B. ovatus MPRL 2370
(PPY); 9, B. ovatus MPRL 2370 (VT); 10, B. ovatus MPRL 2370 (HISS); 11, B.
variabilis VPI 11368 (PPY); 12, B. variabilis VPI 11368 (VT); 13, B. variabilis VPI
11368 (HISS); 14, B. variabilis MPRL 2244 (PPY); 15, B. variabilis MPRL 2244
(VT); 16, B. variabilis MPRL 2244 (HISS).
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9e. Tracks: 1, B. uniformis ATCC 8492 (PPY); 2, B. uniformis ATCC 8492 (VT); 3,
B. uniformis ATCC 8492 (HISS); 4, B. uniformis MPRL 1542 (PPY); 5, B. uniformis
MPRL 1542 (VT); 6, B. uniformis MPRL 1542 (HISS); 7,Mr markers.
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3.1.4 COLONY MORPHOLOGY AND LIPOPOLYSACCHARIDE PROFILES
OF DIFFERENT CELL SUB-POPULATIONS FROM PERCOLL
GRADIENTS
To look at differences in sub-populations of cells in selected strains, bacteria were
grown in VT (or VT + 10% HISS for B. vulgatus) and centrifuged in Percoll
gradients as before. Sub-populations were then removed from the gradients, grown in
fresh medium and streaked onto CBA plates. Following growth to early stationary
phase in liquid medium, Percoll centrifugation was repeated and Proteinase K
extractions were carried out. Plates were incubated for 72 h before colony
morphology was examined.
No major differences were observed in any of the strain sub-populations in colony
morphology following growth on CBA. When colonies were inoculated into fresh
VT or VT + 10% HISS and centrifuged in Percoll as before, the cells had reverted to
the phenotypes seen in Figure 8c.
Capsulate cells remained capsulate after sub-culture. In most cases, in LC
populations, some SC cells had appeared following sub-culture (although the majority
were still of the LC phenotype), and the reverse was true for SC populations. NC
cells had reverted to a mixture of capsulate and NC cells following sub-culture,
although the majority were still NC (results not shown). Bearing this in mind, the
LPS profiles of the different sub-populations are shown in Figure lOa-b. There were
differences in the LPS profiles of some strain sub-populations, both in the low and
highMr regions. Of particular interest is B. ovatus MPRL 2370, which had an extra
lowMr band in the NC sub-population, and the two B. fragilis strains, which showed
differences in the high and low Mr regions in different sub-populations. B. vulgatus
was the only species with an obvious ladder pattern.
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Figure 10a. Silver-stained PAGE (14% acrylamide) LPS profiles of Proteinase K
extracts of sub-populations of 11 Bacteroides strains grown to early stationary phase
in VT. Tracks: 1, B. vulgatus MPRL 1985 (LC); 2, B. vulgatus MPRL 1985 (SC); 3,
B. vulgatus MPRL 1651 (LC); 4, B. vulgatus MPRL 1651 (SC); 5, B. caccae MPRL
1555 (LC); 6, B. caccae MPRL 1555 (SC); 7, B. variabilis VPI 11368 (LC); 8, B.
variabilis VPI 11368 (SC); 9, B. ovatus MPRL 2370 (LC); 10, B. ovatus MPRL 2370
(NC); 11, B. eggerthu NCTC 11155 (NC).
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Figure 10b. Tracks: 1, B. thetaiotaomicron NCTC 10582 (SC: 20-40% interface);
2, B. thetaiotaomicron NCTC 10582 (SC: 40-60% interface); 3, B. thetaiotaomicron
(NC); 4, B. distasonis ATCC 8503 (SC); 5, B. distasonis ATCC 8503 (NC); 6, B.
uniformis ATCC 8492 (LC); 7, B. uniformis ATCC 8492 (SC); 8, B. fragilis NCTC
9343 (SC); 9, B. fragilis NCTC 9343 (NC); 10, B. fragilis MPRL 1504 (LC).
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3.2 BACTERICIDAL ACTIVITY OF HUMAN SERUM AGAINST
RACTEROIDES SPECIES
Resistance to the bactericidal effects of serum complement is a well-recognised
virulence determinant, but to date, work carried out on complement resistance of
Bacteroides spp. has been very limited. The purpose of these experiments was
therefore i) to investigate whether different growth environments affected the
sensitivity of Bacteroides spp. to serum, ii) to investigate the mechanism of
complement resistance in Bacteroides spp., iii) to investigate whether different
mechanisms of processing serum affected its bactericidal capabilities, iv) to
investigate classical and alternative pathway activation of complement by Bacteroides
strains and v) to compare the bactericidal capability of serum from healthy
individuals with that from SIRS patients.
3.2.1 COMPARISON OF TWO METHODS OF SERUM PROCESSING
Serum from five healthy volunteers was processed by two different methods termed
A and B (described in Section 2.1.2). It was then tested for its ability to kill B.
fragilis NCTC 9343, B. fragilis MPRL 1504 and B. vulgatus MPRL 1985 grown in
PPY (Figure 11). The individual and pooled serum samples collected by the two
different methods were also examined by a sheep erythrocyte lysis assay to determine
the haemolytic complement value or CH50 (Table 3). In this assay, a normal CH50
value was within the range 50 to 150 CH50 units / ml.
With all three strains, serum processed by method A was more bactericidal than that
processed by method B. In addition, the CH50 values of the individual and pooled
sera were greater in serum processed by method A, indicating that complement
activity was better preserved with this method; in three individuals, and in the pooled
serum, CH50 values had decreased to below normal values when processed by
method B. Therefore, in all subsequent experiments, serum processed by method A
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Figure 11. Bactericidal activity of pooled serum from healthy volunteers processed




Table 3. CH50 values of individual and pooled serum from healthy volunteers
processed by two different methods.
CH50 (units / ml)
Method A
CH50 (units / ml)
Method B
Volunteer 1 56.2 48.9
Volunteer 2 123.0 88.6
Volunteer 3 83.2 71.9
Volunteer 4 49.9 32.5
Volunteer 5 59.1 39.5
Pooled serum (all volunteers) 63.1 49.1
3.2.2 THE INFLUENCE OF GROWTH MEDIUM ON SERUM SENSITIVITY
OF BACTEROIDES SPECIES
To investigate whether growth environment affected the sensitivity of Bacteroides
spp. to complement, 12 strains (some clinical, some faecal isolates) were grown in
PPY, VT (or VT + 10% HISS for B. vulgatus) and HISS, and then tested for their
ability to resist complement. When grown in PPY, all strains were, to varying
degrees, sensitive to complement. However, when grown in VT, six of the strains
(B. fragilis NCTC 9343, B. fragilis MPRL 1504, B. caccae MPRL 1555, B.
thetaiotaomicron MPRL 1959, B. ovatus MPRL 2370 and B. vulgatus MPRL 1985)
became markedly more resistant to complement. With the exception of B. vulgatus
MPRL 1985, these strains became totally resistant to complement when grown in
HISS. In every case, survival in CFTB alone was between 90 and 100%. Heat
inactivation of serum destroyed bactericidal activity in every case where a strain was
killed by active serum. Figure 12a-b shows two examples of strains tested, one of
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Figure 12. Survival of a: B. fragilis MPRL 1504 and b: B. distasonis ATCC 8503
in 40% pooled human serum following growth in three media. Points show mean
percentage survival calculated from four replicates.
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resistance when grown in the different media, and the other of which (B. distasonis
ATCC 8503) remained sensitive to complement in the different media. Table 4
shows the results for all 12 strains incubated with 40% serum.
Table 4. Survival of 12 Bacteroides strains after 1 h in 40% human serum following
growth in three media. Figures shown are mean percentage survival of bacteria
calculated from at least two replicates.
Percent Survival of Bacteria Grown in
Strain PPY VT HISS
B. fragilis MPRL 1504 7.8 37.9 92.2
B. fragilis NCTC 9343 14.0 68.1 94.2
B. caccae MPRL 1555 10.2 48.9 91.3
B. ovatus MPRL 2370 74.4 85.6 98.1
B. thetaiotaomicron MPRL 1959 52.9 71.8 97.6
B. thetaiotaomicron NCTC 10582 23.3 19.7 25.1
B. uniformis ATCC 8492 13.0 11.3 10.6
B. vulgatus MPRL 1985 49.0 61.1 41.5
B. vulgatus MPRL 1651 14.4 21.5 15.5
B. eggerthii NCTC 11155 0.0 3.2 0.0
B. distasonis ATCC 8503 6.7 0.0 2.6
B. variabilis VPI 11368 0.0 0.0 1.2
3.2.3 INVESTIGATION OF THE MECHANISM OF COMPLEMENT
RESISTANCE IN BACTEROIDES FRAGILIS
To investigate the biochemical basis for the observed changes in complement
resistance of certain strains when grown in different media, the two B. fragilis strains
(NCTC 9343 and MPRL 1504) which demonstrated these differences were used.
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Expression of cell surface Ags and binding of C3b to the cell surface were
investigated in the three media. As cells had to be grown in 1 L cultures for
extraction of cell surface Ags, instead of using HISS alone, a mixture of 50% HISS /
50% VT (VT & S) was used; cells grown in this were still totally resistant to
complement (results not shown).
3 ,2.3a Capsulation of Cells in Different Media
Differences in cell capsulation in different media, both between different strains
grown in the same media, and within any given strain grown in different media, have
already been demonstrated (Figure 8c).
3 .2.3b Outer Membrane Protein Expression in Different Media
Sarkosyl extracts of cells grown in the three media were visualised by PAGE
followed by Coomassie blue staining (Figure 13) and immunoblotting (Figure 14a-b).
In both strains, the protein concentration of the extracts from cells grown in VT was
too weak for the proteins to stain with Coomassie blue. However, several differences
in OMP expression were seen between cells grown in PPY and VT & S by Coomassie
blue staining. The OMP profiles of the two strains were similar, and varied in a
similar manner according to growth medium. Both strains had six bands
corresponding to proteins of approximately 72, 39, 34, 25, 16 and 10 kDa which
stained stronger following growth in PPY than in VT & S. Both strains grown in VT
& S had three proteins of approximately 91, 64 and 16.5 kDa which stained more
heavily than in PPY. Immunoblots of the OMPs using hyperimmune rabbit serum
gave similar profiles to those seen with Coomassie blue, except the OMPs from the
VT-grown cells stained stronger (although not strongly enough to be able to make




Figure 13. Coomassie blue-stained SDS-PAGE (10% acrylamide) OMP profiles of
sarkosyl extracts of B. fragilis NCTC 9343 and B. fragilis MPRL 1504 following
growth to early stationary phase in PPY, VT and VT & S. Tracks: 1,Mr markers; 2,
MPRL 1504 (VT); 3, MPRL 1504 (VT & S); 4, MPRL 1504 (PPY); 5, NCTC 9343
(VT); 6, NCTC 9343 (VT & S); 7, NCTC 9343 (PPY). Amounts of protein added
per track were: tracks 3, 4, 6 and 7-40 (ig; track 2-7 |ig; track 5-14 |ig.
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Figure 14a. Immunoblot of SDS-polyacrylamide (10%) gel of OMPs from B.
fragilis NCTC 9343 and B. fragilis MPRL 1504 following growth to early stationary
phase in PPY, VT and VT & S, using hyperimmune polyclonal rabbit serum (raised
against the OMPs ofB. fragilis NCTC 9344). Tracks and protein concentrations as in
Figure 13.
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Figure 14b. Immunoblot of SDS-polyacrylamide (10%) gel of OMPs from B.
fragilis NCTC 9343 and B. fragilis MPRL 1504 following growth to early stationary
phase in PPY, VT and VT & S, using hyperimmune polyclonal rabbit serum (raised
against B. fragilis MPRL 1504 whole cells). Tracks and protein concentrations as in
Figure 13.
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In a previous study, Patrick & Lutton (1990) found that B.fragilis NCTC 9343 grown
in vivo appeared to express proteins not seen when grown in vitro, these proteins
were subsequently shown to be mouse albumin and IgG, and could be removed by
washing. In the present study, cells were washed prior to extracting OMPs, which
should have removed any media-derived associated proteins. However, as a further
control, to examine whether any of the bands could be attributed to the growth media,
PPY alone and VT & S alone were electrophoresed and stained with Coomassie blue
and silver. Apart from the dye front, no bands were seen (results not shown).
3 ,2.3c Lipopolvsaccharide Profiles of Cells Grown in Different Media
Aqueous phenol extracts of cells (with the final ultracentrifugation step omitted),
were examined by PAGE, followed by silver staining and immunoblotting. The
silver-stained PAGE profiles are shown in Figure 15. The staining of these aqueous
phenol extracts was stronger than that of the rapid phenol extracts in Figure 9a,
probably reflecting differences in the concentration of material added to the tracks.
However, a similar pattern of staining was observed in the full-scale aqueous phenol
extracts; low and highMr-staining material and the common Ag were present in both
strains in all media, but there was no evidence of an evenly-spaced ladder pattern
characteristic of smooth LPS. Some bands were present in the smooth LPS region,
especially in VT & S-grown bacteria, but they did not look like the classical ladder
pattern of smooth LPS, and may have been contaminating protein. The biggest
differences in the silver-stained aqueous phenol extracts were in the highMr material,
which may have not been LPS.
Immunoblotting of the aqueous phenol extracts using hyperimmune rabbit serum
(Figure 16) revealed differences not observed with silver staining. Low Mr material
(below the common Ag) was poorly stained, as was also observed in immunoblots of
OMPs. B. fragilis NCTC 9343 extracts showed no evidence of a ladder pattern after
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Figure 15. Silver-stained PAGE (14% acrylamide) profiles of aqueous phenol
extracts (100 (ig / track) of B. fragilis MPRL 1504 and B. fragilis NCTC 9343
following growth to early stationary phase in PPY, VT and VT & S. Tracks: 1,
MPRL 1504 (PPY); 2, MPRL 1504 (VT); 3, MPRL 1504 (VT & S); 4, NCTC 9343
(PPY); 5, NCTC 9343 (VT); 6, NCTC 9343 (VT & S). Abbreviations as in Figure
9a.
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Figure 16. Immunoblot of polyacrylamide (14%) gel of aqueous phenol extracts
(200 |ig / track) of B. fragilis MPRL 1504 and B. fragilis NCTC 9343 following
growth to early stationary phase in PPY, VT and VT & S, using hyperimmune rabbit
serum raised against B. fragilis NCTC 9344 whole cells. Tracks: 1, MPRL 1504
(VT); 2, MPRL 1504 (VT & S); 3, MPRL 1504 (PPY); 4, NCTC 9343 (VT); 5,
NCTC 9343 (VT & S); 6, NCTC 9343 (PPY). Abbreviations as in Figure 9a.
123
growth in PPY (where they were sensitive to complement). However, after growth in
VT (where they were intermediately resistant to complement), a weak ladder pattern
was evident, and after growth in VT & S (where they were totally resistant to
complement) a strong ladder pattern was evident. A ladder pattern was not present in
B. fragilis MPRL 1504, although some dark stained material was present in the
smooth LPS region, which increased in intensity from PPY to VT to VT & S, as the
ladder pattern did in B. fragilis NCTC 9343.
3.2.3d Binding of C3b to the Cell Surface
Binding of complement component C3b to the bacterial cell surface is a crucial initial
step in the sequence leading to cell lysis. To see whether this occurred equally to
bacteria grown in different media, whole bacterial cells were coated onto microtitre
plates, and binding of C3b to the cells was assessed by ELISA. The results of this are
shown in Figure 17. C3b bound to both strains grown in all media. Although there
were differences in OD (and therefore the amount of C3b bound) within each given
strain, these were relatively small, and when the standard errors were taken into
consideration, there was no significant difference in binding of C3b to the cells of
either strain when grown in different media. The amount of C3b bound to B. fragilis
MPRL 1504 was slightly greater than that bound to B. fragilis NCTC 9343, but this
may have reflected small differences in numbers of cells coated onto plates.
3 2 3e Complement Resistance of Cells Grown in VT & S then PPY
In order to see whether cells grown in VT & S maintained their ability to resist
complement, bacteria were grown initially in VT & S, and then a 1% inoculum of the
resulting culture was placed into PPY. Following growth, the cells were assayed for
complement resistance, a further 1% inoculum of cells was added to fresh PPY and
the above process was repeated. As a control, the same strains were grown initially in
PPY then treated as above. The result of this experiment is shown in Figure 18. In
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Figure 17. Measurement of binding of C3b to whole cells of B. fragilis NCTC 9343
and B. fragilis MPRL 1504 in ELISA. Cells were grown to early stationary phase in
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Figure 18. Resistance of B. fragilis MPRL 1504 and B. fragilis NCTC 9343 to 40%
human serum after sub-culture from VT & S or PPY. Results shown are mean
percentage survival of bacteria calculated from four replicates. T = standard error.
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both strains, initial growth in VT & S did appear to increase complement resistance
when cells were then sub-cultured into PPY, but this increased resistance was
diminished by further sub-cultures of cells into PPY. After two to three sub-cultures
into PPY, resistance of cells initially grown in VT & S was no different from those
initially grown in PPY.
3 ,2 3f Complement Resistance ofMore Bacteroides fragilis Strains
It was decided to try to find a B. fragilis strain which remained sensitive to
complement after growth in VT & S so that its cell surface Ag expression could be
compared to that of the strains which became resistant. Twelve further B. fragilis
strains were therefore tested for their ability to resist complement after growth in PPY
and VT & S. These strains had variable resistance to complement after growth in
PPY, but all 12 became much more resistant after growth in VT & S (Table 5).
Table 5. Survival of 12 B. fragilis strains after 1 h in 40% human serum following
growth in PPY and VT & S. Figures shown are mean percentage survival of bacteria
calculated from two replicates.
Percent Survival of Bacteria Grown in
Strain PPY VT & S
B. fragilis MPRL 1652
B. fragilisMPRL 1978
B. fragilis NCTC 9344
B. fragilisMPRL 1582
B. fragilis MPRL 1583
B. fragilisMPRL 1584
B. fragilisMPRL 1585
B. fragilis MPRL 1586
B. fragilis MPRL 1588
B. fragilis MPRL 1590
B. fragilis MPRL 1981


























3.2.4 INVESTIGATION OF THE MECHANISM OF COMPLEMENT
RESISTANCE IN BACTEROIDES THETAIOTAOMICRON
As a B. fragilis strain which was sensitive to complement following growth in VT &
S could not be found, it was decided to look at the two B. thetaiotaomicron strains
already tested for complement resistance; one of these strains (MPRL 1959) became
resistant to complement after growth in VT & S, whereas the other (NCTC 10582)
remained sensitive (Table 4).
Degree of encapsulation, LPS and OMP expression were compared in the two B.
thetaiotaomicron strains. Differences in degree of encapsulation and in silver-stained
LPS profiles between the two strains have already been demonstrated (Figures 8 and
9 respectively). The LPSs were further compared by immunoblotting (Figure 19),
and OMP profiles were compared by PAGE followed by Coomassie blue staining and
immunoblotting (Figures 20 and 21). Unfortunately, the quality of the LPS
immunoblot was poor, possibly due to the age (18 years) of the rabbit serum used.
However, some differences were apparent both within each strain grown in different
media, and between strains grown in the same media. Interestingly, no bands were
present in either strain grown in VT & S. It is not possible to say whether bands
visible on the blot were LPS components, or whether they were other material (e.g.
protein, other polysaccharides) which may also have been present in aqueous phenol
extracts. Differences in OMP profiles were also apparent both by Coomassie blue
staining and immunoblotting. There were differences in OMP expression by MPRL
1959 and NCTC 10582 in PPY, and differences in OMP expression in PPY compared
to VT & S in NCTC 10582. Immunoblotting gave better resolution of the high Mr
bands than Coomassie blue. The protein concentration of the extracts from MPRL
1959 grown in VT & S was not strong enough to be visualised by Coomassie blue or
immunoblotting.
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Figure 19. Immunoblot of polyacrylamide (14%) gel of rapid phenol extracts of B.
thetaiotaomicron NCTC 10582 and B. thetaiotaomicron MPRL 1959 following
growth to early stationary phase in PPY, VT and VT & S, using hyperimmune
polyclonal rabbit serum raised against B. thetaiotaomicron NCTC 10582 whole cells.
Tracks: 1, NCTC 10582 (PPY); 2, NCTC 10582 (VT); 3, NCTC 10582 (VT & S);
4, MPRL 1959 (PPY); 5, MPRL 1959 (VT); 6, MPRL 1959 (VT & S).
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Figure 20. Coomassie blue-stained SDS-PAGE (10% acrylamide) OMP profiles of
Sarkosyl extracts of B. thetaiotaomicron NCTC 10582 and B. thetaiotaomicron
MPRL 1959 following growth to early stationary phase in PPY and VT & S. Tracks:
1, MPRL 1959 (PPY); 2, MPRL 1959 (VT & S); 3, NCTC 10582 (PPY); 4, NCTC
10582 (VT & S). Amounts of protein added per track were: tracks 1 and 3-40 |ig;
track 2-8 pig; track 4-25 |ig.
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Figure 21. Immunoblot of SDS-polyacrylamide (10%) gel of OMPs from B.
thetaiotaomicron NCTC 10582 and B. thetaiotaomicron MPRL 1959 grown to early
stationary phase in PPY and VT & S, using hyperimmune polyclonal rabbit serum
raised against B. thetaiotaomicron NCTC 10582 OMPs. Tracks: 1, NCTC 10582
(PPY); 2, NCTC 10582 (VT & S); 3, MPRL 1959 (PPY).
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3.2.5 CLASSICAL VERSUS ALTERNATIVE PATHWAY ACTIVATION
The aim of this study was to find out whether killing of selected Bacteroides strains
occurred via the classical or alternative pathway, and to see whether the pathway of
complement activation changed in any given strain with growth medium.
3 .2.5a Pre-Incubation of Serum with Bacteroides fragilis MPRL 1504
Serum was subjected to a series of absorptions with B. fragilis MPRL 1504 whole
cells grown in PPY or VT as described in Section 2.2.25a in order to absorb out any
species-specific Abs. It was then used in a serum sensitivity assay to measure killing
ofB. fragilis MPRL 1504 grown in PPY or VT respectively. Pre-absorption of serum
should result in inhibition of the classical pathway, and should indicate whether
species-specific Abs in serum are necessary to activate the complement cascade. The
results are shown in Figure 22. There was a reduction in bacterial killing following
pre-incubation of serum with bacteria, with cells grown in PPY and VT. The
reduction in killing was greater in PPY-grown cells, suggesting that killing of these
cells was more dependent on the classical complement pathway, and on specific Ab,
than killing ofVT-grown cells.
A potential problem with this experiment was that there could have been anti-
bacteroides Abs present in the HISS, which would stick to the cells during growth. If
they were not removed during the washing process, they would opsonise the bacteria,
and could give false positive results - i.e. they could activate the complement cascade
rather than Abs present in human serum. Therefore whole cells of B. fragilis MPRL
1504 grown in VT & S were coated onto ELISA plates, and IgG levels in HISS were
measured. There was anti-2?. fragilis IgG present in the sheep serum, comparable to
levels seen in low titre human serum (see Section 3.4). Therefore the possibility that
the sheep Abs were opsonising the bacteria could not be ruled out.
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Time of exposure to serum (min)
CFTB control
PPY (serum pre-absorbed)
PPY (serum not pre-absorbed)
VT (serum pre-absorbed)
VT (serum not pre-absorbed)
Figure 22. Killing of B. fragilis MPRL 1504 after growth in PPY and VT by 40%
human serum. Serum was subjected to a series of absorptions with B. fragilis MPRL
1504 whole cells grown in PPY or VT prior to using it in the complement sensitivity
assay in order to remove specific Ab.
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3 .2.5b Treatment of Serum with EGTA
To try to overcome the drawbacks of the above experiment, EGTA was added to
serum prior to using it in the complement sensitivity assay, in order to chelate Ca2+
ions and therefore specifically inactivate the classical pathway. Several Bacteroides
strains were tested, some of which became resistant to complement after growth in
VT & S, and others of which remained sensitive (Figure 23). Addition of EGTA to
serum reduced bacterial killing in all cases, indicating that the classical pathway was
being activated. However, the degree of activation of the classical and alternative
pathways both between strains grown in the same media, and within a given strain
grown in different media, varied considerably. In all strains, the biggest reduction in
killing with EGTA was in cells grown in PPY, followed by cells grown in VT,
followed by cells grown in VT & S. This indicated that classical pathway activation
was greatest for PPY-grown cells, followed by VT-grown cells, followed by VT & S-
grown cells. The opposite was true for alternative pathway activation. Addition of
EGTA to serum practically abolished killing of B. variabilis VPI 11368 grown in
PPY, indicating that complement activation in this case was more or less exclusively
via the classical pathway. In the other strains grown in PPY, killing was reduced in
the presence of EGTA, but not completely abolished, indicating that complement
activation was occurring partly via the classical, and partly via the alternative
pathway. B. vulgatus MPRL 1985 showed the smallest reductions in killing in the
presence of EGTA, suggesting that complement activation in this case was mainly via
the alternative pathway. There was no obvious correlation between pathway of
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3.2.6 BACTERIAL KILLING BY SERUM FROM SYSTEMIC
INFLAMMATORY RESPONSE SYNDROME PATIENTS
Whole blood was obtained from two patients with SIRS and the serum processed by
method A. Each serum sample was then tested for its ability to kill B. fragilis MPRL
1504 grown in PPY, and the haemolytic complement values (CH50) were measured.
Bactericidal capabilities and CH50 values were compared to those of four healthy
volunteers (Table 6). Bacterial killing and CH50 values were considerably reduced in
both patients' sera compared to serum from healthy individuals. Although there was
considerable variation in CH50 values between the healthy individuals' sera, all of
these sera killed the bacteria with approximately the same efficiency, probably
because they were all within the normal (50-150 units / ml) CH50 range. On the
other hand, the CH50 values (and therefore complement levels) of the SIRS patients'
sera were well below the normal range, the result of which was less efficient bacterial
killing.
Table 6. Survival of B. fragilis MPRL 1504 grown in PPY in 10% and 40% serum
from SIRS patients and healthy individuals. Results shown are means calculated
from two replicates.
Percentage survival of B. fragilis
MPRL 1504 after 1 l in:
Serum from: CH50 (units / ml) 10% serum 40% serum
Volunteer 1 56.2 8.9 7.8
Volunteer 2 123.0 13.4 10.2
Volunteer 3 83.2 12.0 9.0
Volunteer 4 59.1 12.2 8.3
SIRS patient 1 23.9 31.3 18.4
SIRS patient 2 31.6 43.0 20.2
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3.3 ANALYSIS OF THE SURFACE POLYSACCHARIDE COMPLEX OF
BACTEROTDES ERAGILIS
There is much controversy and confusion surrounding the composition and structure
of the surface polysaccharide complex of B. fragilis. This confusion has led to many
different interpretations of results, particularly with regard to possible roles of surface
polysaccharides in pathogenicity. In addition, it was suspected in earlier experiments
performed in this thesis that the aqueous phenol extracts were not pure LPS. The aim
of these experiments was to try to determine what was present in the surface
polysaccharide complex of B. fragilis, and to try to purify and analyse the different
components, in an attempt to address some of the unresolved questions which
surround this subject.
3.3.1 COMPARISON OF ULTRACENTRIFUGED AND NON-
ULTRACENTRIFUGED AQUEOUS PHENOL EXTRACTS
Aqueous phenol extracts ofB. fragilis NCTC 9343 and B. fragilis MPRL 1504 grown
in PPY, VT and VT & S were examined in a variety of ways. Initially, each extract
was divided into two; one half was subjected to the final rotary evaporation and
ultracentrifugation steps in the extraction method (Hancock & Poxton 1988), whilst
the other half was lyophilised without these final steps, and percentage yields were
calculated. In case material was present in the phenol phase, this was also collected
and lyophilised without ultracentrifugation. The ultracentrifuged and non-
ultracentrifuged samples were then assayed for protein, carbohydrate and
phosphorous, and were compared by PAGE followed by silver staining and
immunoblotting.
3,3,1a Percentage Yields ofExtracts
Percentage yields of the ultracentrifuged and non-ultracentrifuged aqueous phenol
extracts from cells grown in the three media were calculated (Table 7). In all cases,
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the yield of material from the phenol phase was very low. For both strains, the lowest
yield in the aqueous phase was from cells grown in PPY, then in VT & S, then in VT,
for both ultracentrifuged and non-ultracentrifuged extracts. In all cases except MPRL
1504 grown in VT & S, the percentage yield from the non-ultracentrifuged extracts
was greater than the yield from the ultracentrifuged ones.
Table 7. Percentage yields of ultracentrifuged and non-ultracentrifuged aqueous
phenol extracts of B. fragilis NCTC 9343 and B. fragilis MPRL 1504 grown in PPY,












NCTC 9343 (PPY) 0.01 0.59 0.56
NCTC 9343 (VT) 0.01 1.33 0.75
NCTC 9343 (VT & S) 0.02 0.89 0.63
MPRL 1504 (PPY) 0.02 0.7 0.63
MPRL 1504 (VT) 0.03 2.02 1.15
MPRL 1504 (VT & S) 0.02 0.86 0.88
* (weight of lyophilised aqueous phenol extract -s- weight of lyophilised cells) x 100.
3.3 .1b Polyacrvlamide Gel Electrophoresis of Extracts
Ultracentrifuged and non-ultracentrifuged aqueous phase extracts, and phenol phase
extracts were compared by PAGE followed by silver staining (Figure 24) and
immunoblotting (Figure 25). There was only sufficient material from the phenol
phases to run on one gel, and this was stained with silver; the resultant profiles were
similar to the profiles from the aqueous layers, except weaker (not shown). Silver
139
Figure 24. Silver-stained PAGE (14%) profiles of ultracentrifuged (+ uc) and non-
ultracentrifuged (- uc) aqueous phenol extracts (50 |ig / track) of B. fragilis NCTC
9343 and B. fragilis MPRL 1504 grown to early stationary phase in PPY, VT and VT
& S. Tracks: 1, NCTC 9343 (+ uc, PPY); 2, NCTC 9343 (- uc, PPY); 3, NCTC
9343 (+ uc, VT); 4, NCTC 9343 (- uc, VT); 5, NCTC 9343 (+ uc, VT & S); 6, NCTC
9343 (- uc, VT & S); 7, MPRL 1504 (+ uc, PPY); 8, MPRL 1504 (- uc, PPY); 9,
MPRL 1504 (+ uc, VT); 10, MPRL 1504 (- uc, VT); 11, MPRL 1504 (- uc, VT & S);
12, MPRL 1504 (+ uc, VT & S). Abbreviations as in Figure 9a.
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Figure 25. Immunoblot of polyacrylamide (14%) gel of ultracentrifuged (+ uc) and
non-ultracentrifuged (- uc) aqueous phenol extracts (100 pg / track) of B. fragilis
NCTC 9343 and B. fragilis MPRL 1504 grown to early stationary phase in PPY, VT
and VT & S, using hyperimmune rabbit serum raised against B. fragilis MPRL 1504
whole cells. Tracks: 1, NCTC 9343 (+ uc, PPY); 2, NCTC 9343 (- uc, PPY); 3,
NCTC 9343 (+ uc, VT); 4, NCTC 9343 (- uc, VT); 5, NCTC 9343 (+ uc, VT & S); 6,
NCTC 9343 (- uc, VT & S); 7, MPRL 1504 (+ uc, PPY); 8, MPRL 1504 (- uc, PPY);
9, MPRL 1504 (+ uc, VT); 10, MPRL 1504 (- uc, VT); 11, MPRL 1504 (+ uc, VT &
S); 12, MPRL 1504 (- uc, VT & S). Abbreviations as in Figure 9a
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staining of the aqueous phase ultracentrifuged and non-ultracentrifuged extracts
revealed some differences. In both strains grown in PPY and VT & S,
ultracentrifuged extracts had a greater amount of low Mr material present than non-
ultracentrifuged extracts, whereas in both strains grown in VT, the amount of low Mr
material in ultracentrifuged and non-ultracentrifuged extracts was approximately
equal. There were differences in all cases between the high Mr material in the
ultracentrifuged, compared to the non-ultracentrifuged extracts. In some cases
(NCTC 9343 in VT & S, MPRL 1504 in PPY and MPRL 1504 in VT & S) the
amount of high Mr material was greater in non-ultracentrifuged extracts. Generally,
the highMr material was less well defined in non-ultracentrifuged extracts. The non-
ultracentrifuged extracts of the two strains grown in VT had a greater amount of
poorly defined, dark staining material in the smooth LPS region compared to the
ultracentrifuged extracts. No obvious ladder patterns were evident in any of the
extracts.
The quality of staining of the immunoblot was poor. In all cases except NCTC 9343
grown in PPY, the non-ultracentrifuged extracts stained stronger than the
ultracentrifuged extracts. Material from the ultracentrifuged extract of MPRL 1504
in VT did not stain at all. Material below the common Ag did not stain in any
extract. Evenly spaced bands, which could have possibly been a ladder pattern, were
evident in the ultracentrifuged extract ofMPRL 1504 grown in VT & S. It is possible
that there were ladder patterns present in some of the other extracts which were not
visible due to the poor quality of the blot.
3 3 ,1c Estimation of Protein. Carbohydrate and Organic Phosphorus in Extracts
The relative amounts of protein, carbohydrate (neutral sugars) and organic
phosphorus were measured in the ultracentrifuged and non-ultracentrifuged aqueous
phenol extracts of B. fragilis NCTC 9343 and B. fragilis MPRL 1504 grown in the
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three media. The results are in Figure 26a-b. To standardise all results,
concentrations were worked out as a percentage of the dry weight of the extract. In
the non-ultracentrifuged extracts compared to the ultracentrifuged ones, there was a
relatively greater amount of protein and a smaller amount of carbohydrate. In two
cases (NCTC 9343 in VT & S and MPRL 1504 in PPY) phosphorus levels were
noticeably greater in non-ultracentrifuged extracts compared to ultracentrifuged ones,
whilst in the other cases phosphorus levels were very similar in non-ultracentrifuged
and ultracentrifuged extracts. These results suggest that ultracentrifugation did not
pellet out all of the protein in the extracts. This experiment also confirmed earlier
suspicions that the aqueous phenol extracts were not pure LPS, but also contained
protein.
As a control, the non-ultracentrifuged extract of B. jragilis NCTC 9343 grown in
PPY was assayed for KDO without prior dephosphorylation. The amount present
was extremely low (0.03%).
It was decided in all future experiments to use non-ultracentrifuged aqueous phenol
extracts, as ultracentrifugation did not purify the LPS and it was possible that
important antigenic determinants were being lost as a result of the ultracentrifugation
process.
3.3.2 TREATMENT OF AQUEOUS PHENOL EXTRACTS WITH
PROTEINASE K AND PERIODATE
The non-ultracentrifuged aqueous phenol extracts were further examined by PAGE,
silver staining and immunoblotting following digestion with Proteinase K (to destroy
protein) and periodate (to destroy carbohydrate). The silver-stained gel is shown in
Figure 27. Proteinase K treatment did not make a large difference to the aqueous











Figure 26a. Percentage of protein, carbohydrate and organic phosphorus in
ultracentrifuged (+ UC) and non-ultracentrifuged (- UC) aqueous phenol extracts of
B. fragilis NCTC 9343 grown to early stationary phase in three media. Results
shown are means calculated from at least two replicates.
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Figure 26b. Percentage of protein, carbohydrate and organic phosphorus in
ultracentrifuged and non-ultracentrifuged aqueous phenol extracts of B. fragilis
MPRL 1504 grown to early stationary phase in three media. Results shown are
means calculated from at least two replicates.
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Figure 27. Silver-stained PAGE (14% acrylamide) LPS profiles of aqueous phenol
extracts (100 |ig / track) of B. fragilis NCTC 9343 and B. fragilis MPRL 1504 grown
to early stationary phase in PPY, VT and VT & S. Extracts were treated with
Proteinase K (PrK), periodate (Per) or untreated (Utd). Tracks: 1, NCTC 9343
(PPY, Utd); 2, NCTC 9343 (PPY, PrK); 3, NCTC 9343 (PPY, Per); 4, NCTC 9343
(VT, Utd); 5, NCTC 9343 (VT, PrK), 6, NCTC 9343 (VT, Per); 7, NCTC 9343 (VT
& S, Utd); 8, NCTC 9343 (VT & S, PrK); 9, NCTC 9343 (VT & S, Per); 10,
MPRL 1504 (PPY, Utd); 11, MPRL 1504 (PPY, PrK); 12, MPRL 1504 (PPY, Per);
13, MPRL 1504 (VT, Utd); 14, MPRL 1504 (VT, PrK); 15, MPRL 1504 (VT, Per);
16, MPRL 1504 (VT & S, Utd); 17, MPRL 1504 (VT & S, PrK); 18, MPRL 1504
(VT & S, Per). Abbreviations as in Figure 9a.
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PPY) it removed unevenly-spaced bands in the smooth LPS region. It did not remove
the very high, or lowMr material. The common Ag was not visible on this gel in all
cases, but in those cases where it was visible (NCTC 9343 in PPY and MPRL 1504 in
all media) it disappeared following Proteinase K treatment. Periodate destroyed the
low Mr material either completely or almost completely in all cases. It also either
destroyed, or considerably reduced the amount of the highMr material. The common
Ag band had disappeared following periodate treatment, but immediately below the
region where the common Ag was in the untreated samples, there was a larger, more
diffuse band present in the periodate-treated samples. Immunoblotting using
hyperimmune rabbit serum raised against B. fragilis MPRL 1504 whole cells failed to
show any material in the Proteinase K and periodate-treated samples (gel not shown).
Material in the untreated lanes was as previously seen in Figure 25.
An attempt was made to estimate the amount of carbohydrate remaining in the
aqueous phenol extracts following periodate treatment. However, this was
unsuccessful as the periodate present in the samples caused the final colour in the
carbohydrate assay to be brown rather than yellow. This brown colour had a different
absorption maximum to the usual yellow end colour, and so the sample could not be
adequately compared with the control. It was not possible to carry out a protein assay
on the Proteinase K-treated samples, as the presence of Proteinase K would have
given a positive result.
3.3.3 FRACTIONATION OF THE SURFACE POLYSACCHARIDE
COMPLEX OF BACTEROIDES FRAGILIS NCTC 9343
An attempt was made to separate and purify the different components of the surface
polysaccharide complex of B. fragilis NCTC 9343, so that the different components
could then be analysed. An aqueous phenol extract of B. fragilis NCTC 9343 was





Figure 28. Silver-stained PAGE (10% acrylamide) profiles of fractions of a partially
purified aqueous phenol extract of B. fragilis NCTC 9343. Fractions were separated
by gel filtration chromatography. Abbreviations: H = high Mr material, I =
intermediate Mr material, L = low Mr material.
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2.2.9. The first fractionation was carried out on a gel filtration (Sephacryl S-300)
column; fractions were collected and visualised by PAGE and silver staining. The
material to be separated was passed through the column in two batches, and the
resultant gels are shown in Figure 28a-b. Three different classes of material were
evident; highMr, intermediateMr and lowMr. There is no intermediateMr material
visible in Figure 28b; it was visible on the gel, but not picked up on the photograph.
The gel represented in Figure 28b had a feint line at the dye front in the same tracks
as the highMr material.
Half of the high Mr material (assumed to be CP) was subjected to acid hydrolysis to
separate it into its two polysaccharide components - PSA and PSB. These were then
separated on an ion exchange column (DEAE-Sephacel).
3.3.4 ESTIMATION OF PROTEIN, CARBOHYDRATE AND ORGANIC
PHOSPHORUS IN SURFACE POLYSACCHARIDE FRACTIONS
The relative amounts of protein, carbohydrate and organic phosphorus were measured
in the surface polysaccharide fractions. The results are in Figure 29. To standardise
all results, the concentrations were worked out as a percentage of the dry weight of
the extract. The amount of carbohydrate was highest in the high Mr fraction and
lowest in the intermediate Mr fraction. Amounts of protein were very low in all
fractions except the intermediate Mr fraction. Organic phosphorus levels were very
low in all fractions except the low Mr fraction. The phosphorus level in PSA and
PSB was much lower than that in the low Mr fraction; it is possible that acid
hydrolysis of the lowMr material, and the subsequent ion exchange chromatography
were responsible for this reduction.
The lowMr fraction was assayed for KDO content without prior dephosphorylation.
The amount was extremely low (0.02%).
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Figure 29. Percentage of protein, carbohydrate and organic phosphorus in surface
polysaccharide fractions of B. fragilis NCTC 9343. Results are means calculated
from at least two replicates.
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3.3.5 CHARACTERISATION OF AN AQUEOUS PHENOL EXTRACT AND
SURFACE POLYSACCHARIDE FRACTIONS OF BACTEROIDES FRAGILIS
NCTC 9343 BY DOT BLOTTING AND IMMUNOBLOTTING
To try to characterise the surface polysaccharide complex of B. fragilis NCTC 9343
further, a non-ultracentrifuged aqueous phenol extract of the bacterium grown in
PPY, and the surface polysaccharide fractions were probed with hyperimmune rabbit
serum and with a panel of MAbs which reacted specifically against the surface Ags of
B. fragilis NCTC 9343 (listed in Table 2). Dot blotting, and subsequently
immunoblotting following PAGE were used.
3.3.5a Dot Blotting
The results of the dot blotting are shown in Table 8. The reactivities of the Abs with
the aqueous phenol extract were very similar to the reactivities with the high Mr
fraction. All of the Abs except 3F6 (against an undefined epitope in the SC
population) reacted with the aqueous phenol extract, and all of the Abs except 6G3
(possibly against the common Ag) and 3F6 reacted with the high Mr fraction. The
only Ab to react with all fractions was the rabbit serum, and PSA and the low Mr
fraction only reacted with the rabbit serum. Of the characterised MAbs, PSB and the
intermediate Mr fraction reacted with those against the LC and EDL (3D7 and 4C5),
and in addition the intermediate Mr fraction reacted with 3C8 (against the O-Ag).
Fractionation of the high Mr material into PSA and PSB considerably reduced their
reactivity with the MAbs.
Dot blotting was useful to show patterns of reactivity of the different Abs with the
cell surface fractions, but could not give any more information. Therefore to attempt
to characterise the cell surface Ags further, it was decided to examine them by PAGE
and immunoblotting.
151
Table 8. Reactivities of polyclonal rabbit serum and MAbs against an aqueous
phenol extract and different surface polysaccharide fractions of B. fragilis NCTC
9343 by dot blotting.





AP extract +++ +++ +++ +++ +/- ++ +++ +++ +++ +++ +++ +
HighMr ++ +++ +++ ++ ++ +++ +++ +++ +++ ++ +
PSA ++
PSB ++ +/- +/- + +1- +/-
Intermed. Mr + + +/- + +/- + + + +
Low Mr +
Abbreviations: R = Rabbit polyclonal hyperimmune serum against B. fragilis MPRL
1504 whole cells, # = 2 day supernate, * = 7 day supernate, AP = aqueous phenol, +++
= strong reaction to - = no reaction.
3,3.5b Immunoblotting
The aqueous phenol extract and the surface polysaccharide fractions were
electrophoresed and were then probed with the Abs which gave a positive reaction in
the dot blots. In addition, they were probed with polyclonal rabbit sera raised against
B. fragilis NCTC 9343, B. fragilis NCTC 9344 and the B. fragilis common Ag.
Initially the samples were electrophoresed and stained with silver. This was done in
order to find the percentage of acrylamide in the separating gel, and the distance to let
the samples run in the separating gel which gave good separation of the different
fractions, but which did not separate them so much that they became very diffuse and
difficult to see. It was found that running the samples approximately 5 cm down an
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8% acrylamide separating gel gave the best resolution (Figure 30). PSB did not stain
with silver.
Multiblots of the aqueous phenol extract, and the high Mr material are shown in
Figure 31a-b. Immunoblotting of the aqueous phenol extract with polyclonal rabbit
sera against NCTC 9344 whole cells, NCTC 9343 LC and MPRL 1504 whole cells
revealed dark-staining material in the high and intermediate Mr regions, but little in
the lowMr region. The rabbit serum against the common Ag revealed only one band
towards the top of the track. This band was also evident in the blot using the mouse
MAb 6G3 (possibly anti-common Ag). Of the other mouse MAbs, 3C8 (anti-O-Ag),
3D7 (anti-LC and EDL populations) and 2E12 complexed with material at the top of
the tracks, 3H5, 5B7, 1A4 (reactive with 99% of B. fragilis isolates) and 1E2
complexed with material slightly lower on the tracks, and 2B8 and 3C10 complexed
with material slightly lower again. No staining was observed with MAb 3F6 (against
an undefined epitope in the SC population). Immunoblotting of the highMr material
with polyclonal rabbit sera only revealed material when serum against NCTC 9343
LC and serum against NCTC 9344 whole cells were used. In both of these cases, the
material was in the high Mr region of the gel. Rabbit serum against the common Ag,
and the mouse MAb 6G3 did not reveal any material. Of the other mouse MAbs, 3C8
and 3D7 complexed with high Mr material, 3H5 and 3C10 complexed with material
slightly lower on the tracks, and 2B8 complexed with material slightly lower again.
None of the other MAbs revealed any material. The other fractions (PSA, PSB,
intermediate Mr and lowMr) which were visible on certain dot blots were not visible
by immunoblotting following PAGE.
153
1 2 3 4 5 6
u
Figure 30. Silver-stained PAGE (8% acrylamide) profiles of an aqueous phenol
extract and surface polysaccharide fractions of B. fragilis NCTC 9343 (20 |ig /
track). Tracks: 1, whole aqueous phenol extract; 2, high Mr material; 3, PSA; 4,
PSB; 5, intermediate Mr material; 6, lowMr material.
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Figure 31a. Multiblots of polyacrylamide (8%) gel of a whole aqueous phenol
extract of B. fragilis NCTC 9343 using polyclonal rabbit serum and murine MAbs.
Tracks: Rabbit sera: 1, against B. fragilis NCTC 9344 whole cells; 2, against B.
fragilis MPRL 1504 whole cells; 3, against B. fragilis NCTC 9343 LC; 4, against B.
fragilis common Ag; Murine MAbs: 5, 3C8; 6, 3H5; 7, 3D7; 8, 6G3; 9, 5B7; 10,
2B8; 11, 1A4; 12, 3C10; 13, 4C5; 14, 1E2; 15, 2E12; 16, 3F6 (7 day supernate).
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Figure 31b. Multiblots of polyacrylamide (8%) gel of the high Mr fraction of the
surface polysaccharide complex of B. fragilis NCTC 9343, using polyclonal rabbit
serum and murine MAbs. Tracks: Rabbit sera: 1, against B. fragilis MPRL 1504
whole cells; 2, against B. fragilis NCTC 9343 LC; 3, against B. fragilis common Ag;
4. against B. fragilis NCTC 9344: Murine MAbs: 5, 3C8; 6, 3H5; 7, 3D7; 8, 6G3;
9, 5B7; 10, 2B8; 11, 1A4; 12, 3C10; 13, 4C5; 14, 1E2; 15, 2E12; 16, 3F6 (2 day
supernate); 17, 3F6 (7 day supernate).
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3.4 ANTIBODIES TO BACTEROIDES TN HEALTH AND DISEASE
The aim of this study was to carry out a comprehensive investigation of IgG levels to
bacteroides in serum, both in health and disease. IgG was chosen as its presence in
serum indicates previous exposure to an Ag, and in disease a sudden consumption of
IgG against a particular Ag may indicate re-exposure. Unless otherwise indicated, the
conjugate used to detect serum Abs was an anti-human IgG (whole molecule)
conjugated to alkaline phosphatase.
3.4.1 ANTIGENS USED FOR MEASURING IGG IN SERA
The Ags chosen to measure Ab levels against were non-ultracentrifuged aqueous
phenol extracts of selected Bacteroides spp. (grown in PPY) and a cocktail of PCP-
extracted LPS from E. coli, S. typhimurium, K. pneumoniae and P. aeruginosa. The
silver-stained profiles of the different extracts are shown in Figure 32. The only
striking difference between the large-scale and the rapid aqueous phenol extracts of
the Bacteroides strains was in B. thetaiotaomicron NCTC 10582; the large-scale
extract had several evenly spaced bands characteristic of smooth LPS above the low
Mr material which were not apparent in the rapid extracts. The PCP-extracted LPSs
were, as expected, all of the rough phenotype.
Although the bacteroides aqueous phenol extracts were not pure LPS, for the sake of
ease in the rest of this section they will be referred to as LPS.
3.4.2 PRELIMINARY SCREEN OF 50 RANDOM BLOOD DONORS FOR
ANTI-BACTEROIDES LIPOPOLYSACCHARIDE IgG
Initially 50 random blood donors were screened by ELISA for IgG against nine
bacteroides LPSs. Scatter graphs were drawn by plotting the OD obtained from each
donor serum with one Ag against the OD obtained from the same serum with another
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Figure 32. Silver-stained PAGE (14%) profiles of aqueous phenol extracts of
selected Bacteroides strains and of PCP extracts of three enterobacteria and P.
aeruginosa 20 |ig / track). Tracks: 1, B. fragilis NCTC 9343; 2, B. fragilis MPRL
1504; 3, B. vulgatus MPRL 1985; 4, B. caccae MPRL 1555, 5, B. thetaiotaomicron
NCTC 10582; 6, B. ovatus MPRL 2370; 7, B. variabilis VPI 11368; 8, B. eggerthii
NCTC 11155; 9, B. uniformis ATCC 8492; 10, E. coli K12 (MPRL 1303); 11, S.
typhimurium Rc 878 (MPRL 0947); 12, K. pneumoniae 10B (MPRL 1954); 13, P.
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Figure 33. Scatter graphs showing relative IgG levels to one bacteroides aqueous
phenol extract compared to IgG levels against another in 49 random blood donors, as
measured by OD405 nm in ELISA (x and y axes). . = one donor; — = best fit line
through points, y = y-axis intercept of best fit line; x = gradient of best fit line; r =
correlation coefficient; P = probability of the correlation occurring by chance; NS —
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Figure 33 (continued).
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Figure 33 (continued).
165
the Ags are shown in Figure 33. There was a high degree of correlation between
most Ags tested - i.e. in any given donor when the IgG levels to one Ag were high,
the levels to the other Ag were correspondingly high and vice-versa. The only case
where the correlation was not significant (r = 0.22; P > 0.5) was between B. fragilis
MPRL 1504 and B. ovatus MPRL 2370. Interestingly, the only cases where
correlation coefficients were not very highly significant (> 0.4; P < 0.001) were
between the B. fragilis strains and some of the other strains.
This study showed that in virtually all cases there was a significant correlation
between the IgG levels to LPSs from different species and strains of Bacteroides.
There were two different ways in which this could have occurred:
• The Abs cross-reacted between different Bacteroides species.
• The Abs were not cross-reactive, but some individuals were exposed to bacteroides
Ags more than others, so when the response to one was high, the response to another
was also correspondingly high.
In an attempt to find out how cross-reactive the anti-bacteroides Abs were, absorption
studies were carried out.
3.4.3 ABSORPTION OF ANTI-BACTEROIDES LIPOPOLYSACCHARIDE
ANTIBODIES USING WHOLE CELLS
Serum pooled from ten random blood donors was subjected to a series of absorptions
with bacteroides whole cells to absorb out specific Abs. It was then used in an
ELISA measuring IgG levels to the different LPSs; a decrease in IgG levels
compared to a non-preabsorbed control would indicate the presence in serum of
cross-reactive Abs. The results of this are shown in Figure 34. To standardise results
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so that they could all be similarly compared, ODs were converted to a percentage of a
non-preabsorbed control (which was given a value of 100%).
In the majority of cases, preabsorption of serum with bacteroides whole cells reduced
the subsequent amount of IgG bound to any given LPS in ELISA. The degree of
reduction was highly dependent on which LPS and cells were used.
Generally, binding of IgG to the different LPSs was reduced to the greatest extent
when serum had been preabsorbed with whole cells of the same strain from which the
LPS was derived. There was one exception to this: binding of IgG to B. eggerthii
NCTC 11155 LPS was reduced almost equally following preabsorption of serum with
B. eggerthii, B. vulgatus and B. thetaiotaomicron whole cells.
The extent by which preabsorption of serum with whole cells reduced IgG binding to
LPS derived from the same cells was variable between different species and strains.
Preabsorption of serum with B. fragilis NCTC 9343 and B. vulgatus MPRL 1985
whole cells reduced the subsequent amount of IgG bound to B. fragilis NCTC 9343
and B. vulgatus MPRL 1985 LPS respectively by about 90%. On the other hand,
preabsorption of serum with B. eggerthii NCTC 11155 and B. thetaiotaomicron
NCTC 10582 reduced the subsequent amount of IgG bound to the respective LPSs by
only 50-60%.
In most cases, a certain degree of cross-reactivity was apparent, but certain Abs
appeared to be more cross-reactive than others, suggesting that LPSs of certain strains
shared more common epitopes than others. There was a high degree of cross-
reactivity between IgG against the two B. fragilis strains, and between IgG
against B. vulgatus MPRL 1985, B. thetaiotaomicron NCTC 10582 and B. variabilis
VPI 11368. Binding of IgG to B. uniformis ATCC 8492 LPS was reduced by at least
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Figure 34. Measurement of IgG levels to bacteroides aqueous phenol-extracted LPS
in ELISA following preabsorption of serum with bacteroides whole cells. OD (405
nm) is expressed as a percentage of a non-preabsorbed control. PA = preabsorbed.
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Figure 34 (continued).
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Figure 34 (continued).
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50% in all cases following preabsorption of serum, suggesting that the LPS of this
strain possibly had an epitope common to all strains tested.
In summary, it appeared that there were some epitopes common to all of the
bacteroides LPSs, but in addition each strain also possessed unique epitopes with
distinctive Abs against them present in serum.
A problem with using whole cells to try to absorb out cross-reactive Abs is that
certain epitopes (e.g. lipid A) are masked on whole cells, and so Abs against these
epitopes are not absorbed out. To try to overcome this problem, Abs were absorbed
out of serum using LPS rather than whole cells, prior to using the serum in ELISA.
3.4.4 ABSORPTION OF ANTI-BACTEROIDES LIPOPOLYSACCHARIDE
ANTIBODIES USING LIPOPOLYSACCHARIDE
For these experiments, the same nine bacteroides LPSs, plus the enterobacterial /
Pseudomonas R-LPS cocktail, were used in the ELISA to measure serum IgG.
However, only four bacteroides LPSs were selected to absorb Abs from serum in
order to make the execution and interpretation of the experiment more manageable.
LPSs used were from B. fragilis NCTC 9343 and B. fragilis MPRL 1504 (as B.
fragilis is the most common anaerobic pathogen), B. thetaiotaomicron NCTC 10582
and B. vu/gatus MPRL 1985 (as these are two of the most common Bacteroides spp.
in faeces) and the enterobacterial / Pseudomonas R-LPS cocktail (in order to assess
degree of cross-reactivity between bacteroides and enterobacterial LPS). In addition,
to compare Ab responses in pooled serum with those in an individual's serum, and to
compare the Ab response between different individuals, absorptions and ELISAs
were carried out with serum pooled from ten random donors and with serum from
two individual volunteers. The results (shown in Figure 35a-e) were standardised as
before.
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The trends and patterns of cross-reactivity were generally the same as those seen with
whole cell absorptions. There were some epitopes on the different bacteroides LPSs
that were common, but also others that were unique to each particular strain. B.
vulgatus MPRL 1985 and B. thetaiotaomicron NCTC 10582 LPS appeared to share
many common epitopes, as was observed in whole cell absorptions; however, IgG
against the two B. fragilis LPSs appeared to show less cross-reactivity when serum
was preabsorbed with LPS as opposed to whole cells.
Although overall trends were the same, there were some differences between degrees
of cross-reactivity of anti-bacteroides LPS IgG between the pooled serum and the two
individuals' sera. For example, the pooled donor serum had more anti-B. fragilis
NCTC 9343 LPS IgG which cross-reacted with B. eggerthii NCTC 11155 LPS than
either of the two individuals, and individual # 2 had a greater amount of anti-5.
fragilis NCTC 9343 LPS IgG which cross-reacted with all of the other bacteroides
LPSs than the pooled serum or than individual # 1. This suggested that the anti-
bacteroides Ab repertoire varied between different individuals, and the cross-
reactivity pattern seen in the pooled serum was the cumulative result of the IgG
repertoires in the ten individuals' sera.
In all cases, binding of IgG to the different LPSs was reduced to the greatest extent
when serum had been preabsorbed with homologous LPS. As with the whole cell
absorptions, the extent to which preabsorption of serum with LPS reduced subsequent
IgG binding to the same LPS was variable between different species and strains, and
between different sera; preabsorption of pooled donor serum with B. vulgatus MPRL
1985 LPS reduced subsequent IgG binding to B. vulgatus MPRL 1985 by over 95%,
whereas in individual # 1 the binding was only reduced by approximately 60% in the
same experiment. Little difference was observed in the amount of cross-reactive Abs
absorbed out when LPS was used for the absorptions as opposed to whole cells. Total
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Figure 35a. Measurement of IgG levels to B. fragilis NCTC 9343 aqueous phenol-
extracted LPS in ELISA following preabsorption of pooled and individual sera with
bacteroides LPS and a cocktail ofPCP-extracted R-LPS from three enterobacteria and
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Figure 35b. Measurement of IgG levels to B. fragilis MPRL 1504 aqueous phenol-
extracted LPS in ELISA following preabsorption of pooled and individual sera with
bacteroides LPS and a cocktail of PCP-extracted R-LPS from three enterobacteria and
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Figure 35c. Measurement of IgG levels to B. vulgatus MPRL 1985 aqueous phenol-
extracted LPS in ELISA following preabsorption of pooled and individual sera with
bacteroides LPS and a cocktail of PCP-extracted R-LPS from three enterobacteria and
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Figure 35d. Measurement of IgG levels to B. thetaiotaomicron NCTC 10582
aqueous phenol-extracted LPS in ELISA following preabsorption of pooled and
individual sera with bacteroides LPS and a cocktail of PCP-extracted R-LPS from
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Figure 35e. Measurement of IgG levels to a cocktail of PCP-extracted R-LPS from
three enterobacteria and P. aeruginosa in ELISA following preabsorption of pooled
and individual sera with bacteroides LPS and the R-LPS cocktail. PA = preabsorbed.
Results shown are means calculated from four replicates.
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absorption of cross-reactivity was not achieved in any case.
The results of these experiments clearly showed that the degree of cross-reactivity
between IgG against the rough enterobacterial / Pseudomonas LPS cocktail and IgG
against bacteroides LPS was very limited. This suggests that there were very few
common epitopes between the enterobacterial LPS and bacteroides LPS.
3.4.5 IMMUNOBLOTTING OF BACTEROIDES LIPOPOLYSACCHARIDES
USING HUMAN SERUM
The aqueous phenol-extracted bacteroides LPS samples were examined by PAGE and
immunoblotting to try to determine the epitopes to which the IgG was binding. Sera
from the two individuals used above in the LPS absorption studies were used. The
resultant immunoblots are shown in Figure 36a-b. In most cases, the LPS samples
were not visualised by immunoblotting with human serum. In those that were, some
differences were apparent between the two individuals. IgG from both individuals
reacted with the smooth LPS from B. vulgatus and B. thetaiotaomicron, and with
high Mr material from B. caccae and B. ovatus at the interface between the stacking
and separating gels. However, in addition IgG from individual # 2 also reacted with
low Mr material from B. fragilis NCTC 9343, high Mr material from B. fragilis
MPRL 1504, low Mr material from B. uniformis, and with B. eggerthii, where a fine
ladder pattern high in the smooth LPS region was apparent.
3.4.6 DETERMINATION OF THE DISTRIBUTION OF ANTI-
LIPOPOLYSACCHARIDE IgG LEVELSWITHIN 641 BLOOD DONORS
Extensive studies have been previously carried out which have investigated
distributions of Ab levels in human serum to enterobacteria and closely related spp.
In contrast, to date there has been very little equivalent work carried out on





Figure 36a. Immunoblots of polyacrylamide (14%) gel of aqueous phenol-extracted
bacteroides LPS (200 |ig / track), using human serum from individual # 1 diluted 1
in 10. Tracks: 1, B. fragilis NCTC 9343; 2, B. fragilis MPRL 1504; 3, B. vulgatus
MPRL 1985; 4, B. caccae MPRL 1555; 5, B. thetaiotaomicron NCTC 10582; 6, B.
ovatus MPRL 2370; 7, B. variabilis VPI 11368; 8, B. eggerthii NCTC 11155; 9, B.
uniformis ATCC 8492.
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Figure 36b. Immunoblots of polyacrylamide (14%) gel of aqueous phenol-extracted
bacteroides LPS (200 jig / track), using human serum from individual # 2 diluted 1
in 10. Tracks as in Figure 36a.
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anti-bacteroides LPS IgG in a large sample of blood donors, and to compare the
distribution with that of anti-enterobacterial IgG. Sera from 641 blood donors were
screened for IgG against aqueous phenol-extracted LPS from B. fragilis NCTC 9343,
B. vulgatus MPRL 1985, B. thetaiotaomicron NCTC 10582 and the R-LPS cocktail
(three enterobacteria and P. aeruginosa). The results of this screen are shown in
Figure 37. Distributions of anti-LPS IgG in the donor population tested were normal
in appearance on histograms, except anti-f?. fragilis NCTC 9343 LPS IgG which
showed a slight negative skew. Every donor screened had anti-bacteroides LPS IgG
and anti-R-LPS cocktail IgG present in their serum.
3.4.7 KINETICS OF ANTI-LIPOPOLYSACCHARIDE IgG RESPONSE IN
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME PATIENTS
Previous studies have investigated the magnitude and kinetics of serum Ab response
to LPS core from a range of enterobacteria and closely related spp. in SIRS patients.
Ab levels, particularly IgG, were found to fluctuate considerably from day to day, and
in some cases a sudden decrease in serum IgG was shown to be concurrent with an
acute episode of endotoxaemia (Barclay et al 1989, Barclay 1990). No such study
has been carried out with Bacteroides spp. The aim of this study was therefore to
look at the kinetics of the IgG response to bacteroides LPS, and compare it with the
kinetics of the response to LPS from enterobacteria and related spp. in SIRS patients.
Patients selected for this study had a diagnosis of abdominal sepsis and were blood
culture negative, and so any LPS present in their blood should have been derived
from the gut. LPSs selected for the study (for the same reasons described in Section
3 .4.4) were aqueous phenol extracts from B. fragilis NCTC 9343, B. vulgatus MPRL
1985, B. thetaiotaomicron NCTC 10582 and the R-LPS cocktail from three
enterobacteria and P. aeruginosa. ELISAs were performed on sera taken daily over
five- to nine-day periods from 12 SIRS patients (six survivors, six non-survivors). In
addition, as a control, serum taken from a healthy individual over six consecutive
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Figure 37. Distribution of anti-LPS IgG in 641 blood donors by quantitative
screening ELISA. * Serum from a donor expressing close to median levels of IgG to
all LPSs tested, selected from the preliminary screen of 50 random blood donors was
included on all plates to standardise OD readings. Standard = 100%. Each donor
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days was also tested. The results are shown in Figure 38. Although no cases were
identical, several broad observations could be made on the overall trends of results.
In every SIRS patient, IgG levels (especially IgG against B. fragilis LPS) fluctuated
over time to a greater extent than levels in a healthy subject. Fluctuations in IgG
against all of the Ags followed similar overall trends, and in most cases anti-
bacteroides LPS IgG, especially that against B. fragilis, showed greater fluctuations
than the anti-enterobacterial / Pseudomonas LPS IgG. In five out of six survivors,
IgG levels to all of the Ags had increased overall at the end of the sampling period.
In five of the six non-survivors, levels stayed approximately the same or decreased,
with an exception showing increasing levels to B. fragilis LPS. In five out of six
non-survivors, IgG levels to B. fragilis LPS were higher than those against the other
LPSs, and in the sixth non-survivor, IgG levels to all Ags were very low throughout
the whole sampling period. Three out of six survivors and three of six non-survivors
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Figure 38. Kinetics of anti-LPS IgG response in 12 SIRS patients (six survivors, six
non-survivors) and in a healthy individual over six- to nine-day periods. *Standard =
100%; serum from a donor expressing close to median levels of IgG to all LPSs
tested, selected from the screen of 641 random blood donors, was included on all
plates to standardise OD readings. Points shown are average percentages calculated
from at least two replicates.
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3.4.8 COMPARISON OF TWO CONJUGATES TO DETECT SERUM IGG
In all previous experiments, the conjugate used to detect serum IgG recognised the
whole IgG molecule (i.e. heavy and light chains). This conjugate was initially chosen
to detect maximum amounts of Ab. However, there could have been some cross-
reactivity between the light chains of different Ig classes. To assess whether this was
the case, and therefore whether Ab classes other than IgG had been detected in the
previous experiments, doubling dilutions of a serum sample from one SIRS patient
(non-survivor # 4) and the healthy individual were tested in ELISA for IgG against B.
fragilis NCTC 9343 and the R-LPS cocktail. The IgG was detected with the whole
molecule-specific conjugate used above, and with a conjugate specific for the heavy
(7) chain of IgG only, and the two sets of results were compared. All of the samples
were tested at the same time, so ODs were compared directly. The results are shown
in Figure 39, and in each case, they show that differences between the two
conjugates, particularly in the straight line regions of the graphs, were extremely
small, and it therefore appeared that the anti-whole molecule IgG conjugate was
detecting mainly IgG and very little else.
3.4.9 COMPARISON OF BINDING OF IgG IN ELISA TO
LIPOPOLYSACCHARIDE ALONE WITH LIPOPOLYSACCHARIDE
COMPLEXEDWITH POLYMYXIN B SULPHATE
In all previous experiments, LPS had been complexed with polymyxin B sulphate
prior to coating it onto microtitre wells, as it has been previously reported that this
enhances LPS binding (Scott & Barclay 1987). As controls for previous experiments,
LPS was coated to plates with and without complexing to polymyxin B sulphate and
then tested in ELISA, in order to find out whether binding was enhanced. To check
that human IgG did not bind to polymyxin B sulphate alone, it was coated onto plates
alone and tested in ELISA. In addition, to see whether polymyxin B sulphate was
preferentially binding certain parts of the LPS molecule and not others, LPS samples
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Figure 39. Comparison of the use of an anti-human IgG (whole molecule) conjugate
with an anti-human IgG (7 chain specific) conjugate to measure anti LPS IgG levels
in serum from A: a SIRS patient (non-survivor # 4) and B: a healthy individual.
Points shown are means calculated from four replicates.
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were complexed with polymyxin B sulphate, ultracentrifuged, and the pellet
(polymyxin B sulphate / LPS complex) and supernate (LPS not complexed) were
compared with untreated LPS samples by PAGE and silver staining. For the ELISAs,
one SIRS patient's consecutive serum samples were used (survivor # 5), and were
tested against the four LPS samples as before. The results are in Figure 40. In all
cases, binding of IgG to polymyxin B sulphate alone was negligible, with ODs
comparable to background levels (not shown). The trends of IgG binding to the
complexed and non-complexed LPSs were similar, but complexing of the LPS to
polymyxin B sulphate enhanced the overall amount of IgG bound, suggesting that the
complexing step enhanced LPS binding to the plates. In addition, complexing
appeared to increase the sensitivity of the ELISA, with differences between samples
being more pronounced when the complexed LPSs were used.
The silver-stained PAGE profiles of the LPSs are shown in Figure 41. The S.
typhimurium Rc 878 LPS was chosen as a "representative" LPS from the cocktail for
this experiment, and in this case, all of the LPS appeared to have complexed with
polymyxin B sulphate; ultracentrifugation of the polymyxin B sulphate / LPS
complex yielded no material in the supernate. For all Bacteroides strains tested, there
was material present in the supernate, indicating that not all of the LPS had
complexed with polymyxin B sulphate. However, polymyxin B sulphate did not
appear to preferentially bind certain parts of the LPS, as the LPS profiles of the
supernates and the pellets were similar. The main difference was that there was more
lowMr material in the polymyxin B sulphate / LPS complex than in the uncomplexed
LPS in the supernate, but this could have been due to the fact that there was a greater
concentration of LPS in the pellet compared to the supernate. Polymyxin B sulphate
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Figure 40. Anti-LPS IgG levels detected in serum samples collected over eight
consecutive days from SIRS patient (survivor # 5) using either LPS complexed with
polymyxin B sulphate or LPS alone coated onto microtitre plates. Results shown are




Figure 41. Silver-stained PAGE (14% acrylamide) LPS profiles of three aqueous
phenol-extracted bacteroides LPSs and PCP-extracted LPS from S. typhimurium Rc
878 (20 (ig / track). LPSs were complexed with polymyxin B sulphate,
ultracentrifuged, and the resultant material in the pellet (P) and the supernate (S) is
shown with untreated controls (U). Tracks: 1, B. fragilis NCTC 9343 (U); 2, B.
fragilis NCTC 9343 (P); 3, B. fragilis NCTC 9343 (S); 4, B. fragilis MPRL 1504
(U); 5, B. fragilis MPRL 1504 (P); 6, B. fragilis MPRL 1504 (S); 7, B. vulgatus
MPRL 1985 (U); 8, B. vulgatus MPRL 1985 (P); 9, B. vulgatus MPRL 1985 (S);
10, S. typhimurium Rc 878 (U); 11, S. typhimurium Rc 878 (P); 12, B.
thetaiotaomicron NCTC 10582 (U); 13, B. thetaiotaomicron NCTC 10582 (P); 14,
B. thetaiotaomicron NCTC 10582 (S).
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3.4.10 ANTI-LIPOPOLYSACCHARIDE IgG LEVELS IN INFLAMMATORY
BOWEL DISEASE PATIENTS
Serum IgG levels against the three bacteroides LPSs and the enterobacterial /
Pseadomonas LPS cocktail were investigated in 28 IBD patients. The results are
shown in Figure 42. ODs (and therefore IgG levels) were standardised in the same
way as IgG levels of the SIRS patients (Section 3 .4.7), using the donor serum selected
from the screen of 641 blood donors which had close to median levels of IgG against
all of the Ags. With the exception of two patients (#16 and 27), all had serum IgG
levels against all of the Ags tested which were equal to, or higher than the median
levels in the random blood donor population. Of the two patients with below median
levels, one had oesophagitis and the other had IBD of unknown cause. At the other
extreme, two patients, one with CD (# 2) and one with coeliac disease (# 28) had
consistently high levels of IgG against all of the Ags. Due to the small total number
of patients in this study (28), the small number with UC (2) and the relatively large
number for which a diagnosis was not available (10) it was not feasible to try to
compare IgG levels between people with different diseases.
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Figure 42. Distribution of anti-LPS IgG in 28 IBD patients by quantitative screening
ELISA. OD readings were standardised as previously described (Section 3.4.7) using
the same donor serum. *Standard = 100%. Each serum was tested four times.
Abbreviations: O = oesophagitis, CP = constipation, PI = pancreatic insufficiency,
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This thesis has examined the interaction between bacteroides and selected aspects of
the immune system, both in health and disease. Particular attention has been paid to
bacteroides cell surface Ags, firstly because these are likely to be the primary sites of
interaction with the immune system and secondly because the nature of the cell
surface of bacteroides is so poorly understood.
Pathogenesis is multi-factorial (Smith 1984), and results obtained in this thesis,
together with previous work demonstrate that bacteroides are no exception to this
rule.
4.1 EXPRESSION OF BACTEROIDES CELL SURFACE ANTTGENS IN
DIFFERENT ENVIRONMENTS
It is well recognised that alterations in growth environment often result in significant
changes in bacterial cell surface Ag expression (Brown & Williams 1985). Despite
this, many previous studies of bacterial virulence have been carried out with bacteria
grown in one medium only, and in many cases this has been a nutrient-rich laboratory
medium, which provides a very different growth environment from that encountered
in vivo.
Results obtained in this thesis have demonstrated that growth environment can
significantly alter the expression of cell surface Ags in Bacteroides species, and
therefore demonstrate that growth environment should be taken into consideration
when studying pathogenicity.
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4.1.1 EXPRESSION OF CAPSULAR POLYSACCHARIDE
In virtually all cases, degree of encapsulation altered with growth environment,
including in the two B. fragilis strains examined under stress conditions (when
chelators were added to the medium to deplete essential cations). It should be
mentioned at this point that the capsule of B. fragilis NCTC 9343 grown in PPY has
been examined using MAbs (S. Patrick, personal communication). It was found that
the "small capsules" (from cells at the 20-40 and 40-60% Percoll interfaces) were
actually small versions of large capsules - i.e. antigenically they were large capsules,
although phenotypically they appeared to be small capsules. On the other hand, the
capsule of this strain grown in VT at the same Percoll interfaces was antigenically and
phenotypically small. To date, it is not known for definite whether similar antigenic
variation occurs in other B. fragilis strains. A previous study by Pantosti et al (1992)
showed limited cross-reactivity of polyclonal and monoclonal Abs raised against the
CP of B. fragilis NCTC 9343 with the CP of other B. fragilis strains; only 17% of
strains tested reacted with hyperimmune polyclonal rabbit antiserum raised against
the CP of B. fragilis NCTC 9343, and only 6% reacted with MAbs against PSA and
PSB ofNCTC 9343. This suggests that there is considerable between-strain variation
in CP structure of B. fragilis, in addition to the within-strain variation observed by
Patrick and colleagues. It is not known whether Bacteroides spp. other than B.
fragilis have sub-populations of cells with antigenically distinct capsules, although the
variation in capsule sizes observed in this thesis suggests that they may do. Extensive
immunological studies would be required to investigate bacteroides CP expression
further.
4.1.2 EXPRESSION OF LIPOPOLYSACCHARIDE
On the whole, silver-stained LPS profiles of any given strain were not vastly different
in the three media. Some differences, usually in the very low and / or the very high
Mr regions, were apparent between the LPS profiles of certain strain sub-populations.
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There was no obvious transition from R- to S-LPS in any case, although the
possibility that silver staining was unable to detect changes such as this cannot be
ruled out (see Section 4.2.4). Lutton et al (1991) demonstrated a ladder pattern
characteristic of S-LPS in the EDL population, but not in the LC and SC populations
of B. fragilis NCTC 9343 by immunoblotting; it is therefore possible that further
differences would have been revealed by immunoblotting rather than silver staining in
the present study.
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4.2 BACTERICIDAL ACTIVITY OF HUMAN SERUM AGAINST
BACTEROWES SPECIES
The mode of action of the complement system is now largely understood, and some
bacterial resistance mechanisms to its lethal effects are known. However, a major
drawback in experimental work on this system is that there is no standardised method
for testing serum sensitivity, and no universal definition of serum sensitivity (Taylor
1983, Crokaert et al 1992). Experiments performed in this thesis highlighted some of
the problems which this lack of consensus can cause.
4.2.1 COMPARISON OF TWO DIFFERENT METHODS OF PROCESSING
SERUM
Two different methods, termed A and B, were used to process fresh human serum;
both methods were obtained from textbooks as standard procedures for serum
collection and processing. However, complement activity (and therefore bacterial
killing) was considerably better with serum processed by method A. Complement
components are heat-labile and are unstable when left unfrozen for any length of
time. Therefore, method A probably resulted in better preservation of complement
activity because it was quicker than method B, and did not involve leaving the blood
to clot overnight. These results highlight the fact that different methods of processing
serum may significantly affect the outcome of an experiment and the conclusions
drawn from it, and whichever method is used to process serum, the CH50 value
should be checked to ensure that it is within the normal range.
4.2.2 THE INFLUENCE OF GROWTH MEDIUM ON SERUM SENSITIVITY
OF BACTEROIDES SPECIES
Previous studies investigating the susceptibility of Bacteroides spp. to complement
have done so after growth in one medium only. However, it is known that a change
in growth environment often alters cell surface Ag expression, and also that the
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expression of certain cell surface Ags can confer complement resistance on the
bacterial cell. The present study demonstrated dramatic changes in the susceptibility
of some Bacteroides strains to complement when growth medium was altered, and
highlighted the need to take growth medium into consideration when studying
bacterial virulence factors.
4.2.3 ORIGIN OF RESISTANT STRAINS
Of the first 12 Bacteroides strains tested for complement resistance (Table 4), all of
the strains which became resistant after growth in HISS were of clinical origin (Table
la). This is in agreement with a previous study by Casciato et al (1979), who found
that faecal isolates of Bacteroides were significantly more sensitive to serum than
clinical isolates. It is logical that virulent strains which are able to resist complement,
and also possibly produce other virulence factors, are more likely to cause infection
than their less virulent counterparts. All 12 of the B. fragilis strains subsequently
tested became complement resistant following growth in HISS (Table 5). Nine of
these strains were of clinical origin, and one was from faeces (Table la). The
observation that all B. fragilis strains tested had the ability to become resistant to
complement following growth in HISS may explain partially why B. fragilis is more
pathogenic than other members of the genus.
4.2.4 MECHANISM OF COMPLEMENT RESISTANCE IN BACTEROIDES
FRAGILIS
Degree of encapsulation, OMP and LPS expression, and binding of C3b to the cell
surface was investigated in B. fragilis NCTC 9343 and B. fragilis MPRL 1504, in
order to try to discover the biochemical basis for the observed changes in complement
resistance with growth medium. The presence of a capsule did not appear to be
responsible for complement resistance; B. fragilis MPRL 1504 grown in HISS was
mainly non-capsulate, and was resistant to complement, whereas the capsulate cells
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(grown in VT and PPY) were sensitive. This is in agreement with a previous study,
where Reid & Patrick (1984) found the non-capsulate variant of B. fragilis ATCC
23475 to be resistant to complement, and the capsulate variant to be sensitive. On the
other hand, B. fragilis NCTC 9343 was mainly capsulate in HISS. Of the other four
strains which became complement-resistant following growth in HISS (Table 4), two
were mainly capsulate and two were mainly non-capsulate. In the cases where
complement-resistant cells were non-capsulate, CP was still produced but appeared to
be present as cell-free slime. It is therefore possible that the cell-free CP is
responsible for "mopping up" complement components at a distance from the
bacterial cell. A very useful way to investigate this would be to generate mutants
which were unable to produce CP of any description, and test their ability to resist
complement.
Differences in OMP expression were observed for both strains grown in PPY and VT
& S. Certain OMPs may be involved in conferring complement sensitivity or
resistance in B. fragilis, but further investigations would be required to discover
whether this was the case. It could prove useful to incorporate a radioactive label into
the growth medium, so that active induction of OMPs could be monitored. Although
no bands were present when VT & S alone, and PPY alone were electrophoresed and
stained with silver, there is still a possibility that certain proteins from the growth
media were associated with specific OMPs, which would cause these protein bands to
appear stronger than they should have done. If this was the case, it would explain
differences in this study compared to that of Patrick & Lutton (1990), who found no
significant differences in OMP expression of B. fragilis grown in different
environments.
The silver-stained aqueous phenol extracts did not reveal any major differences in the
LPS profiles of either strain grown in different media. However, immunoblotting of
205
the aqueous phenol extracts revealed differences not observed by silver staining;
dark-staining material was present in the S-LPS region of MPRL 1504, and a ladder
pattern characteristic of S-LPS was evident in NCTC 9343 grown in VT and VT & S.
There are several reasons why immunoblotting may have revealed differences not
observed by silver staining: silver staining is less sensitive than immunoblotting,
immunoblotting can reveal immunogenic material not visualised by other methods,
and the carbohydrate of the ladder pattern may be resistant to oxidation by periodate -
the first step in the silver stain. A possible reason why MPRL 1504 did not show a
ladder pattern is that it is a very mucoid strain, and it is therefore possible that the
copious amounts of slime present prevented material from entering the separating gel,
or masked its presence on the gel. It would be interesting to screen aqueous phenol
extracts from other B. fragilis strains by immunoblotting to see whether they also
produced ladder patterns.
In this study, C3b bound equally well to all cells. However, it should be stressed that
there could be differences in binding of C3b to bacterial cells coated onto ELISA
plates compared to cells in the body.
In summary, differences in degree of encapsulation, OMPs and LPS were observed in
both strains when grown in different media. In one of the strains (NCTC 9343),
complement resistance could have been due, at least in part, to the presence of S-LPS.
However, the complexity of the surface polysaccharide complex ofB. fragilis, and the
difficulties in purification of its different components (discussed in detail in Section
4.3) prevent any firm conclusions being drawn. The two B. vulgatus strains tested in
this study both remained sensitive to complement, suggesting that the presence of S-
LPS alone was not sufficient to confer complement resistance. However, it should be
noted that the S-LPS of B. vulgatus has a much lowerMr than the classical S-LPS of
enterobacteria, and a lower Mr than the material seen in the S-LPS region in B.
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fragilis NCTC 9343. It is therefore possible that complement resistance is dependent
on the Mr of the S-LPS. Moreover, it is possible that the presence of S-LPS in B.
fragilis is only one of several factors which confer complement resistance, and other
factors which were not examined in this study, such as secreted or cell-bound
proteases, or incorrect assembly of the membrane attack complex could also
contribute to complement resistance in this species. The interaction of several
different factors resulting in the ability to resist complement would be a classic
example of the multi-factorial nature of pathogenicity.
4.2.5 MECHANISM OF COMPLEMENT RESISTANCE IN BACTEROIDES
THETA10TAOMICRON
The two B. thetaiotaomicron strains, one of which (NCTC 10582) remained sensitive
to complement and the other of which (MPRL 1959) became resistant showed
differences in encapsulation, OMPs and LPS profiles. However, the mechanism of
complement resistance in B. thetaiotaomicron cannot be determined from these
results alone. Later examination of a full-scale aqueous phenol extract of NCTC
10582 revealed a ladder pattern characteristic of S-LPS which was not evident in
rapid phenol or Proteinase K extracts (Section 3.4.1). This suggests, as was the case
with B. vulgatus, that S-LPS alone is not sufficient to confer complement resistance.
4.2.6 COMPLEMENT RESISTANCE OF BACTEROIDES FRAGILIS GROWN
IN VT & S THEN PPY
The two B. fragilis strains tested in this experiment were initially more resistant to
complement after subculture from VT & S to PPY, as opposed to sub-culture from
PPY to PPY. This increased resistance was diminished on further sub-culture in
PPY. This result suggests that the virulence determinant(s) which are expressed in
VT & S are gradually lost. This could be because of the amount of energy required to
make them. Growth in VT & S was slower than growth in PPY, possibly because
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certain proteins and / or carbohydrates which are necessary for growth and survival in
VT & S, and which also confer complement resistance, require a lot of energy to
produce. If these molecules were not required for growth and survival in PPY, then
energy generated would be used for faster growth.
4.2.7 CLASSICAL PATHWAY VERSUS ALTERNATIVE PATHWAY
ACTIVATION
Initially it was attempted to look at classical and alternative pathway activation by
using whole cells to absorb out specific Abs. Results suggested that in B. fragilis
MPRL 1504 grown in PPY, some activation was occurring via the classical, and some
via the alternative pathway. However, this method of trying to inhibit the classical
pathway has a number of major shortcomings:
• Although specific Ab is absorbed out, there is no means of knowing whether it has
all been removed, and any residual Ab left could still activate the classical pathway.
• Some Ab classes (IgA, IgG4) activate the alternative pathway.
• The amount of Ab removed will increase with increasing numbers of absorptions,
but the longer the serum is left before using it in the serum sensitivity assay, the more
likely it is to become complement-depleted.
• Anti-bacteroides sheep Abs which stuck to the cells during growth in VT & S and
were not removed by washing would activate complement.
• The classical pathway can be initiated by means other than Ab / Ag complexes (e.g.
lipid A, porins).
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To circumvent these potential problems, a second method was used to look at
complement activation. The addition of EGTA to serum chelates Ca2+ ions, and
therefore specifically inactivates the classical pathway. Results from this experiment
showed that the method of complement activation was dependent on both growth
medium and bacterial strain. In all cases (except B. variabilis VPI 11368 grown in
PPY where complement activation was by the classical pathway alone), activation
was occurring partially via the classical, and partially via the alternative pathway.
Activation of complement by B. vulgatus was mainly via the alternative pathway in
all three media. This could be because the O-Ag is known to activate the alternative
pathway (Eisen & Gefter 1990), and B. vulgatus has the most obvious, presumably
well-exposed O-Ag of all of the Bacteroides spp. From these experiments alone, it is
not possible to say whether the method of activation is important in complement
resistance of Bacteroides spp., although the fact that it is activated partially by both
pathways in nearly all cases suggests that if complement activation was prevented by
the bacterium, it would have to prevent both pathways of activation. In these
experiments, it was not possible to see whether complement was being activated in
those cases where the cells were totally resistant. A useful follow-up would be to
measure concentrations of complement components in serum in those cases where
totally resistant cells had been added.
4.2.8 BACTERICIDAL ACTIVITY OF SERUM FROM SYSTEMIC
INFLAMMATORY RESPONSE SYNDROME PATIENTS
The complement cascade is initiated as part of the pathophysiology of SIRS, resulting
in depletion of all complement proteins. CH50 levels in both patients' sera were well
below normal levels, with the result that the efficiency of bacterial killing was
reduced. This has important implications in the management of SIRS patients - they
will be less able to fight potential pathogens and more vulnerable to septicaemia and
other infections than healthy individuals. Bacteria which are readily killed in serum
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from a healthy individual will be more likely to survive in serum from a SIRS patient,
and this should be borne in mind when studying complement resistance and any other
aspect of the host / pathogen interaction in these patients.
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4.3 ANALYSIS OF THE SURFACE POLYSACCHARIDE COMPLEX OF
BACTEROIDES FRAGIUS
These experiments were designed to analyse the surface polysaccharide complex of B.
fragilis, both visually and chemically, in order to try to make sense of some of the
confusion which surrounds this subject.
4.3.1 ANALYSIS OF ULTRACENTRIFUGED AND NON-
ULTRACENTRIFUGED AQUEOUS PHENOL EXTRACTS OF
BACTEROIDES FRAGILIS
Earlier work carried out in this thesis had aroused suspicions that rapid phenol and
Proteinase K extracts of B. fragilis were not pure LPS. Moreover, it was not clear
what effect the final rotary evaporation and ultracentrifugation steps in the large-scale
aqueous phenol extraction method would have on the composition of the material in
the extracts. Therefore, initially two B. fragilis strains (NCTC 9343 and MPRL
1504) were grown in three media, aqueous phenol extractions were carried out and
half of the resultant material from the aqueous phase was subjected to rotary
evaporation and ultracentrifugation, whilst the other half was lyophilised without
these steps.
The percentage yield from the non-ultracentrifuged extracts was greater than that
from the ultracentrifuged ones in all cases except MPRL 1504 grown in VT & S.
This one anomalous result was probably due to inaccuracy in dividing the original
extract in two. Ignoring this result, the others suggest that ultracentrifugation was not
precipitating all material in the extracts.
Further analysis of the extracts revealed differences in composition between strains,
between different growth media and between ultracentrifuged and non-
ultracentrifuged samples. The main observations are summarised below:
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• The aqueous phenol extracts were not pure LPS, but also contained protein.
• Ultracentrifugation decreased the relative amount of protein and increased the
relative amount of carbohydrate in the extracts, suggesting that the material left
behind during ultracentrifugation was mainly protein. Silver staining revealed greater
amounts of, or better defined low and high Mr material (mainly carbohydrate: see
Section 4.3.2) in the ultracentrifiiged, as opposed to the non-ultracentrifuged extracts.
• In both strains, growth in VT resulted in the greatest amount of carbohydrate
production, followed by growth in VT & S, followed by growth in PPY. This
probably reflects the amount of readily accessible carbohydrate in the growth
medium; it has been found that an excess of carbohydrate, together with a lack of
phosphate, nitrogen or sulphate favours CP production (Sutherland 1972). VT
contains 1% glucose and is therefore a very rich source of carbohydrate. In stationary
phase in VT medium, most nutrients would be in short supply, but there would still be
excess glucose present which could be used for CP production.
• It had been noted previously (Section 4.2.4) that MPRL 1504 was a very mucoid
strain. Chemical analysis of the surface polysaccharides confirmed this: in all cases,
the amount of carbohydrate produced by this strain was nearly double that produced
by NCTC 9343. This provides further evidence of variation of CP between different
B. fragilis strains.
• Large amounts of carbohydrate in mainly non-capsulate cells (NCTC 9343 in VT
and MPRL 1504 in VT & S), together with highMr material present on silver-stained
gels, strongly suggested that large amounts of cell-free slime were present in these
cases.
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• KDO measurements were negligible. This confirms previous work (Beckmann et al
1989) which found that it was necessary to dephosphorylate the KDO of Bacteroides
spp. with hydrofluoric acid before it would give a positive reading in a KDO assay.
A previous study reported that extraction of P. aeruginosa LPS with aqueous phenol
resulted in a larger amount of material in the phenol phase of the extract than in the
aqueous phase (McVie 1993). To see whether this was the case in B. fragilis, the
phenol phases were examined. In all cases, the material in the phenol phase had
similar PAGE profiles to the material from the aqueous phase, but the percentage
yields from the phenol phases were very low, indicating that in B. fragilis, the
majority of material was located in the aqueous phase.
Immunoblots of the extracts, carried out using polyclonal rabbit serum raised against
B. fragilis whole cells, failed to show lowMr material. This was also the case with
previous immunoblots (Section 3.2). The reason for this is probably that low Mr
material such as lipid A and LPS core is very close to, or embedded in the outer
membrane ofwhole cells, and is therefore hidden from the immune system.
In summary, ultracentrifugation appeared to be partially "purifying" the extracts in
that it was reducing the amount of protein present, but it was decided to use non-
ultracentrifuged extracts in future experiments, so that no important antigenic
determinants were lost.
4.3.2 TREATMENT OF AQUEOUS PHENOL EXTRACTS WITH
PROTEINASE K AND PERIODATE
Proteinase K destroyed unevenly-spaced bands in the S-LPS region, providing further
evidence that these bands were protein and not S-LPS. Periodate destroyed the vast
majority of the very high Mr (probably CP) and the very low Mr (lipid A and LPS
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core) material, both of which would be expected to be very high in carbohydrate.
Immunoblotting of Proteinase K- and periodate-treated extracts failed to show any
material, suggesting that the treatments either reduced the antigenicity of the samples
to such an extent that the Abs no longer recognised the epitopes, or that such a large
amount of material was destroyed by the treatments that there was not enough left to
be visualised by immunoblotting.
The common Ag was of particular interest in the treated extracts. To date, the
structure of the B. fragilis common Ag has not been elucidated. In these experiments,
it was destroyed by Proteinase K, which would suggest that it is made of protein.
Further supporting evidence for this is that the common Ag was not present on silver-
stained PAGE profiles of whole cell Proteinase K extracts of B. fragi/is (Figure 10b).
However, the defined common Ag band also disappeared from the periodate-treated
extracts, and a larger, more diffuse band appeared immediately below. A similar
pattern of results has also been obtained by immunoblotting of Proteinase K- and
periodate-treated extracts using polyclonal and monoclonal Abs against the common
Ag (S. Patrick, personal communication). Enterobacteria possess a common Ag,
which is usually composed of a carbohydrate polymer of A-acetyl-D-glucosamine and
iV-acetyl-D-mannosaminouronic acid linked to membrane-bound fatty acids (Poxton
1993). Given the considerable differences between the other surface Ags of
enterobacteria and B. fragilis, it is unlikely that their common Ags are similar in
structure. If the B. fragilis common Ag was exclusively composed of carbohydrate, it
would not have been destroyed by Proteinase K. At present, all that can be concluded
from these results that the common Ag of B. fragilis is complex in structure, as are
the rest of its surface Ags.
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4.3.3 FRACTIONATION OF THE SURFACE POLYSACCHARIDE
COMPLEX OF BACTEROIDES FRAGIIJS NCTC 9343
The surface polysaccharide complex ofB. fragilis NCTC 9343 was fractionated to try
to separate out and purify the different components. Initially a partially purified
aqueous phenol extract was separated into different components by gel filtration
chromatography, which resulted in three different sets of material as visualised by
PAGE and silver staining - high, intermediate and low Mr. On one of the gels
(Figure 28b) a faint line was evident in the lowMr region in the same tracks as the
highMr material. Assuming that this was not an artefact, it suggests that the highMr
material was strongly linked to some lowMr material. The possibility that it was an
artefact cannot be ruled out, as it was not present on the other gel (Figure 28a). Other
bacterial capsules are known to be linked to lipid and anchored to the outer membrane
(e.g. some E. coli capsules: Poxton & Arbuthnott 1990), and it is possible that this is
also the case in B. fragilis.
Some of the high Mr material (assumed to be CP) was subjected to acid hydrolysis to
split it into its two component polysaccharides - PSA and PSB. Chemical analysis
was performed on the high, intermediate and lowMr material, and on PSA and PSB.
Overall, the results from this were largely as would be expected: the high Mr
material, PSA and PSB (all presumably CP) were high in carbohydrate, and the low
Mr material (presumably lipid A and core oligosaccharide) was high in phosphorus
and also fairly high in carbohydrate. The intermediate Mr fraction (possibly O-Ag)
had some carbohydrate present, and also protein which could have been residual
Pronase left over from the purification procedure, or protein from the original extract
which had not been destroyed by Pronase, or both.
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4.3.4 CHARACTERISATION OF THE SURFACE ANTIGENS OF
BACTEROIDES FRAGILIS NCTC 9343 BY DOT BLOTTING AND
IMMUNOBLOTTING
A crude aqueous phenol extract of B. fragilis NCTC 9343, and the surface
polysaccharide fractions were examined using polyclonal and monoclonal Abs. Many
results obtained from this study are not clear-cut and some are confusing, but this is
probably a reflection of the complexity of the surface Ag complex of B. fragilis. The
main points to be noted are listed below:
• PSB showed some reactivity with polyclonal and monoclonal Abs in dot blots, but
it did not stain with silver and did not react with any Abs following PAGE. PSB is
periodate-labile (Baumann et al 1992), so possible reasons why it was not visualised
by silver staining or immunoblotting could have been that it was at too weak a
concentration to stain - acid hydrolysis yields only very small amounts of PSB (A.
Tzianabos, personal communication), or that it did not enter the separating gel.
• The intermediate and low Mr material, and PSA alone did not react with any Abs
following PAGE, but did stain with silver. It is possible that the Ags on the gel and /
or the Abs used to detect them were not sufficiently concentrated.
• PSA and PSB alone gave much poorer reactivity in dot blots and immunoblots than
PSA and PSB together. It is possible that the acid hydrolysis and ion exchange
chromatography, and / or the physical separation destroyed much of their antigenicity.
• Results from the dot blots and immunoblots allow some speculation as to what
some of the epitopes of the uncharacterised MAbs may be: 2E12 could be specific
for the LC or O-Ag, 3H5 and 1E2 could be specific for the O-Ag, and 2B8, 3C10 and
4C5 could be specific for the LC and EDL populations. However, this is only
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speculative, and extensive further studies would need to be carried out before these
could be confirmed.
• The high Mr material from the crude aqueous phenol extract, and the fractionated
high Mr material both reacted with polyclonal rabbit serum against the LC of NCTC
9343 and with MAb 3D7 (specific for the LC and EDL populations). This confirmed
that the high Mr material seen on PAGE profiles was, as suspected, CP and not LPS.
• MAb 6G3 produced one band only on the immunoblot, and the same single band
was produced by polyclonal rabbit serum raised against the common Ag. This
strongly suggests that 6G3 is specific for the common Ag, and further supporting
evidence for this is that the same result has been obtained elsewhere using an
independently prepared aqueous phenol extract of B. fragilis NCTC 9343 (S. Patrick,
personal communication).
• MAb 3F6 (against an undefined non-capsular epitope in the SC population) did not
react with any of the Ags in dot blots or immunoblots. The reason for this is that the
cells for this experiment were grown in PPY, and as previously mentioned (Section
4.1.1) there do not appear to be any cells present in PPY which have antigenically
small capsules. It was unfortunate that there was no MAb specific for the capsule of
the SC population, as it would have been interesting to discover whether an anti-SC
MAb reacted with PSA or PSB, to see whether these polysaccharides were present in
the SC population. Conversely, it would have also been interesting to find out
whether MAbs specific for PSA and PSB recognised LC, SC and EDL cells, and if
so, to what extent. Studies such as these could perhaps shed more light on the
diversity of the CP structures in B. fragilis.
The most striking observation from these studies, in agreement with previous work, is
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the complex nature of the surface of B. fragilis. In some other bacteria the definition
of LPS and capsule is unclear. For example in E. coli 0111 a high Mr surface
polymer, located external to the LPS, consists of polymeric O-polysaccharide which
is not linked to core or lipid A (Peterson & McGroarty 1985). It is also difficult to
recognise a division between LPS and CP in B. fragilis. One of the major reasons for
this is the within-strain variation of surface structures which makes consistent analysis
extremely difficult, further complicated by the fact that many workers do not take this
variation into consideration. Publications by Kasper and colleagues state that "pure
CP" is obtained following fractionation and purification. However, one member of
this group recently admitted that the CP which they prepare varies considerably from
batch to batch in the relative amounts of PSA and PSB present. Moreover, it is
invariably contaminated, to varying degrees from batch to batch, with LPS (A.
Tzianabos, personal communication).
It has recently been suggested that "purified" CP from B. fragilis could be used as a
vaccine to be administered prophylactically to patients at high risk of developing
abscesses (Tzianabos et al 1995), as it has been previously shown that injection of B.
fragilis CP into rats prevents subsequent abscess formation (Onderdonk et al 1982).
In my opinion, this idea is somewhat over-ambitious, as it would be dangerous to
administer any substance to a patient which is so variable in nature, and which is
contaminated, to an unknown degree, with other substances including LPS.
In summary, despite much research and some slow progress, many unanswered
questions about the surface of B. fragilis, and of course the other Bacteroides spp.,
remain. Further immunological studies may reveal more, but for a fuller
understanding of this subject it will probably be necessary to carry out genetic studies,
which at present are still in their infancy.
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4.4 ANTIBODIES TO BACTEROIDES IN HEALTH AND DISEASE
To date, limited studies have been carried out on antibodies to bacteroides in human
serum. Previous studies, carried out a long time before the genus Bacteroides was
restricted to ten species, and before many of the species today classified as
Bacteroides had been recognised, reported the presence of anti-bacteroides LPS Abs
in serum from healthy individuals and from individuals with infections (reviewed by
Hofstad [1979]). Experiments in this thesis were designed to build on these previous
studies, and to try to discover whether bacteroides were significant in certain diseases
(namely SIRS and IBD) where they had previously been assumed to be largely
insignificant.
For many of the experiments in this study, in addition to measuring Abs to
bacteroides LPS, Abs to a cocktail of R-LPS from three enterobacteria and P.
aeruginosa were also measured. The aim of the study was not to make direct
comparisons between bacteroides LPS and the R-LPS mixture, but rather to observe
and compare the IgG responses in order to see whether that against bacteroides LPS
was significant.
Non-ultracentrifuged aqueous phenol extracts of bacteroides LPS were used to
measure IgG levels. It was known that these extracts were not pure LPS. However, it
was decided not to try to purify the LPS further, as the aim was to mimic the in vivo
situation as closely as possible; if hot phenol failed to separate the surface
components of bacteroides completely, then the LPS is unlikely to be present in pure
form in the body.
4.4.1 ANTI-BACTEROIDES LIPOPOLYSACCHARIDE IgG IN HEALTHY
INDIVIDUALS
Every blood donor tested had anti-bacteroides and anti-enterobacterial / Pseudomonas
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LPS IgG present in their serum. This suggests that healthy individuals are exposed to
bacteroides LPS, and the most likely source of this is the gut. It is thought that anti-
enterobacterial LPS Abs arise following exposure to gut-derived enterobacterial LPS
(Barclay 1990, Windsor et al 1993, Barclay 1994), and it is therefore logical that anti-
bacteroides LPS Abs would arise in the same way, especially when the differences in
numbers of enterobacteria and bacteroides in the gut are taken into consideration. If
LPS does translocate through the gut, then these results suggest that translocation
must occur in healthy people, and they suggest that the gut is not the completely
impenetrable barrier that it is often thought to be.
4.4.2 LEVELS OF ANTI-BACTEROIDES LIPOPOLYSACCHARIDE IgG IN
HEALTHY INDIVIDUALS
The levels of anti-bacteroides LPS IgG in serum were highly variable between
different individuals. In addition, when IgG was looked at in two different
individuals by inhibition ELISA and immunoblotting (Sections 3.4.4 and 3.4.5),
different IgG repertoires were seen, and individual # 2 appeared to have a greater
amount of anti-bacteroides LPS IgG overall in their serum than individual # 1. This
suggests that different individuals are exposed to bacteroides LPS to different extents.
Assuming the source of the LPS is the gut, then the degree of exposure would be
dependent on the degree of translocation. The degree of translocation would probably
be dependent on lots of factors such as gut barrier function, diet, general state of
health, age and previous illnesses.
Of note in one of the immunoblots of bacteroides LPS using human serum (Figure
36b) was a fine ladder pattern, characteristic of S-LPS, in B. eggerthii. This ladder
pattern had not been observed by silver staining during the course of this thesis,
although it has been observed by silver staining in a previous study (Maskell 1991).
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4.4.3 CROSS-REACTIVITY OF ANTI-BACTEROIDES
LIPOPOLYSACCHARIDE IgG
Inhibition ELISAs showed that whilst there were some epitopes shared between the
different bacteroides LPSs, there were very few between bacteroides LPS and the
enterobacterial / Pseudomonas LPS mixture. This is not surprising given that the
lipid A structure of B. fragilis, and probably the other Bacteroides spp., is markedly
different from that of the enterobacteria (Magnuson et al 1989, Lindberg et al 1990).
Results from the inhibition experiments suggested that whilst there were some
epitopes shared between the different bacteroides LPSs, each species had its own
unique epitopes. This also appeared to be the case in the two B. fragilis strains tested,
which is in keeping with previous studies showing limited cross-reactivity of MAbs
raised against the CP ofB. fragilis NCTC 9343 with the CP of other B. fragilis strains
(Pantosti et al 1992, Pantosti et al 1993).
In the inhibition experiments, total absorption of all of the IgG was not achieved, not
even when LPS derived from the same strain as the LPS coated onto ELISA strips
was used for the absorptions. This could be to do with the accessibility of LPS in
serum to Abs. LPS is notoriously difficult to detect in serum, and the reason for this
is thought to be that it quickly becomes bound up in serum proteins, and as such
becomes hidden from the immune system (Nelson 1991, Majde 1992). It is therefore
possible that the LPS used to absorb out Abs became bound to serum proteins - for
example high and low density lipoproteins (Wurtel et al 1994) and lipopolysaccharide
binding protein (Tobias et al 1986, Tobias et al 1989) before all of the Abs had been
absorbed out.
The graphs measuring correlation coefficients between IgG levels to different
bacteroides LPSs (Figure 33) show a significant correlation in all cases except one.
Whether the high level of correlation is due to the degree of exposure of individuals
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to bacteroides LPS (i.e. if exposure to one Ag is high, exposure to another is
correspondingly high and vice-versa), or due to a high degree of cross-reactivity of
anti-bacteroides LPS IgG is a matter of debate. Both factors are probably involved.
In some cases, a high correlation coefficient was observed together with a high level
of inhibition (e.g. B. fragilis NCTC 9343 and B. fragilis MPRL 1504; B. caccae
MPRL 1555 and B. thetaiotaomicron NCTC 10582), suggesting a high degree of
cross-reactivity, whereas in other cases a high correlation coefficient was obtained but
the level of inhibition was very low (e.g. B. variabilis VPI 11368 and B. eggerthii
NCTC 11155; B. vulgatus MPRL 1985 and B. ovatus MPRL 2370), suggesting that
the high correlation was due to the degree of exposure of individuals to bacteroides
LPS.
4.4.4 KINETICS OF ANTI-LIPOPOLYSACCHARIDE IgG RESPONSE IN
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME PATIENTS
In all SIRS patients, IgG levels against all Ags followed similar overall trends. In
some cases, a sudden consumption of IgG was shown to be concurrent with an
episode of endotoxaemia (confirmed previously by LAL assays [Scottish Sepsis
Intervention Group, unpublished data]). In other cases, there was a decrease in IgG
against all Ags but no endotoxin detected in the serum. However, as discussed above,
endotoxaemia is often very transient and may not be detected in a LAL assay (Majde
1992), so IgG levels may prove a more accurate method of detecting it.
One of the most striking observations in this study was that in five out of six of the
non-survivors, IgG levels against B. fragilis LPS were higher than levels of IgG
against the other Ags. This only occurred in one survivor. Due to the small number
of sepsis patients studied here, it is not possible to draw any firm conclusions linking
certain Ab levels or kinetics to a fatal or non-fatal outcome. However, the study has
demonstrated a definite IgG response to bacteroides LPS which was independent of,
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but showed similar overall trends to, the response to enterobacterial LPS. Other
recent studies have shown bacteroides LPS to be more biologically active in certain
endotoxin assays than previously thought (Delahooke et al 1995a, Poxton & Edmond
1995). This, together with the nature of the IgG response, suggests that bacteroides
LPS could be more important than previously thought in the development and
outcome of SIRS.
It has recently been shown that in a TNF induction assay, when B. fragilis LPS is
added in excess of E. coli LPS, rather than a cumulative effect, the B. fragilis LPS
reduces the amount of TNF produced, with the amount produced being less than if E.
coli LPS had been added alone (Delahooke et al 1995b). Bearing this in mind, an
interesting hypothesis is that in fatal cases of SIRS, where anti-5. fragilis LPS IgG
levels are high, the bacteroides LPS is being efficiently neutralised. Its neutralisation
removes the immunomodulatory effect that it has on E. coli LPS, leaving the E. coli
LPS to exert its full pathophysiological effects. In survivors, where levels of anti-B.
fragilis LPS IgG are lower, the B. fragilis LPS is not as efficiently neutralised.
Therefore, more B. fragilis LPS is present in serum, which exerts an
immunomodulatory effect on E. coli LPS. Obviously this hypothesis is highly
speculative, but if it was shown to be correct, it would have major implications in the
management of SIRS patients. Moreover, measurement of anti-/?. fragilis LPS IgG
relative to other anti-LPS IgG could prove a useful means of identifying high risk
patients.
4.4.5 ANTI-LIPOPOLYSACCHARIDE IgG IN INFLAMMATORY BOWEL
DISEASE PATIENTS
Of the 28 IBD patients examined in this study, 26 had above median levels of IgG
against all of the LPSs tested. This suggests that most people with IBD have more
permeable gut walls than healthy individuals, which allow greater translocation of
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bacteria and their products into the systemic circulation. A previous study found
abnormally high levels of IgGl in UC patients, and abnormally high levels of IgG2 in
CD patients (MacDermott et al 1989). It would be interesting to measure IgG
subclasses in the sera of the patients in this study, to see whether specific subclasses
were being induced against given LPSs. Another study found high levels of total IgG
in CD patients, but normal levels in UC patients (O'Mahony et al 1990). The present
study found high levels of anti-LPS IgG in both CD and UC patients. However, no
firm conclusions can be drawn from this as only two UC patients were included in the
study.
In this study, serum IgG levels only were examined, as at the time these were the only
samples available. However, previous studies have shown that it is better to look at
the gut mucosal Ab levels in IBD rather than the serum Ab levels, as there is
sometimes a lack of correlation between the systemic and the gut immune responses
(O'Mahony et al 1990, O'Mahony et al 1991). Probably the easiest and most accurate
way of examining gut Abs is to use whole gut lavage fluid, which is obtained by a
relatively simple, non-invasive process using an orally-administered polyethylene
glycol-based isotonic solution (O'Mahony et al 1990, Poxton et al 1995). It would
have been useful if paired samples of serum and whole gut lavage fluid had been
available from each patient, so that the systemic and mucosal immune responses
could have been compared.
In addition to IgG, it would be interesting to look at levels of other Ab classes, both in
serum and gut lavage fluid. Levels of IgA in the gut against bacteroides LPS and
outer membranes have recently been shown to be significantly raised in people with
CD (Poxton et al 1995). It would be very interesting to look at IgE levels, especially
in the gut, against bacteroides and other Ags, as excessive IgE is produced in
hypersensitivity reactions. Therefore, if an allergic reaction was occurring in the gut
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against, for example, bacteroides LPS, then IgE levels against bacteroides LPS would
be expected to be elevated.
In summary, this study showed raised serum anti-LPS IgG levels in 26 of 28 IBD
patients, which suggests that LPS could be translocating from the gut to a greater
degree in people with IBD than in healthy individuals. Due to the small number of
serum samples used in this study and the lack of gut lavage fluid samples, it is not
possible to draw any other conclusions. However, the results obtained do create the
possibility that bacteroides could be involved in the pathogenesis of IBD, and indicate
that the study would be worth extending.
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CONCLUSIONS
• Growth environment often has a profound effect on cell surface Ag expression in
Bacteroides spp.
• Growth environment has a major influence on the susceptibility of certain
Bacteroides strains to the bactericidal effects of serum complement.
• In one B. fragilis strain, complement resistance could be due, at least in part, to the
expression of S-LPS.
• All healthy adults appear to have anti-bacteroides LPS IgG in their serum, with
levels varying from individual to individual. The anti-bacteroides LPS IgG is not
simply anti-enterobacterial LPS IgG which cross-reacts with bacteroides LPS; the
two are independent of each other.
• Certain trends in anti-bacteroides LPS IgG kinetics in SIRS patients have been
demonstrated, which suggest that bacteroides LPS could be significant in SIRS.
• Anti-bacteroides LPS IgG has been found, often in high levels, in the serum of
people with IBD, suggesting that bacteroides could be significant in the pathogenesis
of this disease.
• Work carried out on the surface polysaccharide complex of B. fragilis has revealed
a very complex situation, in agreement with previous studies. Much more work needs
to be carried out in this area before any firm conclusions can be drawn.
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The influence of growth medium on serum sensitivity of
Bacteroides species
E. ALLAN and I. R. POXTON*
Department of Medical Microbiology, University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG
Summary. The susceptibility of 12 different Bacteroides strains (representing nine species) to
the bactericidal effect of human serum complement was investigated. When grown in
nutrient-rich proteose peptone-yeast extract medium, all 12 strains were, to varying degrees,
sensitive to serum. However, when grown in Van Tassell and Wilkins's minimal medium, six
of the 12 strains became markedly more serum resistant. Five of these six strains became
totally resistant to serum when grown in heat-inactivated (56°C, 30 min) sheep serum. By
Percoll discontinuous density centrifugation and light microscopy, the ratio of bacteria with
large and small capsules was found to vary with the growth medium used. Lipopolysaccharide
(LPS) was extracted with aqueous phenol after growth in the three media. Polyacrylamide gel
electrophoresis (PAGE) and silver staining of the LPS showed some differences in LPS
profiles in all strains tested. Therefore, variation of growth conditions results in alterations of
both the expression of surface structures and, in some cases, sensitivity to serum. The
biochemical basis for these changes requires further investigation.
Introduction
Members of the genus Bacteroides (formerly the
Bacteroidesfragilis group) are common components of
the healthy colonic flora and are often involved in both
pure and mixed infections in man—e.g., intra¬
abdominal abscesses, bacteraemia, wound and uro¬
genital infections. B. fragilis, the type species, is the
anaerobe isolated most commonly from clinical speci¬
mens, and the most common cause of anaerobic
bacteraemia.1 4 The surface polysaccharides of the B.
fragilis group are widely considered to be major
virulence determinants.5 6 However, despite extensive
research, there is still debate as to whether the
lipopolysaccharide (LPS) of B. fragilis is rough5 or
smooth7 and the roles of the capsule and LPS as
virulence factors are unclear. This is further confused
by the recognition, which has not been considered by
many workers, that following fractionation by Percoll
discontinuous density centrifugation,8 a wild-type
laboratory culture of B. fragilis has been shown to be
morphologically heterogeneous with respect to both
size9 and antigenicity10,11 of its capsule.
Resistance to the bactericidal effects of serum
complement has been clearly shown to be associated
with virulence in a wide range of species.12,13 In some
cases, the mechanism of resistance is known, and both
the O polysaccharide of LPS and capsular poly¬
saccharide (CP) have been implicated as important
virulence determinants. For example, wild-type Sal¬
Received 9 Dec. 1993; accepted 19 Jan. 1994.
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monella Minnesota (with smooth LPS) is highly
resistant to complement, whereas the rough mutant is
extremely sensitive.14 In the case of Escherichia coli K1
strains, the CP is responsible for complement re¬
sistance.15
Previous studies have shown that Bacteroides strains
isolated from infections are generally more resistant to
complement than those isolated from faeces.16 Clinical
isolates of B. fragilis have been found to be more
resistant to complement than clinical isolates of other
Bacteroides species.17 Also, complement-resistant
strains of B. fragilis have been shown to survive better
than complement-sensitive strains in a subcutaneous
model of infection.18 However, the mechanism of
complement resistance in Bacteroides strains is un-
Table I. Bacteroides strains
Species Strain no. Source
B. fragilis MPRL 1504 Wound
B. fragilis NCTC 9343 Appendix abscess
B. uniformis ATCC 8492 Unknown
B. vulgatus MPRL 1985 Faeces
B. vulgatus MPRL 1651 Faeces
B. caccae MPRL 1555 Wound
B. ovatus MPRL 2370 Blood
B. eggerthii NCTC 11155 Faeces
B. distasonis ATCC 8503 Unknown
B. thetaiotaomicron MPRL 1959 Blood
B. thetaiotaomicron NCTC 10582 Faeces
B. variabilis VPI 11368 Unknown
MPRL, departmental stock culture; NCTC, National Collection of
Type Cultures; ATCC, American Type Culture Collection; VPI.
Virginia Polytechnic Institute, USA.
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known, but CP is not thought to enhance resistance,19
while the role of LPS is unclear.
It is well recognised that the growth environment of
bacteria greatly influences the phenotypic expression
of surface molecules. This can be fundamental in the
adaptive process that enables an invading pathogenic
bacterium to survive.2021 The aims of this study were:
to investigate whether different growth conditions
affected the sensitivity of Bacteroides spp. to serum; to
determine whether any change in sensitivity was
concomitant with a change in surface chemistry; and
to investigate whether different methods of processing
serum affected its bactericidal capabilities.
Materials and methods
Bacteria and growth conditions
The strains used and their source are listed in table
I. Bacteria were grown to early stationary phase in
nutrient-rich proteose peptone-yeast extract medium
(PPY),22 Van Tassell and Wilkins's minimal medium
(VT and W)23 and heat-inactivated (56°C, 30 min)
sheep serum (HISS). Cultures were incubated at 37°C
in an atmosphere of H2 10%, C02 10% and N2 80%
in an anaerobic cabinet (Forma), and were checked for
purity by Gram's stain and by aerobic and anaerobic
incubation on Columbia Blood Agar (Oxoid).
Collection of serum
Human serum, used as a source of complement, was
collected from five healthy adult volunteers in two
ways as follows. (A) Freshly drawn blood was allowed
to clot at 37°C for 30 min, then centrifuged at 4000 g
for 10 min. Sera were removed, centrifuged as before
and the supernates were pooled and stored at — 70°C
in 1-ml volumes until just before use. (B) Freshly
drawn blood was left to clot overnight at room
temperature. It was then placed at 4°C for 30 mm
before removal of serum. The sera were centrifuged at
4000 g for 10 min before the supernates were pooled
and stored at — 70°C in 1-ml volumes until just before
use.
The haemolytic complement value (CH50) of the
individual and pooled serum samples was checked as
described previously24 except that phosphate-buffered
saline (PBS; Oxoid) was used instead of barbitone-
bufifered saline. Frozen specimens were thawed only
once.
Serum sensitivity assay
Bacteria washed once in complement fixation test
buffer (CFTB; Oxoid) were resuspended to a con¬
centration of c. 105 cfu/ml in either CFTB only
(control), CFTB + serum 10 % or CFTB + serum 40%
and incubated aerobically (2 ml in 2-5-ml closed plastic
tubes) at 37°C for 2 h with end-over-end rotation.
Samples (100 pX) were taken at 0, 1 and 2 h, diluted 1
in 50 in CFTB. and 100 p\ of the resulting suspension
were spread on Columbia blood agar in duplicate.
After anaerobic incubation for 48 h, colonies were
counted and the percentage survival compared to the
control was calculated. All experiments were repeated
at least twice. As a further control, all bacteria found
to be sensitive to serum were resuspended to 105 cfu/
ml in CFTB + heat-inactivated (56°C, 30 min) human
serum 40% and treated as above. In a preliminary
experiment complement-mediated killing in an an¬
aerobic environment with reduced (anaerobic) buffers
was compared with the aerobic system described
above. No differences were seen in bacterial survival.
Percoll gradients
Cell capsulation was assessed by Percoll (Phar¬
macia) discontinuous density centrifugation. Percoll
was diluted as described previously,8 and a step
gradient was produced by layering 1-ml volumes of
80% (bottom), then 60 %, 40 % and 20 % (top) Percoll
into 70 x 20-mm glass test tubes. A sample of an early
stationary phase culture of the test organism (1-25 ml)
was applied to the top of the 20% layer and the
gradient was centrifuged at 2600 g for 20 min.
LPS preparation
LPS was prepared from washed cells obtained from
a 10-ml early stationary phase culture by the micro-
method developed by Fomsgaard et a/.,25 which was
based on the aqueous phenol method ofWestphal and
Luderitz.26
PAGE
PAGE was performed on acrylamide 14 % w/v slab
gels with the Laemmli buffer system,27 except that SDS
was omitted from the stacking and separating buffers.
Samples (20 pX) of the aqueous phenol LPS extracts
were loaded on the gels and the separating gel was
stained with silver by the method developed by Tsai
and Frasch,28 as modified by Hancock and Poxton.29
Results
Comparison of two methods ofserum processing
Human serum processed by methods A and B was
tested for its ability to kill B. fragilis MPRL 1504, B.
fragilis NCTC 9343 and B. vulgatus MPRL 1985
grown in PPY (table II). With all three strains, serum
processed by method A was more bactericidal than
that processed by method B. The CH50 values of the
sera (method A = 631 units/ml, method B =
49-1 units/ml) showed complement activity to be better
preserved in serum processed by method A. Therefore,
in all subsequent experiments, serum processed by
method A was used.
Serum sensitivity of 12 Bacteroides strains grown in
three different media
The 12 Bacteroides strains listed in table I were
grown in three different media (PPY, VT and W, and
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Table II. Complement killing of three Bacteroides strains grown in PPY by serum





Method A Method B
(CH50 = 63 1) (CH50 = 491)
B. fragilis CFTB only 95-2 94-6
MPRL 1504 (control)
10% serum 8-9 161
40% serum 7-8 101
B. fragilis CFTB only 95-3 93-8
NCTC 9343 (control)
10% serum 55-1 77-6
40% serum 14-2 37-3
B. vulgatus CFTB only 91-9 930
MPRL 1985 (control)
10% serum 56-2 68-3
40% serum 49-8 58-3
*SurvivaI after 1 h compared to time 0.
Time of exposure to serum (min)
Fig. 1. Survival of B.fragilisMPRL 1504 in 40 % human serum after
growth in threemedia: ■ ■ control (no serum): A ▲ PPY: #-#
VT and W; ♦ -♦ HISS. Points shown are mean percentage survival
calculated from four replicates.
HISS) and then tested for their ability to survive in
10% human serum, 40% human serum and buffer
only (control). Table III shows the results for all 12
strains with 40% serum. When grown in PPY, all
strains were sensitive to serum to varying degrees.
However, when grown in VT and W, six of the 12
strains (B.fragilis MPRL 1504, B.fragilis NCTC 9343,
B. caccae MPRL 1555, B. thetaiotaomicron MPRL
1959, B. ovatus MPRL 2370 and B. vulgatus MPRL
1985) became markedly more resistant to serum. With
the exception of B. vulgatus MPRL 1985, these strains
became totally resistant to serum when grown in
HISS. In every case, survival in CFTB alone was
between 90 and 100%. Fig. 1 shows the survival of B.
fragilis MPRL 1504 in serum after growth in the three
Table III. Survival of 12 Bacteroides strains after 1 h in 40%
human serum following growth in three media
Percentage survival of
„ . bacteria grown inStrain no.
PPY VT and W HISS
B.fragilis MPRL 1504 7-8 37-9 92-2
B. fragilis NCTC 9343 14-2 68-1 94-2
B. caccae MPRL 1555 10-2 48-9 91-3
B. ovatus MPRL 2370 74-4 85-6 98-1
B. thetaiotaomicron MPRL 1959 52-9 71-8 97-6
B. thetaiotaomicron NCTC 10582 23-3 19-7 25-1
B. uniformis ATCC 8492 130 11-3 10-6
B. vulgatus MPRL 1985 49-8 611 41-5
B. vulgatus MPRL 1651 14-4 21-5 15-5
B. eggerthii NCTC 11155 00 3-2 0-0
B. distasonis ATCC 8503 6-7 0-0 2-6
B. variabilis VPI 11368 00 00 1-2
media. Heat inactivation of serum destroyed bac¬
tericidal activity in every case where a strain was killed
by active serum.
Capsulation of cells in three media
A step gradient of Percoll was used to assess the
degree of capsulation of the 12 Bacteroides strains
grown in three different media. All of the strains
(except B. eggerthii NCTC 11155 which was non-
capsulate) had a characteristic ratio of cells with
large:small:no capsule, and in all cases, this ratio
varied with the growth medium. The Percoll gradients
of B. fragilis MPRL 1504 after growth in the different
media are shown in fig. 2a. India ink smears of the
three cell types of B. fragilis MPRL 1504 (i.e., large,
small, no capsule), extracted from the Percoll gradi¬
ents, are shown in fig. 2b.
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Fig. 2. a, four-step (20, 40, 60 and 80 %) Percoll density gradients after centrifugation with cultures of B. fragilis MPRL 1504 grown in three
media. Cells with large capsules were found at the 0-20 % interface, those with small capsules at the 20-40% and 40-60 % interfaces and those
with no capsule at the 60^80% interface, b, photomicrographs of B. fragilis MPRL 1504 showing bacteria with: i, large capsules (from VT
and W); ii, small capsules (from PPY); iii, no capsules (from HISS). Cells were removed from the most concentrated band in each of the
Percoll gradients and stained with India ink. Bar markers = c. 2 /xm.
LPS profiles of bacteria grown in three media
The LPS profiles of all 12 Bacteroides strains grown
in the three media were examined by aqueous phenol
extraction followed by PAGE and silver staining. Fig.
3 shows the silver-stained PAGE profiles of the LPS of
the six strains that showed most altered sensitivity to
serum in different media. Each species had a character¬
istic profile, with some obvious differences seen in
that of any given strain when grown in different
media. B. vulgatus was the only species to show a
distinct ladder pattern that is characteristic of smooth
LPS as seen in enterobacteria, and this strain showed
the least differences in staining pattern. Other profiles
were similar to those published previously,7'30 with
low Mr bands characteristic of rough or semi-rough
strains, but all also had a few strongly staining high Mr
bands which we have shown previously to be made up
of closely spaced ladder patterns.7 The apparent weak
staining of B. fragilis MPRL 1504 (tracks 4—6) is
probably because this is an extremely mucoid strain
and much of the extract may be of such a high Mr that
it is unable to enter the polyacrylamide gel. There is no
obvious correlation between pattern and change in
sensitivity to serum.
Discussion
The mode of action of the complement system is
now largely understood, and some bacterial resistance
mechanisms to its lethal effects are known. However, a
major drawback in experimental work on this system
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Fig. 3. Silver-stained PAGE (14% acrylamide) LPS profiles of aqueous phenol extracts of six Bacteroides strains following growth to early
stationary phase in PPY. HISS and VT and W. Tracks: 1, B.fragilis NCTC 9343 (PPY): 2, B.fragilis NCTC 9343 (VT and W); 3, B.fragilis
NCTC 9343 (HISS): 4, B.fragilis MPRL 1504 (PPY): 5, B. fragilis MPRL 1504 (VT and W); 6, B.fragilis MPRL 1504 (HISS); 7. B. caccae
MPRL 1555 (PPY); 8, B. caccae MPRL 1555 (VT and W); 9, B. caccae MPRL 1555 (HISS); 10, B. ovatus MPRL 2370 (PPY); 11, B. ovalus
MPRL 2370 (VT and W); 12, B. ovatusMPRL 2370 (HISS); 13,5. thetaiotaomicron MPRL 1959 (PPY); 14. B. thetaiotaomicron MPRL 1959
(VT and W); 15. B. thetaiotaomicron MPRL 1959 (HISS); 16, B. vulgatus MPRL 1985 (PPY); 17, B. vulgatus MPRL 1985 (VT and W); 18,
B. vulgatus MPRL 1985 (HISS).
is that there is no standardised method for testing
serum sensitivity, and also no universal definition of
serum sensitivity.13 Many papers do not specify how
serum used in sensitivity experiments was processed
and stored. This study has shown that different
methods of processing serum affect complement ac¬
tivity (and therefore bacterial killing), and so may
significantly affect the outcome of an experiment and
the conclusions drawn from it.
Previous studies investigating the susceptibility of
Bacteroides spp. to serum have done so after growth in
one medium only. However, this study has shown
dramatic changes in the sensitivity of some Bacteroides
strains to serum when growth medium is altered.
These results demonstrate a need to take growth
medium into consideration when assessing serum
sensitivity of bacteria, and also possibly when assessing
other virulence factors.
All the Bacteroides strains in this study that became
totally resistant to serum when grown in HISS (table
II) were of clinical origin (table I). This is in agreement
with a previous study by Casciato et a/.,16 who found
that faecal isolates of Bacteroides were significantly
more sensitive to serum than those isolated from
clinical infections. Resistance to complement-
mediated killing is a well recognised virulence factor
and is usually associated with the presence of a capsule
or smooth LPS. This relationship does not seem to
hold for the Bacteroides strains investigated here. B.
fragilisMPRL 1504 grown in HISS was non-capsulate,
and was resistant to complement, whereas the cap-
sulate cells (grown in PPY and VT and W) were
sensitive. This is in agreement with a previous study,
where Reid and Patrick19 found the non-capsulate
variant of B. fragilis ATCC 23745 to be resistant to
complement, and the capsulate variant to be sensitive.
Of the other four strains in this study that became
resistant to serum after growth in HISS, two were
mainly non-capsulate and two were capsulate. Al¬
though differences were seen in the LPS patterns of
any given strain when grown in three different media,
we were unable to relate changes in pattern to changes
in sensitivity to serum. However, the resolution of
Bacteroides LPS with silver staining tends to be much
poorer than that of many other organisms (e.g., the
Enterobacteriaceae).21,31 Also, we suspect that certain
high Mr polysaccharides may not be entering the gel
and it is, therefore, possible that there were differences
that were undetected by this method. B. vulgatus (with
smooth LPS) remained sensitive to serum, suggesting
that smooth LPS alone is not responsible for serum
resistance in Bacteroides.
Although it has been demonstrated that variation in
culture conditions can markedly affect sensitivity to
serum complement, the biochemical basis is still
uncertain. This can be resolved only when the surface
chemistry of Bacteroides strains is understood more
fully.
This work was funded by the Medical Research Council. We
thank C. Blackwood for carrying out preliminary experiments, Dr J.
Stewart for helpful suggestions and R. Brown and M. Kerr for
practical assistance.
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Abstract
Members of the genus Bacteroides greatly outnumber enterobacteria in the human colon and therefore represent a vast
potential pool of biologically active LPS. An enzyme-linked immunosorbent assay was developed to estimate the distribution
of IgG levels to LPS from B. fragilis, B. vulgatus, B. thetaiotaomicron and to a mixture of rough LPS from three
enterobacteria and Pseudomonas aeruginosa in sera from 641 adult blood donors. By inhibition ELISA some cross-reactiv¬
ity was demonstrated between the different anti-bacteroides LPS IgG, but with very little between the anti-bacteroides LPS
IgG and the anti-enterobacterial/Pseudomonas LPS IgG. Serum IgG was measured daily over 5-9-day periods in 12 sepsis
patients (6 survivors, 6 non-survivors) and in a healthy individual. In all patients IgG levels fluctuated to a greater extent
than levels in a healthy subject. Variations all followed similar overall trends and indicated that exposure to bacteroides LPS
had occurred. In 5 out of 6 survivors, IgG levels were rising at the end of the period, while 4 of the 6 non-survivors showed
falls, with an exception showing increasing levels to B. fragilis LPS. In 5 out of 6 non-survivors, IgG levels against B.
fragilis LPS were substantially higher than those against the other LPSs. In this small sample some trends in antibody
kinetics have been recognised which suggest bacteroides LPS may be significant in sepsis, and indicate that this study should
be extended.
Keywords: Bacteroides; Lipopolysaccharide; Sepsis; Enzyme-linked immunosorbent assay; IgG
1. Introduction
Despite considerable recent advances in technol¬
ogy and drug therapy, systemic inflammatory re¬
sponse syndrome or 'sepsis' remains the most com¬
mon cause of death in critically ill intensive care
patients [1,2], Endotoxin (lipopolysaccharide; LPS)
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plays a central role in the development of sepsis by
inducing cascades of cytokines, complement and
clotting factors. In severe cases, this will result in
shock, multiple organ failure and a mortality of up to
90% [3],
LPS may enter the circulation either directly from
a site of infection or by translocation across an
ischaemic gut wall [4,5], Previous studies have shown
Gram-negative bacteraemia to be present in only
21-37% of sepsis cases [6], and it is thought that in
patients where there is no obvious Gram-negative
Societies. All rights reserved
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infection, the source of LPS is the gut [7]. It has
previously been assumed that, in those cases where
LPS is gut-derived, it is that of the enterobacteria
(particularly Escherichia coli) which is responsible
for the pathophysiological effects of sepsis, with
other gut organisms not thought to be significant [8].
The outcome of an invasion by any foreign mate¬
rial into the circulation is largely dependent on the
timing and the magnitude of the antibody response
mounted against it. Barclay and colleagues have
carried out extensive studies investigating the magni¬
tude and kinetics of serum antibody response to LPS
core from enterobacteria and closely related species
in sepsis patients. It was found that non-survivors
were more likely to have low endogenous levels of
IgG which failed to recover. In both survivors and
non-survivors, a sudden consumption of antibody
appeared to be indicative of a recent episode of
endotoxaemia (often confirmed by limulus amoebo-
cyte lysate gelation (LAL) assays), and as such was a
useful indirect method of showing when endotox¬
aemia had occurred [9-12],
Members of the genus Bacteroides (formerly the
Bacteroides fragilis group) constitute 20-30% of the
colonic microbial flora [13] and are often involved in
both pure and mixed infections in man. B. fragilis,
the type species, is the most frequently isolated
anaerobe from clinical specimens, and the most com¬
mon cause of anaerobic bacteraemia [14,15]. Anaer¬
obes outnumber enterobacteria in the colon by ap¬
proximately 1000 to 1 [13].
Bacteroides LPS has previously been found to be
100- to 1000-fold less biologically active than enter¬
obacterial LPS in various in vivo and in vitro assays
[16]. However, given the differences in numbers
between E. coli and Bacteroides in the gut, there is
potentially as much if not more biological activity
from bacteroides LPS as there is from that of E. coli.
To date, no data have been published with regard
to serum antibody levels to Bacteroides spp., either
in healthy individuals or in sepsis patients. The aims
of this study were therefore: (i) to develop an en¬
zyme-linked immunosorbent assay (ELISA) measur¬
ing anti-bacteroides LPS IgG in serum which could
then be used indirectly to assess LPS levels in
serum; (ii) to use the assay to determine the distribu¬
tion of anti-bacteroides LPS IgG within a normal




Bacteroides fragilis NCTC 9343
Bacteroides vulgatus MPRL 1985
Bacteroides thetaiotaomicron NCTC 10582
Escherichia coli K12 MPRL 1303
Salmonella typhimurium Rc 878 MPRL 0947
Klebsiella pneumoniae 10B MPRL 0954
Pseudomonas aeruginosa PAC 611 MPRL 1091
NCTC = National Collection of Type Cultures, UK; MPRL =
Departmental stock culture.
follow the kinetics of anti-bacteroides LPS IgG in
sepsis patients where the source of LPS is likely to
be the gut (and where consumption of antibody
would suggest exposure to LPS); (iv) to compare the
kinetics of anti-bacteroides LPS IgG with the kinet¬
ics of anti-enterobacterial LPS IgG; and (v) to try to
determine from these results whether bacteroides
LPS plays a significant part in the course and the
outcome of sepsis.
2. Materials and methods
2.1. Bacteria and growth conditions
Bacterial strains used are listed in Table 1. Bac¬
teroides strains were grown in 1-1 batch cultures to
early stationary phase at 37°C in an atmosphere of
H? 10%, C02 10% and N2 80% in an anaerobic
cabinet (Forma), in proteose peptone-yeast extract
medium [17]. All other bacteria were grown aerobi-
cally at 37°C in 2-1 batch cultures in nutrient broth
(Gibco). All cultures were checked for purity by
Gram's staining and aerobic and anaerobic incuba¬
tion on Columbia blood agar (Oxoid). Cells were
harvested by centrifugation (lOOOOXg, 15 min),
washed twice in phosphate-buffered saline (PBS,
Oxoid) and lyophilised.
2.2. Serum used in study
A random selection of healthy adult (blood donor)
sera was obtained from the South East Scotland
Regional Blood Transfusion Centre, Edinburgh.
Serum samples were obtained from sepsis patients
in a study conducted by the Scottish Sepsis Interven-
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tion Group (paper submitted). Approval was ob¬
tained from the relevant Ethical Committees and
informed consent obtained from all patients.
All sera were stored at — 20°C until use.
2.3. LPS preparation and coating onto ELISA strips
Bacteroides strains
Lyophilised LPS (prepared by the aqueous phenol
method of Westphal and Luderitz [18] as described
by Hancock and Poxton [19]) was complexed with
polymyxin B after the method of Scott and Barclay
[20]. LPS was resuspended in pyrogen-free (PF)
H20 to 1 mg/ml, and an equal volume of a 1
mg/ml solution of polymyxin B sulphate (Sigma)
was added. The mixture was sonicated for 30 s at 10
p, (MSE Soniprep), stirred for 90 min at 20°C, then
re-sonicated as above. Following dialysis for 18 h
(Spectra pore membrane MWCO 2000) against PF
HzO at 4°C, the mixture was diluted 1:50 in ELISA
coating buffer: 0.05 M carbonate /bicarbonate, pH
9.6, containing 0.02% sodium azide. ELISA strips
(Immunomodule polysorp F8 Nunc, Intermed) were
coated at 100 /id/well and incubated at 20°C
overnight. The strips were washed four times with
ELISA wash buffer: PBS, pH 7.4 containing Tween
20 (0.05% w/v, Sigma) and sodium azide (0.05%
w/v). They were then post-coated with bovine serum
albumin (BSA, 5%w/v, ICN) and sodium azide
(0.02% w/v) in PBS at 100 /id/well and were
incubated as above. Finally the strips were washed
four times, rinsed once in PF H20 and stored at
— 20°C until use.
Other bacterial strains
A mixture of equal weights of E. coli, S. ty-
phimurium, K. pneumoniae and P. aeruginosa rough
LPS extracted using the phenol/chloroform/petro-
leum ether method of Galanos et al. [21] was resus¬
pended in PF HzO to 1 mg/ml and complexed with
polymyxin B sulphate and coated onto ELISA strips
as above.
2.4. ELISA
A 1 in 200 dilution of the serum samples to be
tested was made in ELISA dilution buffer: PBS
containing Tween 20 (0.05% w/v), BSA (0.5%
w/v) and polyethylene glycol Ml 6000 (4% w/v,
Sigma). The diluted serum (100 /u.1) was added to
each well on the appropriate LPS-coated ELISA
strips and incubated for 90 min at 37°C before
washing four times. Alkaline phosphatase-conjugated
anti-human IgG (Sigma) was diluted in ELISA dilu¬
tion buffer 1 in 1000 and added at 100 /H/well. The
strips were incubated and washed as above. Alkaline
phosphatase substrate (1 mg/ml p-nitrophenyl phos¬
phate (Sigma) in 0.05 M carbonate/bicarbonate
buffer pH 9.8 containing 1 mM MgCl2) was added
at 100 p\/well. The strips were incubated at 20°C
for 30-40 min, and the absorbances were read at 405
nm in an ELISA plate reader (Anthos 2001, Labtec).
A negative control was included where the serum
was replaced by pure diluent, and the absorbance of
the negative control was subtracted from each of the
test wells.
2.5. Inhibition ELISA
This was carried out as above, except that after
the serum was diluted 1 in 200, LPS was added to a
final concentration of 1 mg/ml, and this was incu¬
bated at 37°C for 30 min prior to carrying out the
ELISA. Control serum was treated identically except
no LPS was added. Serum used in this case was
pooled from 10 random blood donors.
2.6. Determination of the distribution of anti-LPS
IgG levels within blood donor population
Initially a sample of 50 random blood donors was
screened by ELISA for IgG levels to B. fragilis
NCTC 9343, B. vulgatus MPRL 1985, B. thetaio-
taomicron NCTC 10582 and the rough LPS mixture.
Serum containing close to median levels of IgG to
all of the antigens was selected as a standard. A
further 641 donors were then screened, and to stan¬
dardise the optical density (OD) readings, on each
plate a sample of the standard serum was also tested.
The OD of this serum was given an arbitrary value
of 100% in each case, and the ODs of the 641 sera
were converted to percentages using the standard
serum. The median levels of IgG to all of the
antigens within the 641 donors were calculated.
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2.7. Determination of anti-LPS IgG in sepsis patients
ELISAs were performed on sequential serum
samples from 12 sepsis patients. To standardise OD
readings, another serum was selected as a standard
from the 641 screened expressing close to median
levels of IgG to all of the antigens and used as
above. As a control, serum taken from a healthy
individual on 6 consecutive days was also tested.
3. Results
3.1. Determination of average levels of anti-LPS IgG
in 641 random blood donors
Sera from 641 blood donors were screened for





B. vulgatus and B. thetaiotaomicron, and against a
mixture of rough LPS from three enterobacteria and
P. aeruginosa. The results of this screen are shown
on Fig. 1. Distributions of anti-LPS IgG in the donor
population tested were normal in appearance on his¬
tograms, except anti-fl. fragilis IgG which showed a
slight negative skew.
3.2. Estimation of cross-reactivity of antibodies
An inhibition ELISA was used to determine the
degree of cross-reactivity of the antibodies to the
different LPSs. This involved pre-incubating pooled
blood donor serum with the different LPSs to try to
neutralise any cross-reactivity prior to using it in
ELISA, and measuring the reduction in OD com¬
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Fig. 1. Distribution of anti-LPS IgG in 641 blood donors by quantitative screening ELISA. Serum from a donor expressing close to median
levels of IgG to all LPSs tested, selected from a preliminary screen of 50 random blood donors was included on all plates to standardise OD
readings. Each donor serum was tested in duplicate. * Standard = 100%
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LPS. The results of this are shown on Table 2.
Pre-incubation of serum with homologous LPS re¬
duced the OD readings to between 2.4 and 12.7% of
the control (i.e. approx. 87-97% of the IgG was
absorbed out against any given LPS). The greatest
amount of cross-reactivity was between IgG reacting
with B. uulgatus and B. thetaiotaomicron, and there
was limited cross-reactivity between IgG reacting
with B. vulgatus or B. thetaiotaomicron and B.
fragilis. Cross-reactivity between IgG against any of
the bacteroides LPSs and the enterobacterial/Pseu-
domonas rough LPS mixture was very limited.
3.3. Kinetics of anti-LPS IgG response in sepsis
patients
ELISAs were performed on sera taken daily over
5- to 9-day periods from 12 sepsis patients (6 sur¬
vivors, 6 non-survivors) with a clinical diagnosis of
abdominal sepsis and blood culture negative in whom
LPS was thought to be gut derived. Although no
cases were identical, several broad observations could
be made on the overall trend of results, and Fig. 2
illustrates anti-LPS IgG levels in two fatal and two
non-fatal cases, and also those in a healthy individ¬
ual. In all sepsis patients, IgG levels (especially IgG
against B. fragilis LPS) fluctuated over time to a
greater extent than levels in a healthy subject. Also
fluctuations in IgG against all of the antigens fol¬
lowed similar overall trends, and in most cases anti-
bacteroides LPS IgG, especially that against B. frag¬
ilis, showed greater fluctuations than the anti-enter-
obacterial/Pseudomonas rough LPS IgG. In 5 out of
6 survivors, IgG levels to all of the antigens had
increased overall at the end of the sampling period.
In 4 of the 6 non-survivors, levels stayed approxi¬
mately the same or decreased, with an exception
showing increasing levels to B. fragilis LPS. In 5
out of 6 non-survivors, IgG levels to B. fragilis LPS
were higher than those against the other LPSs, and in
the sixth non-survivor, IgG levels to all antigens
were very low throughout the whole sampling pe¬
riod. Three out of 6 survivors and 3 of 6 non-survi¬
vors had low initial levels of anti-LPS IgG (i.e.
below median levels).
Table 2
Results of inhibition ELISA measuring cross-reactivity of serum IgG against different LPSs. Figures shown are average percentages
calculated from 4 replicates
IgG Serum pre-incubated OD as percent of
with non-pre-incubated
control + S.E.
Anti-B. fragilis LPS B. fragilis LPS 10.1 +4.1
B. vulgatus LPS 91.5 ± 1.6
B. thetaiotaomicron LPS 57.5 + 6.6
Rough LPS mixture 94.2 + 4.3
Anti-B. vulgatus LPS B. fragilis LPS 56.8 + 1.1
B. vulgatus LPS 2.4+ 1.1
B. thetaiotaomicron LPS 21.0 + 1.7
Rough LPS mixture 98.6 + 2.7
Anti-B. thetaiotaomicron LPS B. fragilis LPS 63.9 + 1.1
B. vulgatus LPS 26.2 + 0.8
B. thetaiotaomicron LPS 10.3 + 4.1
Rough LPS mixture 96.4 ± 2.9
Anti-rough LPS mixture B. fragilis LPS 89.5 + 6.7
B. vulgatus LPS 98.4 + 4.4
B. thetaiotaomicron LPS 94.2 + 3.9
Rough LPS mixture 12.7 + 3.3
OD = Optical density at 405 nm.
S.E. = Standard error.
Rough LPS mixture = E. coli, K. pneumoniae, S. typhimurium and P. aeruginosa.
%IgGcomparedtstandard*
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4. Discussion
This study investigated serum levels of IgG against
bacteroides LPS in blood donors and in a group of
sepsis patients where endotoxin was thought to be
derived from the gut. It was decided to look at IgG
against aqueous phenol LPS preparations of B. frag¬
ilis, as this is the most common anaerobic pathogen,
and also B. vulgatus and B. thetaiotaomicron, as
these are two of the most numerate of the Bac¬
teroides spp. in faeces [22]. Since enterobacteria and
closely related species are thought to be responsible
for the development of sepsis, we also measured IgG
against a mixture of rough LPS from three enter¬
obacteria plus P. aeruginosa. It is important to stress
that the aim of this study was not to make direct
comparisons between bacteroides LPS and the rough
LPS mixture, but rather to observe and compare the
IgG responses in order to see whether that against
bacteroides LPS was significant. It is also important
to emphasise that the aqueous phenol extracts of
bacteroides were not pure LPS, but also contained
some capsular polysaccharide and protein (E. Allan,
unpublished data). However, it was decided not to
try to purify the LPS further, as we were trying to
mimic the in vivo situation as closely as possible; if
hot phenol failed to separate the surface components
of bacteroides completely, then the LPS is unlikely
to be present in pure form in the body.
In the blood donor population, similar distribu¬
tions of IgG levels were observed for all antigens
tested. It has previously been suggested that IgG
levels against enterobacterial LPS core are dependent
on the degree of long-term exposure, which in turn
may be dependent on the amount of LPS which
translocates naturally across the gut wall and into the
circulation [II]. Our results suggest that this could
also be true for bacteroides LPS.
In all sepsis patients, IgG levels against all anti¬
gens followed similar overall trends. Inhibition
ELISAs showed that whilst there were some epitopes
shared between the different bacteroides LPSs, there
were very few (if any) between bacteroides LPS and
the enterobacterial/Pseudomonas LPS mixture. This
is not surprising given that the lipid A structure of B.
fragilis, and probably the other Bacteroides spp. is
markedly different from that of the enterobacteria
[16,23]. In some cases, a sudden consumption of
antibody was shown to be concurrent with an episode
of endotoxaemia (confirmed previously by LAL as¬
says (Sepsis Intervention Group, unpublished data)).
In other cases, there was a decrease in IgG against
all antigens but no endotoxin detected in the serum.
However, endotoxaemia is often very transient and
may not be detected in a LAL assay [24], so IgG
levels may be a more accurate method for detecting
it. The ELISA used in this study appears to be a
good method of detecting an acute episode of endo¬
toxaemia indirectly.
One of the most striking observations in this study
was that in 5 out of 6 non-survivors, IgG levels
against B. fragilis LPS were higher than levels of
IgG against the other antigens. This only occurred in
one survivor. Due to the small number of sepsis
patients studied here, it is not possible to draw any
firm conclusions linking certain antibody levels or
kinetics to a fatal or non-fatal outcome. Moreover,
by the time the first blood sample is taken, the
patient is often very sick, and the antibody levels at
that time may bear no resemblance to those in health.
However, the study has demonstrated a definite IgG
response to bacteroides LPS which is independent of,
but shows similar overall trends to, the response to
enterobacterial LPS. Other recent studies in our labo¬
ratory have shown bacteroides LPS to be more bio¬
logically active in certain endotoxin assays than pre¬
viously reported [25]. This, together with the nature
of the IgG response, suggests that bacteroides LPS
could be more important than previously thought in
the development and outcome of sepsis.
In summary, we have demonstrated for the first
time that healthy adults have individual endogenous
Fig. 2. (Opposite) Kinetics of anti-LPS IgG response in 4 sepsis patients (2 survivors, 2 non-survivors) and in a healthy individual over 6- to
9-day periods. Serum from a donor expressing close to median levels of IgG to all LPSs tested, selected from a screen of 641 random blood
donors, was included on all plates to standardise OD readings. ♦, B. fragilis NCTC 9343; ■, B. thetaiotaomicron NCTC 10582; ▲. B.
vulgatus MPRL 1985; 0, Enterobacterial /Pseudomonas rough LPS mixture. Points shown are average percentages calculated from at least
4 replicates. * Standard = 100%.
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levels of IgG against bacteroides LPS. We have also
shown that the anti-bacteroides LPS IgG is not sim¬
ply anti-enterobacterial LPS IgG which cross-reacts
with bacteroides LPS, but that the two are indepen¬
dent of each other. We have also demonstrated cer¬
tain trends in anti-bacteroides LPS IgG kinetics in
sepsis patients which suggest that bacteroides LPS
could be significant in sepsis and indicate that the
study should be extended.
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